Structural studies on the sialidases from Streptococcus pneumoniae and Pseudomonas aeruginosa by Xu, Guogang
STRUCTURAL STUDIES ON THE SIALIDASES FROM
STREPTOCOCCUS PNEUMONIAE AND PSEUDOMONAS
AERUGINOSA
Guogang Xu
A Thesis Submitted for the Degree of PhD
at the
University of St. Andrews
2009
Full metadata for this item is available in the St Andrews
Digital Research Repository
at:
https://research-repository.st-andrews.ac.uk/
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10023/778
This item is protected by original copyright
 Structural studies on the sialidases  
from  
Streptococcus pneumoniae  
and  
Pseudomonas aeruginosa  
 
 
 
Guogang Xu 
 
 
A thesis submitted for the degree of  
Doctor of Philosophy 
 
 
University of St Andrews 
March 2009 
Declaration 
 
I, Guogang Xu, certify that this thesis, which is approximately 40,000 words in length 
has been written by me, is the record of work carried out by myself and that it has not 
been submitted in any previous application for a higher degree. 
 
Date:                                                                        Signature of the candidate: 
 
I was admitted as an MRes student to University of St Andrews in September 2005 
and as a candidate for the degree of Ph.D from September 2006; the higher study for 
which this is a record was carried out in the University of St Andrews between 2006 
and 2009. 
 
Date:                                                                        Signature of the candidate: 
 
I hereby certify that the candidate has fulfilled the conditions of the Resolution and 
Regulations appropriate for the degree of Ph.D in the University of St Andrews and 
that the candidate is qualified to submit this thesis in application for that degree. 
 
Date:                                                                       Signature of supervisor: 
 
In submitting this thesis to the University of St Andrews we understand that we are 
giving permission for it to be made available for use in accordance with the regulations 
of the University Library for the time being in force, subject to any copyright vested in 
the work not being affected thereby.  We also understand that the title and the abstract 
will be published, and that a copy of the work may be made and supplied to any bona 
fide library or research worker, that my thesis will be electronically accessible for 
personal or research use unless exempt by award of an embargo as requested below, 
and that the library has the right to migrate my thesis into new electronic forms as 
required to ensure continued access to the thesis. We have obtained any third-party 
copyright permissions that may be required in order to allow such access and 
migration, or have requested the appropriate embargo below. 
 
The following is an agreed request by candidate and supervisor regarding the 
electronic publication of this thesis: Access to Printed copy and electronic publication 
of thesis through the University of St Andrews. 
 
Date:                Signature of the candidate:                  Signature of supervisor: 
  ii 
Abstract 
 
The sialidases are a group of glycosyl hydrolases that specifically remove terminal 
sialic acid (Neu5Ac) residues from various glycans. In the two common human 
pathogenic bacteria Streptococcus pneumoniae and Pseudomonas aeruginosa, these 
enzymes have been shown to be key virulence factors directly involved in bacterial 
colonization and infection. However, little is known about their detailed structural and 
mechanistic features and lack of this information significantly slows down the progress 
of new drug discovery targeting these enzymes. Therefore, we embarked structural and 
kinetic studies towards the three distinct sialidases (designated as NanA, NanB and 
NanC) from S. pneumoniae, as well as the putative sialidase (designated as PaNA) 
from P. aeruginosa. 
Full-length NanA failed to crystallize due to the presence of some natively disordered 
regions. The catalytic domain of NanA (CNanA) was therefore subcloned, which was 
crystallized and the structure was determined to 1.5 Å. CNanA exists as a dimer with 
close contacts between the two monomers. The second pneumococcal sialidase NanB 
only shares 24% sequence identity with NanA. Crystal structure of NanB was also 
determined to 1.7 Å, which exhibits a multi-domain monomeric architecture. In 
general, the core catalytic domain of both CNanA and NanB adopts the classic six-
bladed β-propeller fold (or called sialidase fold), with a set of highly conserved 
residues stacking around the proposed active sites. NanC is a close homologue of 
NanB, sharing over 50% sequence identity. However, NanC crystallization is not 
successful so far. To compare the three sialidases in more detail, a computational 
NanC model was made based on the structure of NanB. Mapping of the active sites of 
CNanA and NanB was achieved using Neu5Ac2en, a general sialidase inhibitor as the 
probe. Although sharing many common features, NanA, NanB and NanC present 
different topologies around the catalytic centre, give these enzymes a high level of 
diversity in enzymatic kinetics, substrate specificity and catalytic properties. NMR 
studies show that NanA acts as a classic hydrolytic sialidase; while NanB is found to 
be an intermolecular trans-sialidase like the leech sialidase; NanC, however, handles 
multiple catalytic roles efficiently, which include releasing Neu5Ac2en from α2,3-
sialyllactose and hydration of Neu5Ac2en to Neu5Ac with high efficiency. S. 
pneumoniae thus expresses NanA, NanB and NanC for disparate but cooperative roles. 
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Such a working pattern of three sialidases in one microbe is unusual in nature, which 
might be essential for pneumococcal pathogenesis at various stages. Based on the 
crystal structures of CNanA and NanB, preliminary work towards S. pneumoniae 
sialidases inhibitor design is under way, in which, a variety of techniques, such as the 
fluorescence-based thermal shift assay, NMR spectroscopy, computational docking 
and X-ray crystallography, are incorporated in.  
The crystal structure of PaNA was determined to 1.9 Å. This protein appeared to be a 
unique trimer in crystal that is associated, in part, by the immunoglobulin-like 
trimerization domain around a three-fold crystallographic axis. The core catalytic 
domain of PaNA also presents the conserved sialidase fold. Surprisingly, no sialidase 
activity was detected with this enzyme. In addition, two key catalytic residues 
including one of the arginine in the arginine triad and the acid/base catalyst aspartic 
acid are missing in PaNA. In silico docking suggests that Phe129 may confer substrate 
selectivity towards pseudaminic acid, which is a specific carbohydrate superficially 
similar to Neu5Ac, but with different stereochemistry at the C-5 position. Site-directed 
mutagenesis further confirmed that mutation of Phe129 to alanine could turn PaNA 
into a poor sialidases. Moreover, the crystal structure of PaNA also indicates that 
His45, Tyr21 and Glu315 may form a charge relay to compensate the missing aspartic 
acid. Subsequent mutagenesis and NMR kinetic studies proved His45-Tyr21-Glu315 
to be a novel charge relay taking the role of the acid/base catalyst. Therefore, PaNA 
could be a pseudaminidase with structural and mechanistic variations. This enzyme, 
together some other uncharacterized fellow proteins, might form a novel subclass in 
the sialidase superfamily. 
The various findings in the current projects provide meaningful insights towards 
several sialidases that have been linked to bacterial virulence, which may contribute to 
a more intensive understanding of S. pneumoniae and P. aeruginosa pathogenesis. 
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I. Amino acids 
 
Ala, A                       Alanine 
Arg, R                       Arginine 
Asn, N                      Asparagine 
Asp, D                      Aspartate 
Cys, C                       Cystine 
Gln, Q                       Glutamine  
Glu, E                        Glutamate 
Gly, G                       Glycine 
His, H                       Histidine 
Ile, I                          Isoleucine 
Leu, L                         Leucine 
Lys, K                         Lysine 
Met, M                        Methionine 
Phe, F                          Phenylalanine 
Pro, P                          Proline 
Ser, S                          Serine 
Thr, T                         Threonine 
Trp, W                        Tryptophan 
Tyr, Y                         Tyrosine 
Val, V                         Valine 
 
 
 
II. Bacteria & other microbes 
 
A. sialophilus         Arthrobacter sialophilus 
A. ureafaciens       Arthobacter ureafaciens 
B. fragilis             Bacteroides fragilis 
C. coli                  Campylobacter coli 
C. jejuni               Campylobacter jejuni 
C. perfingens      Clostridium perfringens 
E. coli                 Escherichia coli  
H. pylori             Helicobacter pylori 
M. decora           Maccrobdella decora 
M. viridifaciens      Micromonospora viridifaciens 
NDV                      Newcastle Disease Virus 
P. aeruginosa         Pseudomonas aeruginosa 
S. tyhimurium        Salmonella tyhimurium  
S. pneumoniae       Streptococcus pneumoniae 
SV5                        Simian virus 5 
T. cruzi                   Trypanosoma cruzi 
T. rangeli               Trypanosoma  rangeli 
V. cholerae            Vibrio cholerae  
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III. Chemicals 
2, 3F-Neu5Ac                2,3-difluoro-N-acetylneuraminic acid 
3SL                                α2,3-sialyllactose, Neu5Ac(α2,3)Gal(β1-4)Glc 
4-MU                             4-methylumbelliferone 
6SL                                α2,6-sialyllactose Neu5Ac(α2,6)Gal(β1-4)Glc 
CHES                             2-n-cyclohexylamino ethane sulfonic acid 
CMP                              Citidine-5'-monophosphate 
D2O                                Deuterated water  
DMSO                           Dimethyl sulfoxide 
DNAse                           Deoxyribonuclease 
EB                                 Ethidum bromide  
EDTA                            Ethylenediaminetetraacetic acid 
Gal                                 Galactose 
Galβ1-4GlcNAc            N-acetyllactosamine 
GalNAc                          N-acetylgalactosamine 
GlcNAc                          N-acetylglucosamine 
GM1                              Monosialotetrahexosylganglioside   
IPTG                              Isopropyl thio-β-D-galactoside 
KDN                              2-keto-3-deoxy-D-glycero-D-galacto-nononic acid 
LB                                  Luria Bertani 
MES                              2-(N-morpholino) ethanesulfonic acid 
MUAN                          2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid 
Neu2,7-anhydro5Ac      2,7-anhydro-N-acetylneuraminic acid  
Neu5Ac                         N-acetylneuraminic acid, NANA 
Neu5Ac2en                    2-deoxy-2,3-didehydro-5-N-acetylneuraminic acid, DANA 
Neu5Gc                         N-glycolylneuraminic acid 
PBS                               Phosphate buffered saline 
pCMBS                         p-chloromercuribenzene-sulfonic 
PEG                               Polyethylene glycol  
pNP-Neu5Ac                2-O-(p-nitrophenyl)-N-acetylneuraminic acid 
PSA                               Poly α2,8-sialic acid, ploySia, colominic acid  
Pse5Ac7Ac                    5,7-diamino-3,5,7,9-tetradeoxy L-glycero-L-manno- 
                                       nonulosonic acid 
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IV. Sialidases 
CNanA                           Catalytic domain of NanA 
endo-N                            endo-N-acylneuraminidase, endosialidase 
HN                                  Heamagglutinin-neuraminidase 
IT trans-sialidase           Intramolecular trans-sialidase 
MvNA                            M. viridifaciens sialidase 
N1, (1-9)                        Influenza virus sialidase subtypes 1-9 
NA                                 Influenza virus sialidase 
NanA                             S. penumoniae sialidase A 
NanB                             S. penumoniae sialidase B 
NanC                             S. penumoniae sialidase C 
NanI                              C. perfingens sialidase 
NanJ                              C. perfingens large sialidase 
NanL                             M. decora sialidase L 
NEU1                            Human lysosomal sialidase  
NEU2                            Human cytosolic sialidase  
NEU3                            Human plasma membrane-associated sialidase 
NEU4                            Human mitochondrial sialidase 
PaNA                             P. aeruginosa sialidase 
TcTS                              T. cruzi  trans-sialidase 
TrSA                              T. rangeli  sialidase 
VcNA                            V. cholerae sialidase 
 
 
V. Symbols 
 
a,b,c                 Unit cell dimensions 
Å                     Angstrom  
α, β, γ              Angles of unit cell  
Δ                      Macroscopic change 
δ                      Chemical shift 
σ (I)                 Error in intensity 
ε                      Extinction coefficient 
λ                     Wavelength 
µ                      Micro (one millionth) 
Ki                    Inhibition constant  
Km                   Michaelis constant 
Tm                    Midpoint temperature 
Vm                   Matthews’ coefficient 
Vmax                 Maximum velocity 
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VI. Technical & Miscellaneous 
 
1H NMR                        Proton nuclear magnetic resonance  
2Fo-Fc                             Maximum likelihood/σA-weighted 2Fo-Fc map  
3-D                                Three dimensions  
ABC transporter            ATP-binding cassette transporter  
ADME                           Absorption, distribution, metabolism and elimination 
Asp box                         Aspartic box motif 
ATCC                            American Type Culture Collection 
a.u.                                Asymmetric unit 
Axe 1                            Acetyl xylan esterase 1  
B-factor                         Temperature factor 
BNR                              Bacterial neuraminidase repeat 
CAZy                            Carbohydrate-Active Enzymes 
CBM                             Carbohydrate binding module 
CCD                              Charge-coupled devices 
CCP4                             Collaborative Computing Project Number 4 
CD15                            3-fucosyl-N-acetyl-lactosamine, Lewis x 
CDD                              Conserved Domain Database 
CF                                 Cystic fibrosis  
Da                                 Dalton 
EDM                             Electron density maps 
EP                                 Ependorf  
ESRF                            European Synchrotron Radiation Facility 
FBDD                           Fragment-based drug discovery  
Fo-Fc                             Maximum likelihood/ σA-weighted Fo-Fc map  
GA                                Genetic algorithm 
GH                                Glycoside hydrolase  
GI                                 GenInfo Identifier number 
GOLD                          Genetic Optimisation for Ligand Docking program 
HA                                Heamagglutinin  
Ig                                   Immunoglobulin 
ITC                               Isothermal titration calorimetry 
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LPS                               Lipopolysaccharides 
M                                  Molar concentration 
MALDI-TOF                Matrix-assisted laser desorption time-of-flight  
MgrA                            M regulator protein trans-acting positive regulator 
MIR                              Multiple isomorphous replacement 
MR                                Molecular replacement 
MS                                Mass spectrometry 
MW                              Molecular weight 
NAlyase                        N-acetylneuraminate lyase 
NMR                             Nuclear magnetic resonance spectroscopy 
OD600                            Optical density at 600 nm 
OM                               Otitis media  
PCR                              Polymerase chain reactions  
PCT                              Pre-crystallization test  
PDB                              Protein Data Bank 
PISA                            Protein Interfaces, Surfaces and Assemblies server 
p.p.m.                           Part per million 
RIP/RLP                      The Arg-Ile-Pro/Arg-Leu-Pro motif 
r.m.s.d                         Root mean square deviation 
r.p.m.                           Round per minute 
SBDD                          Structure-based drug discovery  
SD                               Standard deviation 
SDM                           Site-directed mutagenesis 
SDS-PAGE                 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SIR                             Single-isomorphous replacement 
SIRAS                        SIR combined with anomalous scattering  
STD-NMR                 Saturation transfer difference-NMR spectroscopy 
TBA                           Thiobarbituric acid assays 
TD                              Trimerization domain 
TEV                           Tobacco etches virus  
TF-Z                          Translation function Z score 
TNF                           Tumor necrosis factor 
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Chapter 1 
 
Introduction 
 
1.1 The sialidase superfamily 
Sialidases, or neuraminidases, were first discovered as receptor-destroying enzymes 
from the influenza virus and Vibrio cholerae (V. cholerae) in the 1940s (Gottschalk 
and Lind, 1949; Hirst, 1941). These enzymes were later defined as a type of glycosyl 
hydrolase and are found widely distributed in nature (Taylor, 1996). To date, the 
SWISS-PROT protein sequence database (Bairoch and Apweiler, 2000) has listed 199 
different sialidases from organisms of various species, including viruses, 
bacteriophage, bacteria, fungi, mycoplasma, protozoa and some higher eukaryotes. It 
was hypothesized that the sialidases might have a common origin and the genes might 
have been spread out by horizontal gene transfer (Roggentin et al., 1993), although 
further evidence remains to be determined. Despite the remarkable diversities in their 
distributions, amino acid sequences and biological properties, the sialidases still 
present significant molecular and structural homologies, and thereby are included in 
the sialidase superfamily (EC 3.2.1.18) (Roggentin et al., 1989). 
The sialidases specifically catalyze the removal of sialic acid residues at the non-
reducing end of different surface oligosaccharides, glycoproteins and glycolipids on 
various cells. Such specific functions have associated this enzyme with a wide range of 
biological and aetiological processes (Taylor, 1996). Among the many sialidases, the 
influenza virus sialidases (designated as NAs) continue to be the most intensively 
studied. For several decades, the research into the NAs has been at the frontline due to 
the significance of the viral infections on public health. The influenza virus NAs 
remove sialic acids from the newly assembled virions to prevent their self-aggregation, 
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and thus promote the spreading of progeny virus particles from the infected cell to 
other host cells; they may also play a role in modifying the cell surface during the 
initial infection?(Air and Laver, 1989; Matrosovich et al., 2004). Consequently, NA is 
known as one of the two key virulence factors of influenza viruses, the other being 
haemagglutinin (HA) (Wagner et al., 2002). Another type of viral sialidase well 
characterized is the paramyxovirus enzyme, which is found to present dual functions as 
both an NA and an HA in viral infections. The paramyxovirus sialidases were 
therefore classified as haemagglutinin-neuraminidases (HNs) in the sialidase 
superfamily (Sergel et al., 1993). The significance of the NAs and HNs actions in the 
viral infections assures the viral sialidases as key enzymes with great aetiological 
importance and pharmaceutical interest (Alymova et al., 2005; Kiefel and von Itzstein, 
1999; von Itzstein, 2008a). 
In addition to the viral enzymes, a number of sialidases have been identified from 
some pathogenic bacteria, such as V. cholerae, Clostridium perfringens (C. 
perfringens), Salmonella typhimurium (S. typhimurium), Streptococcus pneumoniae (S. 
pneumoniae) and Pseudomonas aeruginosa (P. aeruginosa) (Roggentin et al., 1993). 
Accordingly, this group of sialidases from a variety of invasive bacteria are also 
believed to be the major virulence factors essential in bacterial colonization and 
infections. In general, the sialidases can desialylate the host cell surface glyconjugates 
to unmask some receptors for the bacterial adherence and colonization (Corfield, 
1992), or expose the monosialotetrahexosylganglioside (GM1) receptor for the toxin 
binding as discovered in V. cholerae pathogenesis (Galen et al., 1992; Snyder and 
Walker, 1987). Meanwhile, the sialic acids excised by sialidases could also be used as 
a carbon and energy source for the survival of the bacteria living in the host (Corfield, 
1992). The sialidases from S. pneumoniae and P. aeruginosa are the main focus of the 
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current thesis projects and will be overviewed later in Section 1.6 and Section 1.7 
respectively. 
Another interesting group of sialidases are the mammalian sialidases, which consists of 
at least thirteen members that have been cloned so far (Monti et al., 2004). Due to their 
different subcellular localizations, the mammalian sialidases are classified into several 
subtypes including the lysosomal, the cytosolic and the plasma-membrane bound 
sialidases (Magesh et al., 2006). Moreover, these sialidases are linked not only to some 
physiological events, but also the progression of various malignancies (Miyagi et al., 
2008b; Miyagi et al., 2008c). For instance, the human lysosomal sialidase NEU1 is key 
in cellular signalling, in immune response and cell differentiation by regulating the 
sialic acid profiles of cells (Liang et al., 2006); the cytosolic NEU2 has a role in 
myotube formation via its enzymatic actions on ganglioside GM3 (Fanzani et al., 
2008); the plasma membrane-associated sialidase NEU3 is a crucial regulator in 
transmembrane signalling and is related to the neural differentiation and tumourigenic 
transformation (Miyagi et al., 2008a; Miyagi et al., 2008b); the mitochondrial 
sialidase, NEU4, is involved in the apoptosis pathway (Monti et al., 2004; Seyrantepe 
et al., 2004). The expression of the cell-surface glycan 3-fucosyl-N-acetyl-lactosamine 
(known as CD15 or Lewis x, Lex), a human myeloid cell differentiation marker, could 
also be regulated by the human sialidases (Gadhoum and Sackstein, 2008).  
There are some other specific sialidases found to exhibit some unique properties that 
are different from all hydrolytic sialidases described above. Trypanosoma cruzi (T. 
cruzi) trans-sialidase (TcTS), for example, can also catalyze the transfer of terminal 
sialic acid residues from the host cell glycoconjugates to the parasite’s own surface 
carbohydrate acceptors. Since trypanosomes do not synthesize sialic acid, this specific 
decoration with host sialic acid by TcTS might protect the protozoan parasite from the 
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host immune system (Haselhorst et al., 2004). The trans-sialidases are also seen in 
other trypanosome species, except Trypanosoma rangeli (T. rangeli). T. rangeli 
sialidase (TrSA) shares 70% sequence identity with TcTS, but does not exhibit any 
trans-sialidase activity (Buschiazzo et al., 2000). In addition, the sialidase L (NanL) 
from the North American leech Macrobdella decora (M. decora) belongs to the 
intramolecular (IT) trans-sialidase subfamily, which produces 2,7-anhydro-N-
acetylneuraminic acid (2,7-anhydro-Neu5Ac or Neu2,7-anhydro5Ac) rather than N-
acetylneuraminic acid (Neu5Ac or NANA) from the sialylated substrates (Chou et al., 
1994; Li et al., 1990). The different sialic acid related carbohydrates are detailed in the 
next section. Distinct from any other sialidases characterized to date, the Arthobacter 
ureafaciens (A. ureafaciens) enzyme is the only sialidase that was reported to be able 
to cleave the internal sialic acid residue from gangliotetraoses (Iwamori et al., 1997). 
There is also an unusual type of sialidase called endo-N-acylneuraminidase (endo-
sialidase or endo-N), identified from bacteriophages, which specifically degrades the 
poly α2,8-sialic acid (polySia, or PSA) from PSA-shielded bacteria, such as 
Escherichia coli (E. coli) K1 strain (Petter and Vimr, 1993).    
It is not difficult to notice that the sialidases discussed above are mainly based on the 
classifications of their origins or the functional properties. An incomplete phylogenetic 
sequence tree of some members in the sialidase superfamily is shown in Figure 1.1, 
which is obtained from the Conserved Domain Database (CDD) search engine 
(Marchler-Bauer et al., 2007). In the dendrogram, the distance between the different 
sialidases represents the level of sequence or evolutional similarity. Therefore, 
sialidases from viruses, bacteriophage, bacteria or mammalia origins are in different 
clusters. Similarly, the Carbohydrate-Active Enzymes (CAZy) database, based on the 
sequence similarities, has classified the sialidase superfamily members into different 
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families: most of the bacterial sialidases, the trans-sialidases, the IT trans-sialidase, 
some simple eukaryotic and viral sialidases are grouped into the glycoside hydrolase 
(GH) family 33 (GH-33); whereas the influenza virus NAs and the paramyxovirus 
HNs belong to GH-34 and GH-83 respectively; the bacteriophage endosialidases are 
included in GH-58 (Cantarel et al., 2009).  
There are also other means of sialidase classifications. For instance, according to the 
enzyme molecular weights (MWs), the sialidases can be grouped into two families, the 
large sialidase family of enzymes with MWs over 60 kDa and the small sialidases 
family of smaller enzymes with MWs of about 42 kDa (Roggentin et al., 1993). 
Moreover, in some contexts, the sialidases are defined as calcium-dependent or 
calcium-independent types. In fact, the majority of sialidases are calcium-independent, 
as they do not need any metal ions for their catalysis or thermostability. However, V. 
cholerae sialidase (VcNA) does require the divalent Ca2+ for stimulation of its enzyme 
activity, which can also be inhibited by ethylenediaminetetraacetic acid (EDTA) at 10 
mM (Galen et al., 1992). Another exception is the influenza A and B virus sialidases, 
which can utilize calcium for enhanced thermostability rather than a direct 
participation in the catalysis (Burmeister et al., 1994).  
All these different sialidases constitute a large sialidase superfamily with diverse roles. 
The importance of the sialidases in biology and diseases attracts intensive research 
attentions towards this field. Current findings of sialidases substrate, substrate 
specificity and structures are detailed below in separate sections. 
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Figure 1.1 Dendrogram of members in the sialidase superfamily. Polygenetic tree made with 
CDTree with the sialidase entry (No. cd00260) from the CDD database. Not all sialidases are included 
in this figure according to SWISS-PROT database. The GenInfo Identifier (GI) number (or PDB code) 
and the species name of individual sialidases are shown.  
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1.2 Sialic acids, the sialidase substrate.  
Sialic acids are a group of nine-carbon carboxylated sugars that are widespread on cell 
surfaces in animal tissues (Schauer, 1982). With natural modifications at C-4, C-5, C-
7, C-8 and C-9 positions of the nine-carbon skeleton, there have been more than 50 
different sialic acids identified so far (Figure 1.2). Such variations make sialic acids the 
most diverse naturally occurring sugars (Varki, 2008).  
Neu5Ac is the most abundant sialic acid; therefore, the term “sialic acid” often refers 
to Neu5Ac. Other common ones include N-glycolylneuraminic acid (Neu5Gc) and 2-
keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN). In particular, Neu5Ac and 
KDN are the metabolic precursors of all known sialic acids (Faillard, 1989). In 
general, the sugar ring of the sialic acids adopts a 2C5 conformation; while the 
sidechains, including the C-5 moiety, are arranged at the equatorial position. When 
dissolved in water, 98% of the free sialic acids appear in the energy favourable β-
configuration, and only 2% remains in the α-anomeric configuration (Wong, 2003).   
 
 
Figure 1.2 Diversity of the sialic acids with modifications at indicated positions. The nine carbon 
atoms were labelled in this sialic acid backbone shown in the α-anomeric configuration. Based on the 
most common Neu5Ac, Neu5Gc and KDN, one or more substitutions with acetyl (Ac), methyl (Me), 
lactyl (Lt), phosphate (PO3H2) or sulfate groups can occur at R4, 7, 8, 9 positions in nature. The 
molecules were drawn with ChemDraw (Li et al., 2004) 
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Neu5Ac: R5=NHAc; R4,7,8,9=H
Neu5Gc: R5=NHGc; R4,7,8,9=H
KDN: R5=OH; R4,7,8,9=H
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Free sialic acids in unsaturated and anhydro forms also exist in nature, which include 
2-deoxy-2,3-didehydro-N-acetylneuraminic acid (Neu5Ac2en, DANA) and Neu2,7-
anhydro5Ac (Figure 1.3). Due to the presence of the C-2 to C-3 double bond, 
Neu5Ac2en exhibits a half-chair conformation, which is more flattened than the 
Neu5Ac 2C5 ring. The Neu5Ac2en molecule mimics the transition state in the 
hydrolytic reactions catalyzed by sialidases, and thus shows a ubiquitous inhibition to 
many sialidases (Kiefel and von Itzstein, 2002). Neu2,7-anhydro5Ac, however, is a 
long-term intermediate product released in the leech IT trans-sialidase catalysis, with 
no clear functions having been annotated till now (Luo et al., 1999).  
 
 
 
 
 
 
Figure 1.3 The structures of Neu5Ac2en (a) and Neu2,7-anhydro5Ac (b). Neu5Ac2en, Formula 
C11H17NO8; MW: 291.255 g/mol; Neu2,7-anhydro5Ac, Formula: C11H17NO8; MW: 291.255 g/mol. 
 
 
In nature, free sialic acid molecules only occupy up to 3% of the total sialic acids and 
derivatives detected in higher animal cells, where the majority are observed in the α-
glycosidically linked form with other carbohydrates (Varki and Varki, 2007). 
Typically, Neu5Ac can form α2,3 linkages to galactose (Gal), N-acetylgalactosamine 
(GalNAc) and N-acetylglucosamine (GlcNAc), or α2,6 linkages to Gal and GalNAc, 
or α2,8 linkages to other sialic acids (Figure 1.4). These three different linkages are the 
main configurations in the Neu5Ac-containing sialosides. In the oligosaccharides on 
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human erythrocytes, sialic acids with the α2,3, α2,6 and α2,8 linkages can all be 
detected. It is reported that the α2,3-linked sialiosides are more abundant than the 
α2,6-linkages in the apical membrane of epithelial cells (Ulloa and Real, 2001). The 
α2,8-linked sialic acids polymers are also found in gangliosides and in glycoproteins 
of neural tissues (Schauer, 1982), and on the surface of some specific bacteria, such as 
the E. coli K1 strain (Kleene and Schachner, 2004). Such a wide distribution of the 
sialiosides in different organisms could make the mammalian immune systems less 
sensitive to those microbes with sialylated decorations (Jodar et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The most common linkages of Neu5Ac to other carbohydrates. (a) The α2,3-linkages of 
Neu5Ac to Gal, GalNAc or GlcNAc; (b) the α2,6-linkages of Neu5Ac to Gal or GalNAc; (c) the α2,8-
linkages of Neu5Ac polymers. 
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Sialic acids present some unique physiochemical properties, such as its high 
hydrophilicity, strong negative charge and high structural diversities. These properties 
may contribute to their multiple functions in vivo. For example, high concentrations of 
the various highly soluble sialic acids are found in human brain and also in human 
milk, where they are thought to have some specific roles in neural transmission and 
infant nutrition (Wang and Brand-Miller, 2003). The negative charge of sialic acids 
present on the cell surfaces could provide some electrostatic repulsive force between 
the circulating blood cells (Izumida et al., 1991). In addition, it is also believed that 
sialic acids mediate a variety of biological functions, including glycans and 
membranes stabilization, receptor and anti-recognition functions, binding and transport 
of ions and drugs or protecting glycoproteins and cells etc. (Varki, 2008). Nonetheless, 
being the sialidase substrates, most of such wide-ranging functions of sialic acids could 
be directly affected by the sialidase actions as aforementioned in the previous section. 
?
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1.3 Sialidase activity assays and the substrate specificity of sialidases 
A variety of techniques are available for the sialidase activity assays. The classic 
method of measuring the released Neu5Ac by sialidases is the thiobarbituric acid 
(TBA) assay; free sialic acid reacts with the TBA reagent to show a red colour, with 
specific optical density measurable at 549 nm (Aminoff, 1961; Warren, 1959). Thin 
layer chromatography (TLC) is yet another easily-applicable choice to separate 
different reaction products, and the released sialic acids can be visualized on a plate by 
resorcinol or diphenylamine reagents (Chou et al., 1994). Both TBA and TLC methods 
are still widely employed for the sialidase substrate specificity assay today.  
The artificial substrate 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-
MU-Neu5Ac, MUAN) is ubiquitously used in the sialidase activity assays (Myers et 
al., 1980). Almost all sialidases reported to date are able to cleave this compound. The 
α-glycosidical linkage of MUAN can be hydrolyzed by sialidases promptly to release 
two products: Neu5Ac and 4-methylumbelliferyl (4-MU), the latter product shows 
fluorescence at 365/450 nm (excitation/emission). An alternative compound is 2-O-(p-
nitrophenyl)-N-acetylneuraminic acid (pNP-Neu5Ac), the leaving group (PNP) of 
which appears yellow under alkaline conditions and can be measured at 405 nm. Other 
techniques rarely used are not discussed here.?
 
 
 
Figure 1.5 The structures of MUAN and PNP-Neu5Ac. (a) MUAN, Formula: C21H24NNaO11; MW: 
489.41 g/mol; (b) PNP-Neu5Ac, Formula: C17H22N2O11; MW: 430.36 g/mol. 
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Almost all sialidases characterized thus far are able to process α2,3-linked sialylated 
substrates (Corfield, 1992). However, different sialidases usually present disparate 
preferences towards the sialylated substrates with α2,6- or α2,8-linkages. It has been 
shown that trypanosome sialidases TcTS, TrSA and the leech IT trans-sialidase NanL 
have very strict substrate specificity towards α2,3-sialylosides and are unable to 
process α2,6- or α2,8- linkages (Buschiazzo et al., 1997; Chou et al., 1994; 
Vandekerckhove et al., 1992). The sialidases from the avian influenza virus and S. 
tryphimurium were found to hydrolyze the α2,3-linkage sialic acid derivatives much 
faster than the α2,6- substrates (Hoyer et al., 1991; Xu et al., 1993). V. cholerae and C. 
perfringens sialidases present relatively broad substrate specificities in cleaving α2,3-, 
α2,6- and α2,8- bonds, but preferentially hydrolyze the α2,3-linkage of sialiosides 
(Corfield et al., 1983). In contrast, the sialidase from A. ureafaciens cleaves the α2,6- 
and α2,8- linkages more efficiently than α2,3-linked substrates (Christensen and 
Egebjerg, 2005). Additionally, the two sialidases from Bacteroides fragilis (B. fragilis) 
SBT3182 hydrolyze α2,8-linkage about two times faster than α2,3 or α2,6 bonds 
(Tanaka et al., 1992, 1994). The bacteriophage endosialidase is very unique, and only 
specifically cleaves the α2,8 linkages of PSA (Petter and Vimr, 1993).  
Although no direct relationship between the substrate specificities and the sialidase 
functions in vivo has been firmly established, it is still important to characterize the 
sialidases with the different substrates in enzymatic studies by TBA assay or TLC 
method. 
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1.4 Structural features of the sialidases 
The first three-dimensional structure of a sialidase, determined over two decades ago, 
was the 2.9 Å crystal structure of the influenza virus sialidase. This structure revealed 
a tetrameric assembly of four identical monomers; each monomer presents a six-bladed 
β-propeller fold (Colman et al., 1983; Varghese et al., 1983). This fold was 
subsequently shown to be well-conserved with the elucidation of increasing numbers 
of crystal structures of sialidases from viruses, bacteria, trypanosome, leech and man. 
All currently published sialidase structures are listed in Table 1.1.  
Type Organism Label  PDB code Reference 
Viral NA group-1 Influenza A N1 2HTY (Russell et al., 2006) 
Viral NA group-2 Influenza A N2 1ING (Singh et al., 1995) 
Viral NA group-1 Influenza A N4 2HTW (Russell et al., 2006) 
Viral NA group-2 Influenza A N6 1V0Z Unpublished 
Viral NA group-1 Influenza A N8 2HT5 (Russell et al., 2006) 
Viral NA group-2 Influenza A N9 1NNA (Bossart-Whitaker et al., 1993) 
Viral NA Influenza B NA 1NSC (Burmeister et al., 1993) 
Viral HN NDV HN 1E8T (Crennell et al., 2000) 
Viral HN Parainfluenza HN 1V2I (Lawrence et al., 2004) 
Viral HN SV5 HN 1Z4Y (Yuan et al., 2005) 
IT trans-sialidase  M. decora NanL 1SLL (Luo et al., 1998) 
trans-sialidase T. cruzi TcTS 1MS4 (Buschiazzo et al., 2002) 
Parasite SA T. rangeli TrSA 1N1S (Amaya et al., 2003) 
Human sialidase H. sapiens NEU2 1SNT (Chavas et al., 2005) 
Bacterial sialidase V. cholerae VcNA 1KIT (Crennell et al., 1994) 
Bacterial sialidase S. typhimurium StNA 2SIL (Crennell et al., 1993) 
Bacterial sialidase C. perfringens NanI 2BF6 (Newstead et al., 2008) 
Bacterial sialidase M. viridifaciens Large 1EUT (Gaskell et al., 1995) 
Bacterial sialidase M. viridifaciens Small 1EUR (Gaskell et al., 1995) 
Endosialidase Phage ΦK1F endo-N 1V0E (Stummeyer et al., 2005) 
 
Table 1.1 List of currently published sialidase structures from various origins. 
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In fact, the sequence identity between viral sialidases and the non-viral sialidases is 
only 15% to 35%, but the β-propeller fold topology of the catalytic domain (~42 kDa) 
is highly conserved in the sialidase superfamily. As is shown in Figure 1.6a, the 
sialidase β-propeller fold consists of six antiparallel β-sheets packing around the six-
fold pseudo-symmetry axis. Each sheet contains four β strands and the fourth strand 
connects to the first strand of its adjacent sheet by a coil element. The N-terminal 
region of the sialidase domain always forms the fourth strand of the sixth β sheet, 
which therefore encloses the whole canonical sialidase fold. The sialidase active sites 
were mapped with the complex structure with Neu5Ac2en, a transition-state analogue 
ligand. It has been found that the active site is also conserved in sialidases with a very 
rigid catalytic cleft in the center of the β-propeller structure (Taylor, 1996).  
In addition, there are two common features for most of the non-viral sialidases, one is 
the RIP/RLP (Arg-Ile/Leu-Pro) motif (REP in viral enzymes), and the other is the Asp-
box motif described as “Ser/Thr-X-Asp-X-Gly-X-Thr-Trp/Phe” (where “X” represents 
any amino acid) (Roggentin et al., 1989). The RIP/RLP motif contains a conserved 
arginine residue related to the substrate stabilization. In contrast, the Asp boxes are 
always remote from the sialidase active site and unlikely participate in the catalysis 
directly. This motif always recurs one to five times along the bacterial sialidase 
sequences and is therefore known as the bacterial neuraminidase repeat (BNR). In 
addition to the bacterial sialidases, the trypanosome trans-sialidase, human sialidase 
and endo-sialidase sequences also possess the Asp-box motifs. In fact, Asp boxes 
normally appear to be conserved β-hairpin turns between the third and fourth strand of 
the β-sheets, which might help maintain the repeating β-sheet conformation of the β-
propeller fold. However, the sialidase-like Asp-box motifs are also found in at least 9 
protein families in addition to the sialidases, which may indicate that this motif is 
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linked to a common function, instead of a sialidase-specific role (Copley et al., 2001). 
The positions of Asp-box motifs in sialidase structures are highlighted in Figure 1.6b 
with dashed rectangle boxes. 
 
 
Figure 1.6 The sialidase six-bladed β-propeller fold. (a) The cartoon presentation of the sialidase 
catalytic domain, which consists of six β-antiparallel sheets packing around the six-fold pseudo-
symmetric axis. The sialidase active site is located in the centre of the β-propeller fold. This picture was 
made with Pymol (http://pymol.sourceforge.net/) using MvNA structure (PDB code: 1EUR); (b) a 
schematic view of the sialidase fold, each sheet contains four β strands and the fourth strand connects to 
the first strand of its adjacent sheet. The N-terminal region of the sialidase domain forms the fourth 
strand of the sixth β sheet. The Asp-box positions of non-viral sialidases are also indicated. 
 
 
The viral sialidases (NAs and HNs) are membrane-associated tetramers of repeating β-
propeller subunits (Air and Laver, 1989; Crennell et al., 2000). The bacteriophage 
endosialidase exists as a unique trimer of three multi-domain monomers, with the core 
sialidase fold flanked by two extended domains (Stummeyer et al., 2005). Most of the 
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non-viral sialidases appear to be secreted monomeric enzymes, although there are few 
sialidases found as surface-attached proteins, such as S. pneumoniae NanA (Camara et 
al., 1994) and the trans-sialidase TcTS (Agusti et al., 1997). The MWs of non-viral 
sialidases also vary significantly, ranging from 42 kDa to over 100 kDa. Large 
sialidases over 60 kDa often exhibit multi-domain architecture, having one or two 
additional domains described as lectins or carbohydrate binding modules (CBMs). 
VcNA, for instance, has the catalytic domain flanked by two CBM domains and the N-
terminal one is designated as CBM family 40 domain (CBM40) that binds to sialic 
acid (Crennell et al., 1994; Moustafa et al., 2004); the M. viridifaciens sialidase 
(MvNA) possesses a C-terminal galactose-binding domain (Gaskell et al., 1995; 
Newstead et al., 2005); Both TcTS and TrSA fold into two domains, with a lectin-like 
domain linked to the C-terminus of the sialidase domain (Amaya et al., 2003; 
Buschiazzo et al., 2002); whereas the leech IT trans-sialidase has an N-terminal lectin-
like domain before the core β-propeller fold (Luo et al., 1999). The presence of these 
lectin or CBM domains in the non-viral sialidases could increase the catalytic 
efficiency towards polysaccharides possibly by promoting substrate recognition and 
binding (Thobhani et al., 2003).   
Despite the structural features detailed above, never have two different sialidases, even 
with very high sequence similarity, shown identical active site and biochemical 
properties. A good example is the two groups of sialidases from influenza A virus, 
which are structurally distinct around the active sites and may need different strategies 
for drug discovery (Russell et al., 2006). Moreover, due to the abundant diversity of 
the sialidases and sialic acids, it is still meaningful to perform structural and kinetic 
characterizations towards various sialidases, especially those from pathogenic 
microorganisms.  
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a. The viral sialidases   
 
 
 
 
 
 
             Influenza virus N1 (2HTY)                       Newcastle disease virus HN (1E8T) 
 
b. The phage endo-sialidase                       c. The IT trans-sialidase 
 
 
 
 
 
 
 
           Phage ΦK1F endo-N (1V0E)                        Leech IT trans-sialidase (1SLL) 
 
d. The trans-sialidases                                 e. The human NEU2 sialidase 
 
 
 
 
 
 
       T. cruzi trans-sialidase TcTS (1MS4)                 Human sialidase NEU2 (1SNT)     
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f. The bacterial sialidases 
 
 
 
 
 
 
                V. cholerae sialidase (1KIT)                               S. typhimurium sialidase (2SIL) 
 
 
 
 
 
 
 
        large M. viridifaciens sialidase (1EUT)                     small MvNA (1EUR) 
 
 
 
 
 
 
 
                                                    C. perfringens sialidase (2BF6)  
 
Figure 1.7 The currently available sialidase structures of different origins. The structures were 
arbitrarily grouped into four categories: (a) viral sialidases; (b) phage endosialidase; (c) IT trans-
sialidase; (d) trans-sialidase; (e) human sialidase and (f) bacterial sialidases. 
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1.5 The proposed catalytic mechanisms for the sialidases 
Although the sequence similarities between enzymes in this superfamily are relatively 
low, all sialidases still possess a common distribution pattern of several conserved 
residues around the active site, many of which are directly involved in the catalysis. 
These include three arginine residues that stabilize the carboxylate group of sialic 
acids, a tyrosine residue acting as the nucleophile and its associated glutamic acid, as 
well as an aspartic acid for acid/base catalyst roles. In addition, there is a hydrophobic 
pocket accommodating the C-5 acetamido group, which is also conserved in all 
sialidases, despite the fact that the residues forming this pocket vary significantly 
(Taylor, 1996).?
With the knowledge of the various sialidase structures in complex with ligands, 
particularly the complex structures of Neu5Ac in a boat conformation and the 
transition-state analogue Neu5Ac2en in a half-chair conformation, determination of the 
precise molecular mechanisms of sialidase catalysis is on the horizon. These findings 
led to the original proposal of a generalized two-step mechanism that involved the 
formation of an oxocarbonium ion intermediate (Burmeister et al., 1993; Buschiazzo et 
al., 2000; Luo et al., 1998; Luo et al., 1999). As shown in Figure 1.8, the pyranose ring 
conformation of the sialic acid residue in the sialiosides is distorted from a chair (2C5) 
conformation to a boat (B2,5) upon binding to the active site of sialidases, which is the 
first step of the catalysis. The main forces that lead to the distortion of the sugar ring 
are believed to be the strong interactions between the arginine triad of the sialidase and 
the carboxylate groups of the Neu5Ac residue, together with the interactions between 
the hydrophobic pocket of the enzyme with the acetamido group of sialic acid. The 
conserved tyrosine and the associated glutamic acid residues are postulated to form a 
charge relay, which allows the tyrosine to act as the nucleophile. The conserved 
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aspartic acid is thought to act as a general acid catalyst, which facilitates the cleavage 
of the α-glycosidic bond of sialiosides. The O-2 atom of leaving group aglycon R is 
able to acquire a proton stabilized by the aspartic acid. In step (b), the formation of a 
sialyl cation (oxocarbonium ion) intermediate adopts a half-chair conformation (4H5), 
which is mimicked by Neu5Ac2en (previously shown in Figure 1.3a); the deprotonated 
tyrosine residue beneath the C-2 atom would stabilize the positive charge on this 
oxocarbonium ion. It has been hypothesized that such a proposed two-step mechanism 
was shared by all sialidases (Buschiazzo et al., 2000; Luo et al., 1999).  
In fact, the following reactions after the formation of oxocarbonium ion transition state 
are disparate in different types of sialidases. For the classic hydrolytic sialidases, a 
water molecule facilitated by the acid/base aspartic acid catalyst as the nucleophile 
attacks the positive charge on C-2 of the sialyl cation, resulting in the production of α-
Neu5Ac as the first product; α-Neu5Ac then mutarotates to β-Neu5Ac, a 
thermodynamically more favourable anomer (Burmeister et al., 1993; Chong et al., 
1992). The trans-sialidases, in contrast, could undergo a substrate-triggered 
conformational switch upon sialic acid binding, which allows the sialic acid acceptor, 
such as β-Gal, to be located at a favourable position, with its hydroxyl group 
performing the nucleophilic attack to the oxocarbonium ion and fulfil the sialic acid 
residue transfer (Buschiazzo et al., 2002). In the IT trans-sialidase NanL, structural 
variations of the ligand binding pocket might force the 6-glycerol group of the sialyl 
cation to adopt an axial configuration, which therefore makes the C-7 hydroxyl close 
enough to attack at the C-2 atom (Luo et al., 1998). After the nucleophilic attack, the 
proton of the C-7 hydroxyl group is acquired by the aspartic acid and subsequently 
released to the solvent (Luo et al., 1999).  
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Figure 1.8 The originally generalized two-step catalytic mechanism for sialidases. In step (b), the 
nucleophile is labelled as HOR’, which could be water, hydroxyl of Neu5Ac or β-Gal in different types 
of sialidases.  
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However, this two-step mechanism does not preclude the possibility that sialidases 
might also operate via a covalent intermediate, as seen in some other retaining 
glycosidases (Rye and Withers, 2000). To investigate this, a covalent-forming 
compound 2,3-difluoro-N-acetylneuraminic acid (2, 3F-Neu5Ac, Figure 1.9) was 
synthesized and subsequently introduced into the sialidase crystallographic studies. 
This compound was found to be able to form a sialyl-enzyme covalent intermediate on 
the conserved tyrosine residue of the trans-sialidase TcTS and the bacterial sialidase C. 
perfringens NanI (Amaya et al., 2004; Newstead et al., 2008; Watts et al., 2003). 
Therefore, the tyrosine residue beneath C-2 position is believed to be the nucleophile 
and all exo-sialidases might adopt the similar catalytic mechanism through the 
formation of a covalent intermediate sialylated enzyme. In combination with all 
previous findings, a more comprehensive five-step mechanism was recently proposed, 
which suggests that the sialidase reactions might all proceed through a catalytic cycle 
of two transition states and a covalent intermediate stage in between (von Itzstein, 
2007). As is shown in Figure 1.10, sialic acid substrate binds in a B2,5 conformation and 
then moves through the first transition state in 4H5 conformation, and then to a covalent 
intermediate in a chair 2C5 conformation. The product formation step (Figure 1.10d) is 
identical to step (b) aforementioned above in the generalized two-step mechanism.  
Despite these insights, further clarification of the sialidase mechanism is still 
necessary. In Chapter 3 of the thesis, the studies of S. pneumoniae NanA and NanB 
add further support to the currently proposed mechanism; however, NanC is found to 
be a unique sialidase that catalyzes multiple reactions. In Chapter 5, a novel charge 
relay system taking the acid/base catalyst role in P. aeruginosa enzyme was identified.  
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Figure 1.9 The structure of the covalent-forming compound 2, 3F-Neu5Ac. Formula: C11H17F2NO8; 
MW: 330.26 g/mol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 The currently proposed mechanism for sialidase catalysis. Modified from a previously 
published enzymatic mechanism of influenza virus NAs (von Itzstein, 2007). 
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1.6 The S. pneumoniae sialidases NanA, NanB and NanC 
S. pneumoniae is a Gram-positive, alpha-haemolytic bacterium that belongs to the 
Bacillus/Lactobacillus/Streptococcus group that also includes Staphylococcus aureus. 
Being a major human pathogen, this bacterium is responsible for numerous cases of 
pneumonia, otitis media (OM), septicaemia and meningitis (Tuomanen, 2004). Today, 
the broad-spectrum antibiotic treatments for pneumococcal infections are increasingly 
unsuccessful with the emergence of many drug-resistant strains. In the US, 
approximately one third of the S. pneumoniae clinical isolates are resistant to penicillin 
and this bacterium continues to be a top-ten cause of human death (Thornsberry et al., 
1999). Worldwide, S. pneumoniae causes over 1 million deaths each year (Williams et 
al., 2002). Normally, a clinical infection of S. pneumoniae is preceded by the bacterial 
colonization in the upper respiratory tract, predominantly in the nasopharynx. It has 
been reported that about 40% of healthy people are asymptomatic carriers, which 
significantly increases the incidence of pneumococcal infections (Bogaert et al., 2004). 
There are multivalent capsular polysaccharide vaccines available for pneumococcal 
disease, but their efficacy in certain high-risk groups has been questioned (Kadioglu et 
al., 2008), including an inability to induce protective antibody responses in children 
under the age of two (Butler et al., 1993). A search is therefore on for new drug and 
vaccine candidates for pneumococcal diseases.  
The successful sequencing of the S. pneumoniae genome identified a number of genes 
encoding proteins for virulent roles or as protective antigens (Tettelin et al., 2001). 
Among the several virulence factors that contribute to the pneumococcal colonization 
and early infection processes, sialidases are of great importance (Jedrzejas, 2001). 
Sialidases specifically catalyze the removal of sialic acid from various cell-surface 
glycoconjugates; such actions might cause damage to host cells and unmask some 
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receptors for bacterial adherence and colonization. All S. pneumoniae clinical isolates 
investigated to date present prominent sialidase activity (Mitchell, 2000). 
It is found that S. pneumoniae expresses three distinct sialidases, designated as NanA, 
NanB and NanC respectively. In a gene screening study, nanA gene is found in all 342 
clinical isolates; while nanB and nanC genes are relatively less prevalent, and were 
identified in 96% and 51% of these strains respectively (Pettigrew et al., 2006). Gene 
knockout experiments in the MF1 mouse models suggest that both NanA and NanB 
sialidases are essential to S. pneumoniae infection of the respiratory tract and sepsis 
(Manco et al., 2006). Moreover, NanA has been shown to play an important role in S. 
pneumoniae long-term nasopharynx and middle ear colonization and may act as a 
protective antigen (Long et al., 2004; Simell et al., 2006). A recent study also showed 
that sialic acid, the cleavage product of sialidase catalysis, is vital for S. pneumoniae 
biofilm formation and translocation to host lung (Trappetti et al., 2009). All these 
findings strongly suggest that S. pneumoniae sialidases are essential in virulence and 
good targets for novel drug design or vaccine development.  
Unlike NanB and NanC, NanA shows some amino acid sequence diversity between S. 
pneumoniae strains, mainly in the C-terminal regions (King et al., 2005). Some clones, 
such as S. pneumoniae serotype 14, were found to express a shorter version of NanA, 
which lacks part of the C-terminal sequence compared to that of the 1035-residue 
NanA from strains R36A, R6 or D39 (Dowson et al., 1993). In fact, the sialidase 
activity of NanA was not affected by the 200 residues at the C-terminus (Lock et al., 
1988). No evidence has been obtained to confirm if the sequence diversity of NanA is 
associated with pneumococcal virulence. However, to investigate the detail of full-
length NanA, the sequence of S. pneumoniae R36A NanA enzyme was used in the 
following context.  
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The three sialidases NanA, NanB and NanC are 115kDa, 78kDa and 82kDa in size 
respectively. Interestingly, NanA and NanB only share very limited similarity in their 
amino acid sequences (up to 24%); whereas NanC is a close homolog of NanB with 
over 50% sequence identity. Sequence analysis shows that the N-terminal signal 
peptide is present in all the three sialidases, which may direct their secretion to the 
outside of cells. However, only NanA is a surface-anchored protein due to the presence 
of an “LPTEG” anchoring motif; this protein also possesses a C-terminal P/G-, T/S-
rich region that is predicted to be naturally disordered, which might provide NanA 
some flexibility when fixed on the cell wall of pneumococci (Camara et al., 1994). 
Similar to some other large sialidases, all the three S. pneumoniae sialidases have the 
CBM40 domain upstream of the catalytic domain. Within the catalytic domain, the 
RIP motif containing a catalytic arginine, as well as four repeating Asp-box motifs, is 
conserved in NanA, NanB and NanC at similar positions of the whole sequence 
(Figure1.11). Both motifs are the signature of bacterial sialidases.  
?
 
 
 
 
 
 
 
Figure 1.11 Schematic views of the three S. pneumoniae sialidases. The sequences of NanA (UniProt 
accession number: P62575), NanB (Q54727) and NanC (Q97Q99) were annotated via bioinformatics 
searches. CBM40 domain and catalytic domain are coloured in red and blue respectively. 
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However, little is known about the conformation and detailed molecular mechanisms 
of S. pneumoniae NanA, NanB and NanC, and even the fundamental question of why 
this bacterium encodes three distinct versions of sialidases is unsolved. The lack of this 
information significantly handicaps the development of novel anti-pneumococci drugs 
or vaccine. Therefore, we embarked upon structural studies of NanA, NanB and NanC 
to gain useful insights to S. pneumoniae pathogenesis.  
The first crystal structure of an S. pneumoniae sialidase was the NanB structure solved 
in my previous MRes project, which has been deposited into the PDB recently (PDB 
code: 2VW0). The structure was determined by molecular replacement (MR) using the 
IT trans-sialidase (PDB code: 1SLL) NanL from M. decora as the search model. These 
two proteins share 43% sequence identity and high structural similarity with an r.m.s.d. 
of 1.49Å over 630 Cα atoms. NanB adopts a multi-domain monomeric architecture 
(Figure 1.12 a, b). The six-bladed catalytic domain of NanB (residues 225-696 
excluding residues 358-454) is linked to the N-terminal CBM40 domain (residues 42-
224). The CBM40 domain is thought to recognize and bind sialic acids as seen in 
VcNA (Moustafa et al., 2004). Residues 358-454 form an additional domain inserted 
between the second and third strands of the second sheet. No role for the inserted 
domain has been annotated so far. This type of inserted segment is seen in the three S. 
pneumoniae sialidases, C. perfringens NanI (PDB code: 2BF6) and the leech NanL. 
Moreover, the electrostatic potential of NanB is distinctly asymmetric. The surface 
charge around the active site is mainly positive, which might promote the binding of 
anionic sialiosides to NanB. Accordingly, the opposite face is negative charged to 
prevent misdirected binding of ligands (Fig 1.12 c, d). In brief, such conformational 
and electrostatic features of NanB may facilitate its substrate binding and processing.  
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Further characterisation of NanB structural and kinetic properties, as well as 
corresponding studies towards NanA and NanC, are detailed later in Chapter 3 and 
Chapter 4. 
 
 
  
 
Figure 1.12 The crystal structure of S. pneumoniae NanB. (a and b) Orthogonal view of the crystal 
structure of NanB. The PDB code of apo-form NanB structure is 2VW0. 658 residues (residue 39 to 
696) of NanB sequence are visible in the final crystal structure. The CBM40 domain (residue 42 to 224) 
is shown in dark yellow, the sialidase domain (residue 225 to 357 and 455 to 697) is shown in red and 
the inserted domain (residue 358 to 454) is shown in green; (c and d) the solvent-accessible surface of 
NanB coloured based on the electrostatic potential from - 7 to + 7 kT/e, calculated using the APBS tool 
(Baker et al., 2001).  
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Since NanB has high sequence and structural similarity to the leech sialidase NanL, it 
therefore may also act as an IT trans-sialidase. Being a close homology of NanB, the 
third pneumococcal sialidase NanC might further facilitate the actions of NanB, albeit 
very limited findings having been reported. NanA, however, being a cell wall-tethered 
large sialidase, possibly has some similar roles to other surface-exposed sialidases, 
such viral sialidases. Thus, it is proposed that S. pneumoniae expresses several forms 
of sialidases to perform disparate functional preferences in different circumstances, 
which is important during various stages of a complete colonization or infection 
process due to the change of environments in the host.  
This proposed cooperative working pattern might significantly extend and magnify the 
sialidase actions in S. pneumoniae pathogenesis. Despite this, there is still some 
ambiguity regarding what the actual similarities/differences in their real conformations 
are and how NanA, NanB and NanC perform during an infection. Crystal structures 
and kinetic studies of S. pneumoniae sialidases are expected to help elucidate these 
problems and provide a platform for drug design, which are the main goals in the 
current research. 
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1.7 The putative sialidase from P. aeruginosa  
P. aeruginosa is an aerobic, Gram-negative bacterium that can live in almost all kinds 
of naturally aqueous environments, primarily in water, soil, insect and vegetation. This 
bacterium is a ubiquitous opportunistic pathogen to plant, animal and human beings 
(Fick, 1993). In recent years, P. aeruginosa is becoming more and more prevalent in 
hospital-acquired infections and accounts for about 16% of all nosocomial pneumonia 
cases (Mesaros et al., 2007). It is also the leading cause of respiratory infections with 
higher antibiotic resistance rate in cystic fibrosis (CF) patients (Lambert, 2002; Oliver 
et al., 2000). With those immune-comprised individuals, P. aeruginosa usually causes 
serious infections of high mortality (Vila-Corcoles et al., 2008). Normally, the initial 
step of a P. aeruginosa infection is the adherence and colonization to the mucosal 
tissues. The bacterial adherence to the epithelium cells is supposed to be mediated by 
the type four pili, as well as the flagella, the key machinery for P. aeruginosa motility 
in the planktonic form (Baltch and Smith, 1994). When the bacterium colonizes in the 
host, it forms biofilm for persistent resistance to the host immune defences and 
antimicrobial therapies (Whiteley et al., 2001).  
It was reported that a P. aeruginosa hypothetical protein (PA2794) is directly involved 
in the adherence and chronic colonization of P. aeruginosa to the respiratory epithelial 
cells in CF, as well as the biofilm formation process in the host (Soong et al., 2006). 
Such specific functions are similar to that of the sialidases in S. pneumoniae 
pathogenesis in some sense. Sequence analysis showed that PA2794 possesses three 
Asp-box motifs (Figure 1.13a), this protein was therefore annotated as sialidase 
(Cacalano et al., 1992; Leprat and Michel-Briand, 1980; Soong et al., 2006). However, 
the sequence does not contain an RI/LP motif, another signature of bacterial sialidases. 
The protein fold recognition program Phyre (Bennett-Lovsey et al., 2008) predicts that 
  31 
PaNA would present a six-bladed β-propeller fold, although it only shares up to 14% 
sequence identity with other sialidases (Figure 1.13b). In the current context, we 
designated the P. aeruginosa sialidase as PaNA.  
 
 
 
Figure 1.13 Sequence analysis and structure prediction of PaNA. (a) The sequence of PaNA 
includes three BNR motifs (Asp boxes), which were shaded with Red; (b) the top two solutions 
predicted by Phyre program with PaNA sequence show 100% estimated precision of a sialidase fold. 
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In several different P. aeruginosa strains, such as PAO1, PA14 and C3719 strains, the 
amino acid sequences of PaNA are found to be identical. A gene screening study of 
162 P. aeruginosa isolates from the CF patients also unveiled several highly conserved 
virulent proteins including PaNA (Lanotte et al., 2004). Very interestingly, the 
hyperosmolar conditions existing in CF lungs could even up-regulate PaNA expression 
(Cacalano et al., 1992). All such findings suggest that this conserved enzyme in P. 
aeruginosa could be a potential therapeutic target.  
Different from many other pathogenic bacteria, P. aeruginosa does not utilize sialic 
acid as a source of energy or as a component of the biofilm (Wozniak et al., 2003). 
Thus, it is quite ambiguous why P. aeruginosa expresses a putative sialidase PaNA. A 
good presumption is that the real substrate for PaNA is not the sialic acid, but actually 
something else essential in the P. aeruginosa pathogenesis. Researchers have 
postulated that pseudaminic acid (5,7-diamino-3,5,7,9-tetradeoxy L-glycero-L-manno-
nonulosonic acid, or Pse5Ac7Ac), a 9-carbon sugar superficially similar to sialic acid 
(Figure 1.14), could be the substrate specifically recognized by PaNA (Soong et al., 
2006). However, there is currently no confirmation that pseudaminic acid exists in the 
biofilm of P. aeruginosa or that PaNA regulates this carbohydrate. Pseudaminic acid 
was first identified in the lipopolysaccharides (LPS) of P. aeruginosa (Knirel et al., 
1984a; Knirel et al., 1984b). The biosynthetic pathway of pseudaminic acid and its 
nucleotide-activated form cytidine-5'-monophosphate (CMP)-Pse5Ac7Ac has also 
been characterized (Schoenhofen et al., 2006a; Schoenhofen et al., 2006b). Compared 
to Neu5Ac, Pse5Ac7Ac has different stereochemistry at the C-5, C-7 and C-8 positions 
(Figure 1.14). Such significant structural variations might lead to disparate 
biochemical properties of the two carbohydrates. 
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Figure 1.14 The Structures of (a) sialic acid (Neu5Ac) and (b) pseudaminic acid (Pse5Ac7Ac). 
Neu5Ac and Pse5Ac7Ac have significant differences in stereochemistry at C-5, C-7 and C-8 positions. 
 
In addition to LPS, pseudaminic acid has been identified from components of the pili 
and flagellin of P. aeruginosa strains (Comer et al., 2002; Rocchetta et al., 1999). Also 
in the P. aeruginosa strain 1244, the glycan of pilin proteins contains an unusual 
serine-linked tri-saccharide, with hydroxybutyryl-formyl-pseudaminic acid (a 
Pse5Ac7Ac analogue) linked to xylose and N-acetyl-fucosamine (Castric et al., 2001). 
In fact, pseudaminic acid was found to be the major decoration on the flagellins of 
Campylobacter (Goon et al., 2003). Without proper glycosylation, the assembly of 
those functional flagellin filaments would be affected (Abu-Qarn et al., 2008). 
Therefore, if PaNA was the enzyme recognizing and cleaving pseudaminic acid, it 
might also affect the modification of P. aeruginosa pili and flagellin by regulating the 
level of pseudaminic acid in a free or bound form.   
To date, there is only very limited information available about the structure and 
detailed mechanism of PaNA, a major virulence factor of P. aeruginosa. Since PaNA 
shares little sequence identities to any other sialidase, it might present significant 
structural and mechanistic variations in the sialidase superfamily. Therefore, a crystal 
structure and structure-based studies could provide meaningful insights towards the 
understanding of this specific enzyme of P. aeruginosa. 
O
COOH
OH
AcHN
HO
HO
OH
OH
1
2
3
4
5
6
7
8
9
O
COOH
OH
NHAc
HO
H3C
AcHN
OH
1
2
3
4
5
678
a b
!-Neu5Ac !-Pse5Ac7Ac
  34 
1.8 Structure-based drug discovery approaches 
In recent years, the structure-based drug discovery (SBDD) shows promise as a good 
way of developing highly specific drugs with high binding affinity (Blundell et al., 
2002; von Itzstein, 2008b). The high-resolution X-ray crystal structures always provide 
valuable information in SBDD, especially the complex structures of the targeted 
enzymes with potential leading compounds. Based on the structural features, 
modification of a candidate compound framework for a more efficient pattern of 
protein-ligand interactions is feasible. Remarkable examples are the SBDD efforts 
targeting the influenza virus sialidases, which successfully yielded two marketed 
antiviral drugs, Zanamivir (von Itzstein et al., 1993) and Oseltamivir (Kim et al., 
1997). Both drugs were developed on the basis of transition-state analogue Neu5Ac2en 
skeleton (previously shown in Section 1.2) with the crystal structures of influenza virus 
N2 and N9 enzymes, and both show nanomolar-range binding affinity towards the 
viral sialidases (von Itzstein, 2007). 
 
 
 
 
 
 
 
 
Figure 1.15 The structures of Zanamivir and Oseltamivir. (a) Zanamivir (Relenza), formula: 
C12H20N4O7; MW: 332.13 g/mol; (b) Oseltamivir (Tamiflu), formula: C14H24N2O4; MW: 284.35 g/mol. 
Pictures were downloaded from BindingDB (Liu et al., 2007).  
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However, it is not simple to obtain an ideal starting framework for rational drug 
design. One strategy is to use the currently known substrate of the targeted enzyme as 
the initial template. Based on the catalytic mechanism, it is aimed to design new 
compounds with higher binding affinity and lower metabolic speed that mimicks the 
transition state of catalysis, as seen in the case of anti-influenza virus development 
(von Itzstein, 2007, 2008b).  
Another promising strategy is a combinatorial screening of the selected target against 
libraries of small molecules with MWs 100-300 Da (termed as fragments) exhibiting 
relatively high ligand efficiency (Bembenek et al., 2008). The well-recognized criteria 
for the fragment selection is “Rule of Three”: the MW of the fragment should be below 
300Da; the number of hydrogen bond acceptors should not exceed 3 and the cLogP is 
≤ 3 (Congreve et al., 2003). The major advantages of the fragment-based drug 
discovery (FBDD) approach include the fact that the small molecules have high 
structural diversity and significantly reduced structural complexity, and no previous 
knowledge of the catalysis of the targeted enzyme is necessary (Fattori et al., 2008).  
During the past decade, such a fragment-based screening strategy has evolved to a 
working procedure that consists of a variety of techniques used at different stages of 
fragment screening, leads optimisation and validation. These techniques now include 
the fluorescence-based thermal shift assay, saturation transfer difference-nuclear 
magnetic resonance (STD-NMR), isothermal titration calorimetry (ITC), fragment 
cocktail crystallography, enzyme kinetics and some virtual docking techniques (Ciulli 
and Abell, 2007), good combination of these techniques would make the FBDD 
screening more efficient.  
The fluorescence-based thermal shift assay is normally selected for the first-line high-
throughput screening against large libraries, as only about 1-10 µM protein and 1-10 
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mM compounds are used in each 50 µl reaction in a 96-well or 384-well plate. In this 
assay, an environment sensitive fluorescent dye Sypro Orange is used, which binds to 
the gradually exposed hydrophobic region of the protein in a thermal unfolding process 
and shows fluorescence at 490/530 nm. The thermal unfolding curve of fluorescence 
intensity against temperature would give the Tm (midpoint temperature of thermal 
unfolding ramp), a key parameter reflecting the thermostability of the protein. 
Compounds that stabilize the protein for a ΔTm of over 0.5 °C could be considered as 
hits (Lo et al., 2004).  
The hits from the thermal shift assay then could be verified by STD-NMR 
spectroscopy, which could detect the fragments with binding affinities in the 10-3 to 10-
8 M range, even from a substance mixture (Klages et al., 2007). In STD-NMR, a 
selective irradiation is applied to the protein, where efficient saturation could be 
transferred within the protein and to the bound ligand via spin diffusion, resulting a 
detectable difference signal compared to a reference spectrum without on-resonance 
irradiation. This technique also enables the mapping of binding epitopes between the 
ligand and protein (Meyer and Peters, 2003). Being a powerful method in FBDD 
approaches, STD-NMR is widely used in both hits screening and leads validation.  
Once high quality protein crystals were obtained, X-ray crystallography could be the 
most powerful tool for obtaining direct evidence of how the fragments or leading 
compounds bind to the protein. In practice, crystals can be soaked with individual hits 
separately or with cocktails of about 10 fragments from the library, where the final 
concentration of the fragments are normally 50-100 mM, about ten times over the 
binding affinity observed in kinetics (Blundell and Patel, 2004; Jhoti et al., 2007).  
In addition, virtual screening approaches also play a key role in SBDD, enjoying major 
advantages in many aspects like high speed, easy operation, low cost and good 
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predictions. Moreover, the computational docking method is particularly important in 
validating the various designs of novel compounds based on previously leads (Villar 
and Hansen, 2007). Some quantitative methods, such as ITC and enzyme kinetics, are 
also essential in lead validation. A combination of these techniques makes SBDD no 
doubt a reliable way for novel antimicrobial development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16 Schematic view of FBDD strategy. Modified from previously published scheme (Ciulli 
and Abell, 2007; Orita et al., 2008). 
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From the fragments lead-like hits, some different approaches are available for the 
development of drug-like molecules. For instance, the fragment evolution approach 
often refers to building a larger compound with more functional groups based on leads. 
In fact, some fragments could be sub-structure components of a starting skeleton, with 
the linking of two or more fragments at suitable placement in the enzyme active site. A 
third approach is fragment self-assembly, which uses the reactive fragments to form an 
active inhibitor on the protein template. The fragment optimisation is also a common 
way in lead progression, which involves engineering the ADME properties 
(absorption, distribution, metabolism and elimination) of only a particular part rather 
than just binding potency of the leading hit (Alex and Flocco, 2007; Rees et al., 2004). 
Once novel drug-like molecules were obtained, further evaluation and validation using 
the various techniques mentioned above will be carried out to confirm if potent 
inhibitors have been achieved. 
The current projects are aiming to determine the crystal structures of sialidases from S. 
pneumoniae and P. aeruginosa. With the crystals of these targets, FBDD from our 
fragment libraries and SBDD from sialic acid analogues would be feasible. 
Preliminary work of our SBDD efforts is present in Chapter 4. 
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Chapter 2 
 
Crystal structure of the S. pneumoniae NanA catalytic domain in 
complex with Neu5Ac2en   
 
2.1 Summary 
The sialidase NanA is of particular importance in S. pneumoniae pathogenesis. This 
chapter describes the structural studies of S. pneumoniae R36A sialidase NanA. 
Recombinant full-length NanA (1035 residues, ~114 kDa) exhibits prominent sialidase 
activity, but this protein failed to crystallize after rounds of screening. Its catalytic 
domain (designated as CNanA) was therefore subcloned and crystallized. The first X-
ray diffraction dataset was collected to 2.5 Å from a crystal grown in the presence of 
10 mM Neu5Ac2en. With this dataset, the CNanA structure was solved by molecular 
replacement (MR) using the C. perfringens sialidase NanI (PDB code: 2BF6) as the 
search model. Residues 322-791 are visible in the final structure. CNanA exists as a 
dimer in the asymmetric unit of the crystal, with close contacts between the two 
monomers. The apo form structure was determined to 1.5 Å at the synchrotron. 
CNanA shows the characteristic features that are common to all sialidases. The key 
residues that are involved in NanA catalysis were mapped with the complex structure 
with Neu5Ac2en. 
The results obtained in the whole process, from protein expression to structure 
determination, are presented in six sections from Section 2.2 to Section 2.7 below; 
while the detailed experimental procedures are described separately in Appendix I 
Materials and Methods. 
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2.2 Expression and purification of full-length NanA 
Small-scale NanA expression trials in E. coli BL21 (DE3) strain were performed to 
find out the optimal conditions for protein production. Proteins extracted from the 
whole cell lysates and supernatants were kept separately and assessed in a sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel (Figure 2.1). As 
is shown, NanA was solubly expressed after inducing the cells with 1 mM isopropyl 
thio-β-D-galactoside (IPTG), for 3 hr at 37 °C, or overnight at 25 °C. NanA protein 
identity was confirmed by matrix-assisted laser desorption time-of-flight (MALDI-
TOF) mass spectrometry (MS) fingerprint. For a large-scale NanA expression, 3 hr 
induction at 37 °C with 1 mM IPTG was selected for easier operation and about 10 g 
of cell pellets were harvested from 4-liter culture. 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 10% SDS-PAGE gel of proteins samples from NanA expression trials. Proteins 
were extracted from the harvested cells with or without IPTG induction. The whole lysates and soluble 
supernatants were run in different lanes. Con, WL and SN represent control with no IPTG, whole cell 
lysate and supernatant respectively. The red asterisks highlight the over-expressed ~114 kDa NanA.  
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Various techniques were employed in the purification strategy of NanA, which include 
Nickel affinity chromatography (HisTrap), salt precipitation, reactive Red A affinity 
chromatography, anion exchange chromatography and size exclusion chromatography 
(Figure 2.2). Since tobacco etch virus (TEV) protease failed to remove the six-histidine 
(6-His) tag from NanA efficiently, the 6-His affinity tag, together with TEV cleavage 
peptide, remained with the protein after purification. NanA showed extremely high 
solubility and stability in all purification stages. In particular, after precipitation by 
45% (w/v) ammonium sulfate, the insoluble precipitant of NanA could be immediately 
re-dissolved in 20 mM phosphate buffer with no loss of sialidase activity, which was 
monitored throughout the purification by using the fluorogenic substrate MUAN. The 
final yield of high-purity NanA was approximately 25 mg from a 4 L cell culture.  
 
 
 
 
 
 
 
 
 
Figure 2.2 NanA purification monitored by 10% SDS-PAGE. (a) Soluble cell extract (labeled as SN) 
was first applied to the Nickel affinity chromatography (HisTrap). All the bound fractions were then 
pooled for ammonium sulfate precipitation (Salt); re-dissolved NanA was run through Reactive Red-A 
column (Red A) and anion exchange chromatography (Anion) respectively; (b) The final purification 
step used was gel filtration to obtain pure NanA. 
 SN HisTrap   Salt      Red A   Anion                       Gel filtration 
a b 
114kDa 
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2.3 Analysis of the natively disordered region in full-length NanA 
The 1035-residue sequence of full-length NanA was submitted to the Regional Order 
Neural Network (RONN) server for analysis (Yang et al., 2005). In NanA, it is 
predicted that some naturally disordered regions exist, of which two regions are of 
particular interest, one is containing residues 4-22/52-110 at the N-terminus, the other 
is towards the C-terminus and encompasses residues 850-1010 (Figure 2.3a).  
Compared to the sequence annotation previously shown in Section 1.6 of Chapter 1, 
the first region is found to be the N-terminal linker between the signal peptide and the 
CBM40 domain, which probably also contains the signal peptide cleavage site and 
might be directly involved in the NanA secretion mechanism in S. pneumoniae. 
Following the core catalytic domain of NanA is the C-terminal naturally disordered 
region of about 200 residues. Sequence analysis shows this region is very rich in 
proline/glycine (P/G) and threonine/serine (T/S) components, which comprise 20% 
and 15% in 185 residues respectively. The P/G residues would give this domain higher 
conformational flexibility (Whitford, 2005). As is shown in Figure 2.3b, there are three 
consecutive “YTGPLGTSGEEPAPTVEKPE” repeats located in between residue 900 
to 959 (labeled in green). However, no detailed function for this repeat is known. The 
presence of such a C-terminal natively disordered region before the “LPETGN” 
anchoring motif is thought to provide some flexibility to NanA when it is tethered to 
the cell wall of S. pneumoniae.  
Another major concern from the RONN analysis is that these disordered regions may 
decrease the possibility of full-length NanA crystallization. In fact, full-length NanA 
failed to crystallize after screening against over 1000 conditions (Detailed in Section I-
7 of Appendix I), which indicates that the highly flexible regions would handicap the 
crystal packing of full-length NanA. Therefore, subcloning of the crystallizable 
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subdomains would be an ideal way to do further X-ray crystallographic studies 
towards S. pneumoniae NanA. 
 
a 
 
b 
 
 
 
Figure 2.3 The natively disordered region of full-length NanA. (a) Prediction by the RONN server. 
Residues above the baseline of “Probability of Disorder” (0.5 at y axis) are thought to be disordered. 
Regions of particular interest include residues 4-22, 52-110 and 850-1010; (b) the sequence analysis of 
C-terminal natively disordered region, which include three 20-residue repeats, an anchoring motif and a 
small hydrophobic region. 
  44 
2.4 Identification of the sequence coverage of NanA catalytic domain  
Attempts to obtain the sequence coverage of a crystallizable domain were performed 
via both sequence alignment and limited proteolysis methods. Sequence alignment of 
the three S. pneumoniae sialidase sequences, together with the NanB crystal structure 
(PDB code: 2vw0) as a reference structure, revealed that residues 319-822 of NanA 
(designated as CNanA) adequately match the sequence of NanB and NanC catalytic 
domains (Details will be shown later in Chapter 3).  
Meanwhile, limited proteolysis of full-length NanA was performed using trypsin 
(Fontana et al., 2004). The digestion of native NanA by trypsin produced a variety of 
cleaved products of different sizes as is shown in the SDS-PAGE gel (Figure 2.4). 
Protein segments with larger MWs disappeared gradually with the reaction time, with 
the exception of a ~56 kDa band. This band remained stable in almost all the reactions 
conducted. The MALDI-TOF MS analysis of this band identified that this stable sub-
domain of NanA contains about 470 residues that spans at least from residue 316 to 
residue 791 (Figure 2.5).  
Therefore, two versions of NanA catalytic domain constructs were therefore sub-
cloned, which were labeled as CNanA1 (residues 319-822 including the catalytic 
domain of NanA) and CNanA2 (residues 319-791) respectively. The following 
structural studies were all based on the purified CNanA proteins.  
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Figure 2.4 Limited proteolysis of full-length NanA with trypsin. (Protein to trypsin ratio used for the 
digestions was 100: 1 (w/w). A 56-kDa sub-domain remained stable in all the reactions up to 4 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 MALTI-TOF MS analysis of the 56 kDa segment. Matched peptides were shown in red 
bold, which spans at least from residue 316 to residue 791. Picture from MASCOT search engine 
(Helsens et al., 2007). 
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2.5 Expression, purification and crystallization of CNanA  
For CNanA production, the same expression condition of full-length NanA was used 
(1 mM IPTG induction at 37 °C for 3 hr). Over-expressed proteins were purified via a 
three-step purification strategy (nickel affinity, anion exchange and gel filtration 
chromatography), which was much simpler compared to the full-length NanA 
purification (Figure 2.6). CNanA1 has a MW of 56 kDa with an N-terminal 6-His tag 
and CNanA2 is 54 kDa with a C-terminal 6-His tag. Both tags were kept with the 
proteins after purification. After gel filtration, no obvious contaminants could be seen 
from SDS-PAGE gels. The yields of pure CNanAs were also far better than that of 
NanA. More than 100 mg CNanA1 and 400 mg CNanA2 were obtained from 4 L 
cultures respectively. Moreover, the CNanA proteins retained full sialidase activity of 
hydrolyzing MUAN according to the sialidase activity assay.          
Figure 2.6 Purification of CNanA1 monitored by SDS-PAGE. Nickel affinity, anion exchange and 
size exclusion chromatography were labeled as HisTrap, Anion exchange and Gel filtration respectively.    
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The pre-crystallization test (PCT) suggested a concentration of 10.9 mg/ml for both 
CNanA1 and CNanA2. After screening against commercialized kits, both proteins 
were crystallized in the conditions of 25% PEG 4K, 0.1 M MES pH6.0 with equal 
amounts of protein solution and reservoir solution (2 µl each). All CNanA1 and 
CNanA2 crystals that grew in this condition crystallize as square hollow tubes. 
Crystals appeared in two days and reached their maximum size (about 0.7 × 0.1 × 0.1 
mm) in one week (Figure 2.7). Crystals of the Neu5Ac2en complex structure were 
grown in the presence of 10 mM Neu5Ac2en in the same condition listed above.          
 
 
Figure 2.7 Crystals of CNanA in 25% PEG 4K, 0.1 M MES pH 6.0. All crystals present the shape of 
square hollow tubes. The scale bar represents 0.5 mm.  
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2.6 Data collection, data processing, molecular replacement and refinement 
The first dataset to 2.5 Å was collected on an in-house Rigaku-MSC Micromax-007 
HF X-ray generator (λ=1.514Å) from a CNanA1 crystal co-crystallized with 
Neu5Ac2en, which belongs to space group P212121, with unit cell parameters of a= 
49.2, b= 95.6, c= 226.6 Å. Data were collected with a crystal to detector distance of 65 
mm and an oscillation angle of 0.2 degree from -90° to 90°. Cell content calculation 
analysis suggested that each asymmetric unit contains two molecules. The apo form 
CNanA dataset was collected with a CNanA2 crystal that diffracted to 1.5 Å at 
European Synchrotron Radiation Facility (ESRF) ID 14-1 beam line (λ= 0.934Å). It 
belongs to the same space group as the CNanA crystals and has slightly smaller unit 
cell parameters, which might be due to the fact that CNanA2 contains 20 residues 
fewer than CNanA1. Data collection and processing statistics are listed in Table 2.1. 
 
Data collection CNanA1-Neu5Ac2en  apo CNanA2 
a, b, c(Å) 49.2/95.6/226.6 47.2/96.6/218.2 
Unit Cell   
α, β, γ (°) α= β= γ =90° α= β= γ =90° 
Space group  P212121 P212121 
Resolution (Å) 20-2.50 (2.54-2.50) 20-1.49 (1.52-1.49) 
X-ray source In-house 1.542 Å ID-14-1 0.934 Å 
No. of observations 198855 623538 
No. of unique reflections 36773 159417 
Completeness  95.2 (71.2) 97.0 (78.3) 
I/σI  27.3 (4.6) 16.0 (2.4) 
Redundancy 2.9 (2.5) 3.9 (3.5) 
Rmerge  0.063 (0.248) 0.067 (0.50) 
Vm (Å3Da-1) with 2 molecules/a.u.* 2.36 2.20 
Solvent (%) 47.9 44.1 
 
Table 2.1 Data collection and processing statistics of CNanA. Numbers in parentheses refer to the 
highest-resolution shell. * a.u. represents asymmetric unit.  
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MR was selected to solve the structure using the C. perfringens NanI structure (PDB 
code: 2BF6) as the search model with the first 2.5 Å CNanA-Neu5Ac2en dataset. 
Automated MR with the PHASER program (McCoy, 2007) in Collaborative 
Computational Project Number 4 (CCP4) program suite (CCP4, 1994) produced two 
solutions with high translation function Z (TF-Z) scores of 20.3, which suggested that 
the MR phasing was successful. The phases generated by PHASER were then applied 
to both ARP-wARP (Perrakis et al., 1999) and Phenix (Zwart et al., 2008) packages for 
model building. Attempts with ARP-wARP all failed. However, Phenix AutoBuild 
managed to build 85% of the residues, with an R factor and Rfree of 0.29 and 0.35 
respectively. Coot (Emsley and Cowtan, 2004), REFMAC5 (Murshudov et al., 1997) 
and Phenix Refine were subsequently used to refine and build the CNanA model. The 
final CNanA structure was validated with MolProbity (Lovell et al., 2003). Residues 
322-791 are visible in the final CNanA model. The first 20 amino acids, including the 
six-histidine tag and TEV cleavage peptide, and the last 20 amino acids are not seen in 
the electron-density maps (EDMs). Molecule A is generally well ordered, whereas 
molecule B shows some disorder in its N- and C-terminal regions. Both monomers 
showed clear Fo-Fc density for Neu5Ac2en in the active sites in this dataset (Figure 
2.13).  
This CNanA-Neu5Ac2en structure was subsequently used for MR against the 1.5 Å 
native dataset. The refined apo form CNanA structure also contains residues 322-791. 
The overall conformations of the native and Neu5ac2en complex structures are 
superficially identical. The refinement and validation statistics of both structures are 
summarized in Table 2.2. 
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Refinement CNanA-Neu5Ac2en  apo CNanA 
Resolution (Å) 20-2.50 (2.54-2.50) 20-1.49 (1.52-1.49) 
No. of used reflections 34868 159301  
Percentage observed (%) 96.43 97.70 
No. of atoms   
                     Protein 7442 7442 
                     Ligands 40 0 
                     Water 129 1024 
Mean B-factor (Å2)   
                     Protein, monomer A/B 29/45 15/19 
                     Ligands, monomer A/B 25/41 ---- 
                     Water 26 28 
R factor 0.255 0.199 
R free 0.295 0.225 
r.m.s.d (bond length Å /bond angle °) 0.006/1.03 0.006/1.23 
Validation   
Clashscore 12.7 6.63 
Rotamer outliers (%) 1.24 1.37 
Cβ deviations >0.25 Å 0 0 
Residues with bad bonds/angles (%) 0/0.11 0/0 
MolProbity Score 2.19 1.71 
Ramachandran favoured/outliers (%) 91.6/2.8 96.4/0.3  
Table 2.2 Model refinement and validation statistics.  Numbers in parentheses refer to the highest-
resolution shell. Rmerge = ∑hkl ∑i |Ihkl, i – 〈 Ihkl 〉| / ∑hkl 〈 Ihkl 〉.  Rcryst and Rfree = (Σ | |Fo| - |Fc| |)/(Σ |Fo|).       
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2.7 Overall structure of CNanA 
CNanA shares 41% amino acid sequence identity with the C. perfringens sialidase 
NanI catalytic domain. Superimposition of the two structures shows an r.m.s.d. of 
1.26 Å over 413 Cα atoms (Figure 2.8). The refined CNanA structure model consists 
of 470 residues from Ala322 to Lys791, among which, residues 322-448 and 532-791 
form the catalytic domain, whereas residues 449-531 form an extra inserted domain.  
In common with all the sialidases, CNanA catalytic domain also exhibits the 
characteristic six-bladed β-propeller fold, which constitutes a core catalytic cavity 
around the six-fold pseudo axis (Figure 2.9). Each of the twisted anti-parallel β sheet 
blades consists of four β strands, with the orientation going from the central tunnel to 
the outside of CNanA. Every fourth strand of each β sheet connects the first strand of 
its adjacent sheet via a long winding loop. The N-terminus of CNanA, although linking 
to the first β sheet with a long loop, actually forms the fourth strand of the sixth β sheet 
and encloses the whole propeller architecture, which is highly conserved in the 
sialidase superfamily (Taylor, 1996). Moreover, there are four Asp box motifs in 
CNanA, which construct the classic β-hairpin turns between the third and fourth strand 
of the first, second, third and fourth β-sheets (Figure 2.9 & Figure 2.10). The 81-
residue additional domain inserts between the second and third strands of the second 
sheet, which does not interfere with the conformation of the catalytic domain. This 
type of inserted domain is also seen in C. perfringens NanI (Newstead et al., 2008), 
leech NanL (Luo et al., 1998), S. pneumoniae NanB (Xu et al., 2008) and NanC 
(sequence analysis). 
CNanA was shown to be a dimer in the asymmetric unit of the crystal. Two CNanA 
monomers (labeled with A and B respectively) are related by non-crystallographic 
twofold axis symmetry. LSQKAB of the CCP4 suite gives spherical polar angles ω, φ, 
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κ of 109.4, -31.4° and 179.7° relating chain A onto chain B. Superimposition of 
monomer A and B shows an r.m.s.d. of 0.39 Å over the 470 Cα atoms. Seen from the 
structure, the two molecules have very close contacts by loops winding outside of the 
third, fourth blades and the additional domain. Residues involved in these contacts 
may include Gln448, Glu451, Lys470, Asp561, Trp562, Lys632, His634, Thr637 and 
Lys683, as well as some water molecules and a possible chloride atom sitting in the 
twofold symmetry axis. The buried surface between the dimer interfaces is about 
1200 Å2, with only 386 Å2 generated from the symmetry operation (Figure 2.10). Such 
crystallographic results indicate that NanA might be a dimer appearing on the bacterial 
surface. However, analysis of the structure with the PISA (Protein interfaces, surfaces 
and assemblies) server (Krissinel and Henrick, 2007) suggests that CNanA is unlikely 
to form a complex in solution (the complexation significance sore is 0). The calibrated 
gel filtration also shows that both full-length NanA and CNanA are predominantly 
monomer is in solution. Therefore, without any further evidence, the polymeric 
assembly of CNanA in the crystal structure could be just an artificial effect of 
crystallization. 
Similar to other sialidase structures, the surface electrostatic potential of the active site 
side is also mostly positive (Figure 2.11), which might promote the adherence of NanA 
to anionic sialoglycoconjugates. It is also worth noticing that a positively charged 
groove is located between the interface of the additional domain and the catalytic 
domain. However, the electrostatic potential inside the active site and throughout the 
opposite face is negatively charged. Such electrostatic potential distribution may help 
prevent some misdirected or non-specific binding in vivo.  
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Figure 2.8 Stereo view of the superimposition of S. pneumoniae CNanA and C. perfingens NanI 
Cα  traces. Neu5Ac2en is shown to indicate CNanA active site. Red Cα trace, CNanA; Green Cα trace, 
NanI. 
 
 
 
 
 
Figure 2.9 Stereo view of the cartoon representation of CNanA mononer A. The 81-residue 
additional domain inserts between the second and third strands of the second sheet. Neu5Ac2en is 
shown to indicate CNanA active site. 
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Figure 2.10 Overall structure of S. pneumoniae CNanA. (a) Cartoon representation of the CNanA 
structure. Each monomer has a Neu5Ac2en molecule bound in the active site; (b) the view after a 90 ° 
rotation from (a). The ligand Neu5Ac2en from CNanA-Neu5Ac2en complex is shown to indicate 
CNanA active site. 
90° 
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Figure 2.11 The surface electrostatic potential of S. pneumoniae CNanA. The solvent-accessible 
surface of CNanA coloured based on the electrostatic potential from - 7 to + 7 kT/e, calculated using the 
APBS tool. Positive charge is shown in blue and negative charge in red. Neu5Ac2en is superimposed to 
indicate CNanA active site. 
90° 
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2.8 The active site of CNanA 
The CNanA structure in complex with the transition-state analogue Neu5Ac2en was 
determined to 2.5 Å. The σA-weighted Fo-Fc electron-density map around the active 
site, contoured at 3.0 σ, clearly shows the shape of a Neu5Ac2en molecule. The sugar 
ring of Neu5Ac2en adopts a half-chair 4H5 conformation due to configurational 
restraint of the C-2 to C-3 double bond (Figure 2.13). In fact, both monomers have 
Neu5Ac2en molecule bound into the active site, with B-factors of 25 Å2 and 41 Å2 in 
monomer A and B respectively. Similar to various previously released sialidase 
structures using Neu5Ac2en to probe the active sites (PDB code: 1E8V, 1EUS, 1F8B, 
1MS1, 1N1T, 1SLI, 1VCU, 1W0O, 1W8N, 2SIM, 2VK6), the current CNanA-
Neu5Ac2en complex also enables us to investigate the active site of CNanA in detail. 
Comparing the crystal structures of CNanA-Neu5Ac2en and the apo-form CNanA, it is 
clear that the overall structure of CNanA does not undergo significant conformational 
changes when interacting with the ligand. The r.m.s.d. value of superimposition of the 
native and complex structures of CNanA is only 0.40 Å over all the Cα atoms. 
However, upon Neu5Ac2en binding, an obvious shift of about 2 Å in a loop region 
containing residues 440-446 is observed, which brings some hydrophobic residues, 
particularly Ile442 and Phe443, much closer to the acetamido group of Neu5Ac2en. 
Phe443 forms a lid of the hydrophobic pocket and the sliding of this residue allows a 
half closure of the mouth of the CNanA active site (Figure 2.14 & Figure 2.15). 
Therefore, this specific conformational change further tightens the CNanA active site 
to accommodate the ligand. Such a ligand-induced hydrophobic lid-sliding feature is 
rarely seen in bacterial sialidases.  
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Figure 2.12 The chemical structure of Neu5Ac2en. Carbon, N5 and O6 atoms are labeled. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Stereo image of unbiased Fo-Fc electron-density map contoured at 3 σ with the final 
refined Neu5Ac2en superimposed. The Neu5Ac2en bound to monomer A is shown here. 
 
 
 
Figure 2.14 Conformational change of CNanA active site upon ligan binding. (a) The solvent-
accessible surface of the apo-form CNanA active site. Neu5Ac2en is suposeimposed as the reference; 
(b) the mouth of CNanA active site is half-closed upon binding of Neu5Ac2en. This conformational 
change is due to the shift of Phe443. The relative position of Asp372 remains unchanged.  
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As is shown in Figure 2.15, CNanA active site contains all the common structural 
features of a sialidase. Besides the hydrophobic pocket shown above, CNanA also has 
the triad cluster of three arginines (Arg347, Arg663, Arg721) that interacts with the 
carboxylate group (O-1 A and O-1 B atoms) of Neu5Ac2en or sialic acid derivatives; 
the nucleophilic tyrosine (Tyr752), and its associated glutamic acid (Glu647), that is 
proposed to attack the C-2 atom of Neu5Ac in sialiosides and form a covalent 
intermediate in the catalytic reactions; and the aspartic acid (Asp372) that acts as an 
acid/base catalyst. These key residues are supposed to be directly involved in the 
hydrolytic actions of this enzyme as seen in other sialidases (Newstead et al., 2008).  
In addition to the interactions of Neu5Ac2en with those conserved catalytic residues, 
the hydroxyl group at C-4 (O-4 atom) on Neu5Ac2en can also form hydrogen bonds 
with an arginine (Arg366) and one of the two aspartic acid residues (Asp372 and 
Asp417). Moreover, Asp372 is hydrogen-bonded with C-7 hydroxyl (O-7 atom) and a 
water molecule W1. This water molecule could also potentially network the O-1 B and 
O-6 atoms of Neu5Ac2en. The C-8 hydroxyl (O-8 atom) of the ligand's glycerol group 
interacts with Tyr590, and also with Tyr695 via a water molecule W2. The C-9 
hydroxyl (O-9 atom) is hydrogen-bonded with Gln602. The acetamido group in 
Neu5Ac2en has favorable contacts with Ile442 and sits in a hydrophobic pocket 
constructed by many residues with hydrophobic side chains. The formation of this 
hydrogen-bond network of Neu5Ac2en with CNanA facilitates a specific binding 
arrangement.  
Details of the key interactions between CNanA and ligand are listed in Table 2.3 
below. 
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Figure 2.15 Stereo view of the active site of CNanA. The apo-form structure is shown in grey and the 
complex in green. The possible hydrogen-bonding interactions is shown in dashed line.  
 
 
Distance (Å) Neu5Ac2en/ 
protein atoms 
Protein/  
water atoms Monomer A Monomer B 
O-1 A Arg347-N-η1 3.35 3.17 
 Arg347-N-η2 2.24 2.82 
 Arg721-N-η1 2.86 3.08 
O-1 B Arg721-N-η1 3.27 3.27 
 Arg721-N-η2 2.79 3.18 
 Arg663-N-η1 3.49 3.31 
O-4 Arg366-N-η2 2.88 2.78 
 Asp372-O-δ1 3.25 3.23 
 Asp417-O-δ1 2.95 3.17 
O-6 H2O (W1) 2.73 2.78 
O-7 Asp372-O-δ2 3.25 3.36 
 H2O (W1) 3.13 3.45 
O-8 Tyr590-O 3.22 3.03 
 H2O (W2) 2.94 2.82 
O-9 Gln602-O-ε1 2.67 2.54 
O-10 -- -- -- 
N-5 Asp417-O-δ2 2.72 2.89 
Glu647-O-ε1 Tyr752-O 2.95 2.85 
 Arg663-N-η1 2.79 2.79 
Glu647-O-ε2 Tyr752-O 2.48 2.64 
Gln602-O-ε1 H2O (W2) 3.45 3.51 
Gln602-N-ε2 Tyr695-O 3.23 3.36 
Arg663-N-η1 Tyr752-O 2.97 2.77 
 H2O (W2) 3.21 3.36 
 
Table 2.3 List of potential interactions between CNanA and Neu5Ac2en.?
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2.9 Discussion 
NanA is the largest sialidase among the three S. pneumoniae sialidases and contains 
several other domains conjugated to the core catalytic domain. Due to the presence of 
both an N-terminal signal peptide and a C-terminal anchoring motif, NanA has been 
proposed to be a cell wall anchored enzyme (Camara et al., 1994), although in some 
strains NanA lacks the C-terminal region and could be a secreted enzyme. It is 
proposed that the naturally disordered C-terminal region (~ 200 residues) of NanA may 
provide this surface-associated sialidase with very good mobility during pneumococcal 
invasion. However, this disordered area significantly handicaps the NanA protein from 
forming good crystals. A stable segment of NanA retaining full enzyme activity was 
subsequently identified by limited proteolysis using trypsin. In fact, the sequence 
coverage of this fragment largely matches that of the catalytic domain of NanA 
deduced by sequence alignments. It is therefore designated as CNanA. Also as 
expected, both versions of CNanA proteins (two subclones contain residues 321 to 822 
and residues 322 to 791 respectively) crystallized much more readily to form large 
hollow tube shaped crystals in 30 % PEG4K, 0.1 M MES pH 6.5.  
The final ligand-free form CNanA crystal structure was determined to 1.5 Å, which 
folds into a catalytic domain (residues 322-448 and 532-791) with a small inserted 
domain (residues 449-531). This 470-residue segment of NanA shares over 40 % 
sequence identity with C. perfringens NanI, but only 27% with the catalytic domain of 
NanB or NanC. In addition, the Asp boxes form β-hairpin turns between the third and 
fourth strand of the β-sheets, but they are located remotely from the active site and 
may not be directly involved in the catalysis. More likely, due to the fact that the 
bacterial sialidases share very limited sequence identities, the Asp boxes may therefore 
contribute to maintain the conformation of the canonical sialidase fold. A recent study 
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reported that this motif also exists in other protein families, such as ribonucleases, 
sulfite oxidases etc (Copley et al., 2001). However, the exact function of these Asp 
boxes is still unclear. 
The CNanA crystal structure shows that there are two CNanA molecules in the 
asymmetric unit. As is shown in Figure 2.10, the third and fourth β sheets and the 
majority of the inserted domain in CNanA may associate the two monomers. The 
buried interface is also significant. Therefore, CNanA might be a dimer, or this might 
be an artifact of crystallization, as currently there is no biological evidence supporting 
an oligomeric state for NanA. In fact, no bacterial sialidase has been shown to form an 
oligomer to date, except PaNA that is presented in Chapter 5 later. Polymeric 
sialidases were previously identified from viruses, for instance, the influenza viruses, 
parainfluenza virus and bacteriophage. The viral NA and HN are presented as surface 
glycoproteins in a stable tetrameric form (Crennell et al., 2000; Wiley, 1983), whereas 
bacteriophage endo-sialidase exists as a trimer (Stummeyer et al., 2005). Due to the 
presence of a C-terminal anchoring motif, NanA is tethered to the cell membrane, 
which is somewhat similar to the influenza virus sialidases. Moreover, the 200-residue 
naturally disordered region might provide surface-associated NanA some flexibility to 
approach the sialyl-glycoconjugates in vivo. 
The topology of the CNanA active site is relatively flat and open, with the catalytic 
residues (Arg347, Arg663, Arg721, Tyr752, Glu647 and Asp372) stacking inside 
following a common distribution pattern of all sialidases. These conserved residues 
construct the structural basis of the substrate recognition, binding and processing. The 
interactions of Neu5Ac2en with all these catalytic residues of CNanA are also similar 
to any other sialidase structures in complex with the same ligand. Superimposition of 
the apo-form and Neu5Ac2en-complexed CNanA crystal structures shows that NanA 
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does not undergo significant conformational changes upon ligand binding. The r.m.s.d 
between the two structures is just 0.38 Å over 470 Cα atoms. However, in contrast to 
other bacterial sialidases that have very rigid catalytic sites, an obvious shift of the 
loop (containing residues 440-446) above the hydrophobic pocket was seen in the 
CNanA structure when Neu5Ac2en was bound to the active site. This change makes 
the hydrophobic pocket much tighter to accommodate the actetamido group of the 
sialic acid or analogues. Such a ligand binding induced half-closure effect in a 
sialidase active site is rarely seen in nature. Moreover, the interactions of Neu5Ac2en 
with Asp372, Tyr590, Gln602 and Tyr695 through the three hydroxyls of the glycerol 
group and two water molecules (W1 and W2) further enhanced the binding stability. 
Such a comprehensive binding pattern may help NanA form very tight binding with 
specific substrates, thereby promoting the efficiency of catalytic reactions, as seen in 
the influenza virus sialidases.  
Kinetic and NMR studies of NanA will be detailed in the next chapter.   
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Chapter 3 
 
Comparison of S. pneumoniae sialidases NanA, NanB and NanC: 
from structures to mechanisms 
 
3.1 Summary 
This chapter presents detailed comparisons of NanA, NanB and NanC in sequences, 
structures and catalysis. NanC has been cloned, over-expressed and purified, but failed 
to crystallize. Therefore, based on the crystal structure of NanB, a model of NanC was 
made with the SWISS-MODEL server (Arnold et al., 2006).  
Although the three enzymes exhibit some common features, there are still some 
remarkable differences in their structures and catalytic roles. Different from NanA, the 
topology of NanB and NanC around the active sites confers strict substrate specificity 
of both enzymes towards α2,3-linakge of sialylated substrates. Furthermore, the NMR 
studies show that NanA acts as a classic hydrolytic sialidase that releases Neu5Ac 
from various sialyllactoses; while NanB is found to be an IT trans-sialidase due to the 
fact that it produces Neu2,7-anhydro5Ac; NanC, however, handles multiple catalytic 
roles efficiently, which include releasing Neu5Ac2en from α2,3-sialyllactose (3SL) 
and hydration of Neu5Ac2en to Neu5Ac when 3SL is depleted. The underlying 
catalytic mechanisms of three S. pneumoniae sialidases are proposed and discussed in 
the Section 3.8. 
Such versatile roles of S. pneumoniae sialidases, therefore, assure them as key 
virulence factors of pneumococci. Moreover, the presence of a CBM40 domain may 
further help NanA, NanB and NanC target the sialiosides in vivo and further improve 
their catalytic efficiency.  
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3.2 The topology of S. pneumoniae sialidases active sites  
The crystal structures of CNanA and NanB are currently available, while NanC has not 
been yet crystallized. In order to get a better understanding of the pneumococcal 
sialidases, a computational model of NanC catalytic domain was made based on the 
structure of its homologue NanB by using the SWISS-MODEL server (Arnold et al., 
2006). The final NanC model (see Appendix II-1 for details) was validated with 
MolProbity and shows high similarity to NanB with an r.m.s.d of 0.49 Å over 470 Cα 
atoms. Although there could be some differences to the real NanC structure, this model 
at least provides some useful insights of the relative positions of those proposed 
functional residues around the active sites.  
The topology around the active site of these three sialidases is significantly different. 
In NanA, the catalytic cavity is relatively flat and open, which might be able to provide 
easy access for various substrates (Figure 3.1a). However, both NanB and NanC 
present a relatively narrow cleft for catalysis (Figure 3.1b, c), due to the presence of a 
bulky tryptophan (Trp674 and Trp716 in NanB and NanC respectively). Such distinct 
topologies around NanA, NanB and NanC active sites may confer different substrate 
preferences towards α2,3-, α2,6- and α2,8-linkages, as the sidechain of the tryptophan 
occupies the space where the glycosidic bond of the sialylated substrate normally sits. 
Therefore, Trp674 and Trp716 could present significant steric hindrance to α2,6- and 
α2,8-linakge substrates. Moreover, an additional tryptophan residue (Trp581) in NanC 
could completely stop the access of non-α2,3-sialylated substrates.  
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Figure 3.1 The topology of S. pneumoniae CNanA (a), NanB (b) and NanC (c) active sites. The apo-
form structures are shown, where ligand from CNanA-Neu5Ac2en is superimposed as a reference. 
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3.3 Substrate specificity of NanA, NanB and NanC 
In accord with the structural features, broad substrate specificity of NanA towards 
α2,3-, α2,6-linkage sialyllactoses and α2,8-polySia (PSA) was observed with the TBA 
assay. Measurement of the released sialic acid from three different substrates revealed 
that NanA has no discrimination in cleaving Neu5Ac from α2,3-, α2,6- and α2,8-
linkages tested (Figure 3.2a). In contrast, NanB shows about 5- and 10-fold 
preferences for α2,3- over α2,6- and α2,8- linkages respectively (Figure 3.2b). Similar 
results were seen the NMR studies that will be shown later in Section 3.6. 
Although NanC showed prominent activity of releasing 4-MU from MUAN in the 
fluoremetric assay, the TBA assay failed to detect any free sialic acid released from 
sialyllactoses, PSA or MUAN with far excessive amount of NanC (0.2 mg per 
reaction) in 1 hr. Therefore, the initial products released by NanC is not Neu5Ac in a 
free form, but something else that could not be visualized in the TBA assay. To further 
investigate this, NMR spectroscopy was employed. Very strict substrate specificity of 
NanC towards only α2,3-linked sialiosides, as well as the exact products formed in 
NanC catalysis, was determined, which will also be shown later in Section 3.6.3 and 
discussed in Section 3.8. 
In general, all the three sialidases showed strong sialidase activity at a wide pH range 
from 4.5 to 8. After standardization, NanA is about 10 times and 30 times more active 
than NanB and NanC respectively, in cleaving α2,3-linkage sialylated  substrates (Data 
not shown).  
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Figure 3.2 TBA assay of NanA (a) and NanB (b) with different sialyllactoses. All reactions were 
replicated at least three times with the error bar represents the standard deviations. ** p<0.01 represents 
significant difference when compared to the reactions with α2,3-sialyllactose. NanC only cleaves α2,3-
linkage, but the reaction product is not visible in TBA assay. 
  * * 
 * * 
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3.4 Sequence alignment of NanA, NanB and NanC catalytic domains 
Alignment of NanA, NanB and NanC sequences of the core catalytic domains shows 
that the pneumococcal sialidases exhibit highly similar secondary structures in this 
region (Figure 3.3). The distribution of all those key catalytic residues is well 
conserved (Marked with a * in Figure 3.3). These include, as is shown in the CNanA 
crystal structure in Chapter 2, the arginine triad formed by Arg347 (Arg245/Arg290 in 
NanB and NanC respectively), Arg663 (557/600) and Arg721 (619/662); the 
nucleophile tyrosine Tyr752 (653/695) and the associated residue Glu647 (541/584); 
the acid/base Asp 372 (270/315). In addition to these residues with defined catalytic 
roles, there are also a number of other residues that are found to be common in NanA, 
NanB and NanC, for instance, Ile416 (326/371), Asp417 (327/371), Asp434 (344/388), 
Tyr590 (509/553), Thr591 (510/554) and Tyr695 (589/632). They may contribute to 
the substrate recognition and interaction in the catalytic cleft. 
When focusing on other residues around the active sites, some differences can be seen 
between the pneumococcal sialidases. The most significant one is Trp674 in NanB and 
Trp716 in NanC, which is likely to confer α2,3-linkage substrate specificity, similar to 
that in NanL, TcTS and TrSA (Buschiazzo et al., 1997; Luo et al., 1998; 
Vandekerckhove et al., 1992). However, in NanA, only a glycine (Gly773) sits in this 
position, which would make the active site of NanA more open to various substrates. 
Another major difference is the loop region containing Gln642 in NanA, in contrast, 
residues sitting in similar place are Ala538 in NanB and Trp581 in NanC. These 
residues may affect the binding affinity of the sialic acid analogue. Other different 
residues around the active site include Phe436/Met 346/Met390, 
Phe443/Asn352/Phe396 (NanA/NanB/NanC). Possible roles of all residues listed 
above will be discussed later in Section 3.5.  
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Figure 3.3 Sequence alignments of S. pneumoniae sialidases catalytic domains. The secondary 
structural elements of NanB and CNanA are shown. The catalytic domain and the inserted domain are 
shaded in blue and green respectively. Four Asp box motifs are labelled. The catalytic residues are 
marked with *, while the major different residues are marked with red arrows. Sequence alignment was 
done with Cluster W (Larkin et al., 2007) and picture was drawn with ESPript (Gouet et al., 2003).  
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3.5 Structural superimposition of S. pneumoniae sialidases catalytic domains 
Superimposition of the three structures (crystal structures of CNanA and NanB, model 
structure of NanC catalytic domains) shows that the overall conformation is similar 
throughout the three sialidases (Figure 3.4). The r.m.s.d values for CNanA v.s. NanB 
catalytic domain and CNanA v.s. NanC model are 2.11 Å and 2.28 Å over 470 Cα 
atoms respectively. The spatial distribution of those conserved residues listed in 
Section 3.1 was further confirmed by this 3-D structure comparison. They are localized 
almost in identical positions throughout the three sialidases (Figure 3.5).  
However, a significant difference can be seen in the loop winding above the active site 
in NanB and NanC around the location of the aglycon, which has the proposed α2,3-
linkage substrate selective residue tryptophan Trp674/716 (NanB/NanC) stacking 
against a tyrosine (Tyr589/632) (Figure 3.4 and Figure 3.5). In NanA, this loop stays 
remote?to the catalytic centre, leaving the active site very open for easy access of 
different sialylated substrates. Enzyme assays and NMR subsequently proved the 
distinct substrate preferences of NanA, NanB and NanC (Section 3.3 and Section 3.6). 
Another distinct topology is the linker between the second and third β-strands of the 
third β-sheet. In NanB and NanC, both are very short turn elements with just two 
residues including a glycine. However, in NanA, there is an 11-residues loop ranging 
from Thr592 to Gln602, winding towards the vicinity of the active site. Moreover, 
Glu602 can form hydrogen bond with C-9 hydroxyl group of Neu5Ac2en, while a 
Leu598 further encloses the hydrophobic pocket to fit for the acetamido group (See 
Chapter 2). Such differences may alter the binding affinity of sialic acid and analogues 
among the pneumococcal sialidases, which will be discussed later in Chapter 4. The 
major conserved residues, as well those different residues, between NanA, NanB and 
NanC around the active sites are summarized in Table 3.1.   
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Figure 3.4 Superimposition of CNanA, NanB and NanC catalytic domains. (a) Superimposition of 
CNanA (shown in green) and NanB (pale blue) structures; (b) comparison of NanB structure and NanC 
model (shown in pale brown). Neu5Ac2en from CNanA-Neu5Ac2en and Trp674 of NanB are shown to 
indicate the active site.?
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Figure 3.5 Stereo view of S. pneumoniae sialidases active sites. NanA and residues labels are shown 
in green, NanB and NanC are shown in pale blue and brown respectively. The conserved catalytic 
residues are not labelled in the figure.  
   
 NanA NanB NanC Possible functions 
Arg347 Arg245 Arg290 
Arg663 Arg557 Arg600 
Arg721 Arg619 Arg662 
Forming the arginine triad 
Forming the arginine triad 
Forming the arginine triad 
Tyr752 Tyr653 Tyr695 
Glu647 Glu541 Glu584 
The nucleophile 
Associated with the nucleophile 
Conserved 
catalytic 
residues 
Asp372 Asp270 Asp315 The acid/base catalyst 
Arg366 Arg264 Arg309 Interacting with ligand 
Ile416 Ile326 Ile371 Forming hydrophobic pocket 
Asp417 Asp327 Asp372 Interacting with ligand 
Asp434 Asp344 Asp388 Interacting with ligand 
Tyr590 (Tyr509) (Tyr553) Interacting with ligand in NanA 
Other 
identical 
residues 
Thr591 Thr510 Thr554 Unknown 
(Gly773) Trp674 Trp716 Conferring substrate specificity 
(Phe443) Asn352 (Phe396) Interacting with ligand 
Gln602 (Ala538) (Trp581) Interacting with ligand 
Tyr695 (Gly590) (Gly633) Interacting with ligand 
(Asn645) Thr539 Ser582 Unknown 
Phe436 Met346 Met390 Unknown 
Different 
residues 
Leu598  ---  --- Forming hydrophobic pocket 
 
Table 3.1 Major residues around the S. pneumoniae sialidases active sites. Residues appear in 
corresponding positions without specified functions are marked with brackets.  
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3.6 1H NMR kinetic studies of S. pneumoniae sialidases  
1H NMR spectroscopy was selected to investigate the catalysis of S. pneumoniae 
sialidases. α2,3-sialyllactose (3SL) and α2,6-sialyllactose (6SL) were used as the major 
substrates. The molar ratio of substrate to protein is fixed at 100:1 in all reactions. To 
monitor the progress of the catalytic reactions, NMR spectra were taken after certain 
time intervals, such as 0.5 hr, 1 hr or 12 hr. All experiments were repeated at two 
different pH values, pH 5.0 (50 mM sodium acetate, 150mM NaCl in D2O) and pH 7.0 
(50 mM sodium phosphate, 150 mM NaCl in D2O).  
The chemicals used in this study are well defined in the 1H NMR spectroscopy. For 
example, protons of 3SL at H3 equatorial and axial positions exhibit characteristic 
signals with chemical shift at 2.66 ppm and 1.68 ppm respectively. Corresponding 
characteristic proton signals of 6SL are 2.56 ppm and 1.59 ppm. Neu5Ac, Neu5Ac2en 
and Neu2,7-anhydro5Ac also show distinct signals in 1H NMR spectroscopy as is 
summarized in Table 3.2, which enable the identification and quantification of the 
products generated in the catalytic reactions.  
 
 H3eq H3ax NHCOCH3  
3SL 2.66 1.68 1.88 
6SL 2.56 1.55 1.88 
α-Neu5Ac 2.60 1.50 1.88 
β-Neu5Ac 2.08 1.68 1.90 
Neu2,7-anhydro5Ac 1.85 2.02 1.89 
Neu5Ac2en Single proton: H3 δ=5.52 1.92 
 
Table 3.2. Characteristic chemical shifts (δ , ppm) of 3SL, 6SL, α-/β-Neu5Ac, Neu5Ac2en and 
Neu2, 7-anhydro5Ac in 1H NMR. NHCOCH3 and NHAc are used interchangeably in the context. 
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Figure 3.6 The structure of chemicals used in the NMR studies. (a) 3SL; (b) 6SL; (c) α-Neu5Ac; (d) 
β-Neu5Ac; (e) Neu5Ac2en; (f) Neu2, 7-anhydro5Ac. 
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3.6.1 Hydrolysis of α2,3- and α2,6-sialyllactose by NanA 
In both reactions with 270 µg α2,3- and α2,6-sialyllactose, the characteristic 
sialyllactose signals (H3eq, H3ax and NCOCH3 peaks) in NMR spectra diminished 
after incubating for 0.5 hr with 0.5 nmol NanA at room temperature, indicating that 
NanA is a very powerful sialidase that could perform fast hydrolysis towards different 
sialyllactoses (Figure 3.7 and Figure 3.8).  
Moreover, the initial product of both reactions was found to be α-Neu5Ac (H3eq δ= 
2.60 ppm, H3ax δ= 1.50 ppm and NHCOCH3 δ= 1.88 ppm). However, in about 24 hr, 
all α-Neu5Ac then gradually mutarotated to β-Neu5Ac (H3eq δ= 2.08 ppm, H3ax δ= 
1.68 ppm and NHCOCH3 δ= 1.90 ppm), which is a thermodynamically more stable 
configuration of Neu5Ac.  
The hydrolytic reactions catalyzed by NanA were also repeated at pH 5.0 and no 
obvious difference was seen (See Appendix II-2 for details). Therefore, 1H NMR 
studies confirmed that NanA is a classic hydrolytic sialidase that hydrolyzes both 
α2,3- and α2,6-sialyllactose substrates to release sialic acid. 
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Figure 3.7 NMR spectra of the hydrolysis of α2,3-sialyllactose (3SL) by NanA.      
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Figure 3.8 NMR spectra of the hydrolysis of α2,6-sialyllactose (6SL) by NanA.  
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3.6.2 Release of Neu2,7-anhydro5Ac from sialyllactose by NanB 
In contrast to the NanA-catalyzed hydrolytic reactions, NanB produces Neu2,7-
anhydro5Ac from the sialyllactoses. Production of Neu2,7-anhydro5Ac was observed 
in both α2,3- and α2,6-sialyllactose reactions with NanB. Thus, NanB can be 
classified as the second IT trans-sialidase in addition to the leech sialidase NanL (Li et 
al., 1990). 
In the NMR spectra, Neu2,7-anhydro5Ac is characterized by H3eq (δ= 1.85 ppm), 
H3ax (δ= 2.02 ppm) and NHCOCH3 (δ= 1.89 ppm) signals. After incubation with 1.5 
nmol NanB for 0.5 hr, the signals of 3SL decreased significantly with the development 
of peaks that represented two different chemicals, Neu2,7-anhydro5Ac  and Neu5Ac. 
The ratio of the two products was quantified by signal integration. Neu2,7-anhydro5Ac  
and Neu5Ac ratio changed with time, which is 9:1, 6:1 and 3:1 after 0.5hr, 24hr and 
48hr respectively (Figure 3.9). In fact, Neu2,7-anhydro5Ac is supposed to be the only 
product in the catalytic reaction, as it is a relatively stable intermediate and can slowly 
turn into Neu5Ac in solution. No Neu2,7-anhydro5Ac can be seen in solution after 30 
days (Data not shown). The experiment was also repeated at pH 5.0 in 50 mM 
deuterated acetate buffer, which gave similar results (See Appendix II-3 for details).  
In the case of 6SL, the catalytic reactions are much slower than that of 3SL shown 
above, which is in line with the substrate specificity of NanB. Only about 30 % of 6SL 
was found processed by NanB in 48 hr (Figure 3.10). In both reactions with 3SL and 
6SL, significant amount of Neu2,7-anhydro5Ac is detected, which is therefore an 
evidence to classify NanB as an IT trans-sialidase.  
Although the exact function of a long-lived intermediate Neu2,7-anhydro5Ac is still 
unclear, some researchers predicted that it might be a secondary substrate of IT trans-
sialidase and could be transferred to suitable carbohydrate acceptors, as seen with 
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TcTS (Haselhorst et al., 2004). To test if NanB could transfer the terminal Neu5Ac 
residue, or the intermediate Neu2,7-anhydro5Ac, from α2,3-sialyllactose to another 
carbohydrate acceptor, a mixture of 2 mM N-acetyllactosamine (Galβ1-4GlcNAc) and 
1 mM α2,3-sialyllactose were incubated with NanB for 48hrs. Both Neu2,7-
anhydro5Ac and Neu5Ac were seen in the reaction, but no α2,3-sialyl-N-
acetyllactosamine or any other product was formed (Appendix II-4). Thus, NanB 
appears to function as an IT trans-sialidase, instead of a normal hydrolyzing sialidase 
or trans-sialidase. The released Neu2,7-anhydro5Ac is probably not ready for a 
secondary reaction, but could, perhaps, be used as a carbon or energy source. 
The catalytic mechanism of NanB is proposed and discussed in Section 3.8.      
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Figure 3.9 NMR spectra of NanB reactions with 3SL.      
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Figure 3.10 NMR spectra of NanB reactions with 6SL.   
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3.6.3 Dual catalytic roles of NanC  
The NMR kinetic studies confirmed that NanC exhibits very strict substrate specificity 
towards α2,3-linkage, as no 6SL is seen cleaved during the 48 hr reactions (Appendix 
II-5).  
Moreover, distinct from the reactions catalyzed by NanA and NanB, the third 
pneumococcal sialidase NanC solely produces Neu5Ac2en (with hallmark signals of 
H3 at δ= 5.52 ppm and NHCOCH3 at δ= 1.92 ppm) from 3SL at the very early stage. 
Within 0.5 hr after the reaction was initiated, no 3SL signals could be seen and equal 
molar ratio of Neu5Ac2en was released (Figure 3.11). Neu5Ac2en is known as a 
general sialidase inhibitor that inhibits many sialidases from different origins (Kiefel 
and von Itzstein, 2002). Previously, it has been reported that only tiny amount of 
Neu5Ac2en appeared as a by-product during the hydrolysis reactions of 3SL catalyzed 
by influenza B virus NA (Burmeister et al., 1993), TcTS (Amaya et al., 2003) and 
VcNA (Moustafa et al., 2004). However, here we found that NanC is a unique 
sialidase that is capable of producing extremely large amount of Neu5Ac2en from 3SL 
with significant high efficiency.  
Furthermore, a secondary reaction was observed in the same experiment after 1 hr 
incubation, despite the fact that 3SL had already been depleted at this time in the 
reaction. Very surprisingly, the intensity of Neu5Ac2en signals was also seen fading 
away within 4 hr. Correspondingly, a clear doublet with the coupling of 5.05 Hz 
appeared at 2.18 ppm and was seen growing with the reaction time. Since all 
experiments were done in the deuterated buffer, the appearance of this characteristic 
doublet (δ= 2.05 ppm, J= 5.05 Hz) means the formation of β-(H3eq, D3ax)-Neu5Ac in 
the reaction. This unique doublet shows H3eq coupling to H4 with a coupling constant 
of ~5 Hz. No H3ax signals were seen at ~1.82 ppm, probably because the proton has 
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already been replaced by deuterium. That is, NanC catalyzes the hydration of 
Neu5Ac2en, which was deuterated at the H3ax position and converted into β-(H3eq, 
D3ax)-Neu5Ac in deuterated buffer.  
The NanC hydration reaction was further investigated with pure Neu5Ac2en. In this 
reaction, 7 mM Neu5Ac2en was incubated with 2.5 µM NanC at room temperature. 
Neu5Ac2en was cleared away gradually with time and the J= 5.05 Hz doublet started 
to show at 2.05 ppm in about 0.5 hr and reached its peak in 24 hr  (Figure 3. 12). In 
fact, extremely slow hydration reaction of Neu5Ac2en has been previously reported in 
reactions catalyzed by Arthrobacter sialophilus (A. sialophilus) sialidase (Flashner et 
al., 1983) and C. perfringens NanI (Newstead et al., 2008). Moreover, the Neu5Ac2en 
hydration reaction is not reversible, as no Neu5Ac was found converted into 
Neu5Ac2en by NanC in either the Neu5Ac2en hydration experiment or in a separate 
experiment of Neu5Ac with NanC.  
Therefore, NanC is the first sialidase shown to handle such specific dual catalytic roles 
in both the formation and hydration of Neu5Ac2en.          
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Figure 3.11 NMR spectra of products released from 3SL by NanC.   
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Figure 3.12 NMR spectra of the hydration of Neu5Ac2en catalyzed by NanC.   
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In summary, the current NMR studies revealed that the three sialidases catalyze 
disparate reactions with the same substrate 3SL (Figure 3.13). NanA acts as a 
hydrolytic sialidase, which hydrolyzes the α-glycosidic bond of 3SL (chemical 1) to 
release α-Neu5Ac (chemical 2), which then gradually mutarotates to β-Neu5Ac 
(chemical 5); In contrast, NanB produces Neu2,7-anhydro5Ac (chemical 3) from 3SL; 
NanC alone catalyzes dual reactions of both producing Neu5Ac2en (chemical 4) and 
hydration of Neu5Ac2en to β-Neu5Ac. Proposed mechanisms of the pneumococcal 
sialidases catalysis are discussed later in Section 3.8.     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Summary of the enzymatic reactions catalyzed by NanA, NanB and NanC. Reactions 
catalyzed by NanA, NanB and NanC are highlighted with green, blue and red arrows respectively, 
where as naturally occurring reactions are labelled with black arrows.  
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3.7 The CBM40 domains of pneumococcal sialidases. 
The overall structure NanB was briefly described in Chapter 1. Its CBM40 domain 
(residues 42-224) displays a β-sandwich fold that is similar to the CBM40 modules 
from leech NanL (PDB code: 2SLI), VCNA (1W0P) and C. perfringens NanJ (2V73). 
The closest NanB CBM40 domain homologue is that from NanJ, sharing 27 % 
sequence identity with an r.m.s.d of 1.64 Å over overlaid 180 Cα atoms. Moreover, in 
line with the proposed functions of CBM40, Neu5Ac was found bound to both VcNA 
(Moustafa et al., 2004) and NanJ CBM40 domains in crystal structures (Boraston et 
al., 2007). Superimposition of NanB CBM40 with the VcNA or NanJ complex 
structures revealed some possible functional residues, including Leu84, Phe105, 
Glu115, Arg117, Leu126, Arg193, Glu197 and Tyr199. Among the residues, Arg117 
and Arg193 may interact with the carboxylate group of sialic acid; Glu115 and Glu197 
could form hydrogen bonds with C-4 and C-8 hydroxyls; whereas Leu84, Phe105, 
Leu126 and Tyr199 make up the hydrophobic pocket for the acetamido group of sialic 
acid (Figure 3.14). Therefore, the CBM40 domain has the structural basis of specific 
sialic acid recognition and binding functions. However, it should be noted that the 
hydrogen-bonding pattern with substrate at these sites is far less comprehensive than 
that in the core sialidase catalytic domain. ?
The N-terminal CBM40 domains also exist in S. pneumoniae NanA and NanC, with 
residues spanning 121-305 (NanA) and 86-269 (NanC) respectively. An alignment of 
the sequences of three pneumococcal sialidases’ CBM40 domains shows that most of 
proposed functional residues listed above are conserved in the NanB and NanC 
CBM40 domains except in NanA (Figure 3.15). However, NanA has polar or 
hydrophobic residues appearing in the same positions to match up. Therefore, the 
CBM40 domains of all pneumococcal sialidases may, like NanJ and VcNA, also 
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recognize and bind sialylated substrate in vivo. However, this needs to be verified by 
further structural characterization.  
 
?
 
 
 
 
 
 
 
Figure 3.14 Putative sialic acid binding site in NanB CBM40 domain by superimposition onto 
NanJ CBM40 complex structure. NanB and NanJ are shown in salmon and cyan respectively. 
Residues are labelled in the order of NanB/NanJ.  
 
 
Figure 3.15 Sequence alignment of S. pneumoniae sialidases CBM40 domains using NanB CBM40 
domain as a reference structure. Potential residues predicted to be involved in sialic acid recognition 
are labelled with “+” (charged/polar) and “O” (hydrophobic) respectively. 
  89 
3.8 Discussion 
Being key virulence factors of S. pneumoniae, both NanA and NanB have been proved 
to be essential in pneumococcal infection and colonization in vivo (Manco et al., 
2006). NanC, the homologue of NanB, remains the least studied sialidase in 
pneumococci. However, it has been an enigma for a long time why S. pneumoniae 
genomes encode three sialidases. Sequence analysis supports that NanA is a cell wall-
associated protein, while the other two are secreted enzymes. Moreover, the three 
enzymes are found to have different optimal pHs for maximum sialidase activity, 
which are pH 6.5-7.0 for NanA (Camara et al., 1994), pH 4.5-5.0 for NanB (Berry et 
al., 1996) and pH 5.0-6.0 for NanC (Measured by myself and Marco Oggioni, Siena) 
respectively. In fact, NanA is a very powerful sialidase in cleaving 3SL compared to 
other bacterial sialidases such as VCNA and NanI (Roggentin et al., 1989). The 
sialidase activity of NanB and NanC, however, are about 10 times and 30 times lower 
than that of NanA in cleaving the artificial substrate MUAN. Therefore, it is likely that 
they may handle some cooperative roles in different circumstances, such as at different 
stages of colonization or infections in blood or in the lung. However, these findings are 
still not sufficient to unveil the mystery of three pneumococcal sialidases as virulence 
factors. Therefore, structural and kinetic studies are of particular importance to explore 
the molecular mechanisms of NanA, NanB and NanC. 
The crystal structures of NanA catalytic domain and full length NanB, as well as a 
NanC model, presented in this study show that these sialidases have different topology 
around the active sites. NanA is open for easy access of a wide scope of cell surface 
glycans. Our TBA assay further confirmed that it has no substrate preference over α2-
3, α2-6 or α2-8 linkages. However, in NanB and NanC, only α2,3-sialosides are free to 
be accommodated in the active site, which have been proved by TBA assay or NMR 
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studies. Strict α2,3-linkage substrate specificity is also seen with the leech sialidase 
NanL and TcTS, both of which present similar packing pattern of the tryptophan 
residue as is seen in NanB and NanC; moreover, this type of topology might also be 
less accessible for solvent compared to classic hydrolytic sialidases (Buschiazzo et al., 
2002; Luo et al., 1998).  
There are a variety of residues conserved or significantly different around the active 
sites of NanA, NanB and NanC. Here, we will not repeat the roles of those key 
catalytic residues. It is worth noticing that there is a conserved tyrosine residue 
(Tyr590/509/553 in NanA/B/C) at similar position in the sialidases’ active sites, but 
showing different sidechain orientation. In NanA, this residue is very close to the 
glycerol group of Neu5Ac2en and is able to form hydrogen bonds with Neu5Ac2en via 
a water molecule; whereas in NanB and NanC, this tyrosine stacks against the 
substrate selective bulky tryptophan residue for enhanced steric hindrance for those 
substrates of non-favourable linkages. Other conserved or different residues listed in 
Table 3.1 are more or less related to the additional protein-ligand interactions. Detailed 
analysis of these differences evidenced with more complex structures will be presented 
in the following chapter.  
It has been a long confusing issue that if NanA, NanB and NanC are all expressed for 
either removing terminal sialic acid residues for unmasking host receptors, or if they 
have disparate roles in S. pneumoniae pathogenesis. The current NMR studies, for the 
first time, unveiled this mystery. The NMR spectroscopy results show that NanA is a 
classic hydrolytic sialidase, which hydrolyzes various sialyllactoses to release sialic 
acid; NanB, however, acts as an IT trans-sialidase that catalyzes an elimination 
reaction to produce Neu2,7-anhydro5Ac; NanC is showing high capacity of producing 
and releasing Neu5Ac2en from α2,3-sialyllactose. Moreover, this unique enzyme can 
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convert Neu5Ac2en to Neu5Ac also with high efficiency when α2,3-sialyllactose was 
not abundant or depleted in the reaction.  
As previously discussed in Section 1.5 of Chapter 1, all sialidases are supposed to 
share a common two-step mechanism of generating a transition-state sialyl cation, or 
operate via a covalently sialylated enzyme intermediate (Figure 1.8 and Figure 1.10). 
In different types of sialidases, with the attacking at C-2 position of the oxocarbonium 
ion by different nucleophiles, such as a water molecule (in hydrolytic sialidase), or the 
O-7 atom of the sialyl cation (in IT trans-sialidase) or another carbohydrate acceptor 
such as βGal (in trans-sialidase), the final products could be Neu5Ac, Neu2,7-
anhydro5Ac or Neu5AcβGal. Here, S. pneumoniae NanA and NanB adequately 
follows the mechanisms of a hydrolytic sialidase and an IT trans-sialidase 
respectively. However, NanC is not in any of the aforementioned category.  
Nonetheless, for first elimination reaction of producing Neu5Ac2en catalyzed by 
NanC, this enzyme might also adopt the generalized mechanism involving the 
formation of a transition-state sialyl cation or a covalently sialylated enzyme 
intermediate. However, different from all other sialidases, there could be no effective 
nucleopilic attack happening in the active site of NanC. This may attribute to, in part, 
the solvent-proof environment created by the shallow catalytic cleft with several bulky 
tryptophan residues stacking around, as well as the lactose leaving group covering on 
top. Furthermore, as is discussed in Section 3.3, NanC is only able to form limited 
hydrogen bonds with Neu5Ac2en due to the presence of abundant aromatic residues 
around the active site. This also makes the sialyl cation less easy to be held by NanC. 
Therefore, it was released as the transition-state analogue Neu5Ac2en, which adds 
further evidences to the currently proposed sialidase mechanisms (Figure 3.16). 
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In different sialidases, the highly conserved catalytic machinery in different sialidases 
could act under different mechanisms. It seems like that the varieties of other residues 
around the active site contribute to the differentiation of product formation once the 
oxocarbonium cation is formed as discussed above. In the present case, the open 
catalytic cleft of NanA could be highly accessible to water molecules, while in NanB 
and NanC, the presence of many aromatic residues in the active site could prevent 
water molecules from being activated by the aspartic acid easily. Further investigations 
on sialidase mechanisms still need to be carried out.?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Proposed catalytic mechanisms of the S. pneumoniae sialidases 
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Besides the Neu5Ac2en-producing reactions, NanC also catalyzes a second 
Neu5Ac2en hydration reaction that adopts a unique mechanism that has been 
previously reported by us in the NanI catalysis (Newstead et al., 2008). Briefly, once 
Neu5Ac2en was acquired by NanC and bound to the catalytic site, the electrons in the 
nucleophilic π bond could attack the proton of the catalytic aspartic acid (Asp315) as is 
shown below in Figure 3.17a, resulting in the formation of an oxocarbonium (Figure 
3.17b). Afterwards, a water molecule could be picked up and activated by Asp315 
(Figure 3.17c). It attacks the positive charge at C-2 position to produce a protonated 
intermediate (Figure 3.17d). The proton then comes back to Asp315 and the final 
product Neu5Ac forms (Figure 3.17e).  
In fact, the hydration reaction speed of NanC is approximately 500 fold over that of 
NanI. Similar reactions were also seen in influenza B virus NA, VcNA and TcTS, 
which produce tiny amount of Neu5Ac2en as a by-product (Amaya et al., 2003; 
Burmeister et al., 1993; Moustafa et al., 2004). The hydration of the alkene double 
bond in Neu5Ac2en with such high efficiency is only seen with NanC. This makes 
NanC a unique sialidase that could do dual jobs of producing and clearing Neu5Ac2en 
in solution with the same set of machinery residues.  
However, if viewed from another aspect, the substrates (3SL or Neu5Ac2en) might 
also be one of the key factors in orientating the NanC catalysis. In the reaction of 
producing Neu5Ac2en from 3SL, it is supposed that the bulky leaving group of 3SL 
covering on top during the catalysis might also contribute to build a solvent-proof 
environment. No water molecule could be accessible to the aspartic acid catalyst in 
NanC active site. Thus, a normal nucleophilic attack seen in other sialidases can hardly 
happen with NanC and Neu5Ac2en is released as the only catalytic product. On the 
other hand, when Neu5Ac2en accumulated to a high concentration, NanC could 
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acquire this transition-state analogue, as well as a water molecule, to initiate a 
hydration reaction. Further investigations are on the way to test the hypothesis. 
  
   
Figure 3.17 Proposed mechanisms of Neu5Ac2en hydration by NanC. Modified from the previously 
published enzymatic mechanism of C. perfringens sialidase NanI (Newstead et al., 2008).  
   
In summary, our current findings suggest that S. pneumoniae expresses three distinct 
sialidases for different but cooperative roles in pneumococcal colonization and 
infections. NanA is the first-line virulence factor for host cell receptor unmasking; 
NanB could produce Neu2,7-anhydro5Ac as a nutritional source for the colonized 
bacteria; NanC, however, could be a regulator for NanA and NanB actions by 
producing or clearing out Neu5Ac2en, the general sialidase inhibitor, from the 
environments.  
OO O
H
H2N
H2N
O O
Asp
Glu
Tyr
Arg
H
H O
H
O
HO
X
O
O
H
N
Ac
a
H
H2N
H2N
O
HO
H
N
X
Ac
O
O
O H
!+
!"
!"
Arg
OO O
H
Glu
Tyr
O O
Asp
H
b
OO O
H
H2N
H2N
O
OH
OH
XH
N
Ac
O
O
O O
Asp
Glu
Tyr
Arg
H
X =
OH
OH
OH
c
  95 
Chapter 4 
 
Inhibition of S. pneumoniae sialidases by Neu5Ac2en and preliminary 
work of structure-based drug discovery  
 
4.1 Summary 
Complex structures and enzyme kinetic studies are always essential in identifying the 
interaction pattern of an inhibitor to a protein, which are also valuble for SBDD. The 
current chapter describes the inhibition studies towards S. pneumoniae sialidases as 
well as some initial SBDD efforts. 
In addition to the previously shown Neu5Ac2en-CNanA complex structure, NanB also 
forms complex with Neu5Ac2en. However, the ligand-protein interaction patterns 
between NanA and NanB are not the same, resulting in a significant difference in the 
inhibition constant (Ki) of Neu5Ac2en to these two sialidases. Neu5Ac2en is found to 
inhibit NanA, NanB and NanC with Ki values of 0.3 µM, 0.3 mM and 1.2 mM 
respectively. Therefore, this general sialidase inhibitor is not working well on S. 
pneumoniae sialidases. In particular, NanC is a unique sialidase with prominent 
Neu5Ac2en hydration capacity. Thus, design of novel S. pneumoniae sialidases 
inhibitors will be the only way of blocking the sialidases virulence in pneumococcal 
colonization and infections. The identification of a new starting framework, CHES (2-
n-cyclohexylamino ethane sulfonic acid) molecule, for sialidase inhibitor design makes 
our SBDD efforts more promising. Moreover, preliminary FBDD work using a 100-
fragment library screened with the thermal shift assay, cocktail crystal soaking and 
computational docking are presented in Section 4.4.2.  
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4.2 Inhibition of S. pneumoniae sialidases by Neu5Ac2en 
Neu5Ac2en is a general sialidase inhibitor that inhibits many sialidases with binding 
affinity typically of the µM to mM range. This transition-state analogue in sialidase 
catalysis has been widely used as a probe for sialidase active site mapping as is 
discussed in previous chapters.  
In Chapter 2, the complex structure of CNanA-Neu5Ac2en has been presented, which 
shows a comprehensive hydrogen-bonding pattern between the ligand and the enzyme. 
To further investigate the inhibition of Neu5Ac2en towards S. pneumoniae sialidases, 
some crystallographic and kinetic studies were performed and presented below.  
 
 
4.2.1 Neu5Ac2en forms complex structures with NanB  
Neu5Ac2en forms a complex with NanB in crystals. The native structure of NanB has 
been previously described in Chapter 1, which was first solved in my MRes project. 
The crystal structure of NanB-Neu5Ac2en complex was obtained by soaking of native 
NanB crystals in 10 % PEG 8K, 0.1 M imidazole, 10 mM Neu5Ac2en and 20% 
glycerol for about 15 min. The complex structure was determined to 2.4 Å on the in-
house X-ray facilities. After refinement with the apo-form NanB model, clear Fo-Fc 
electron density map of a Neu5Ac2en molecule is seen in the active site of NanB 
(Figure 4.1).  
Data collection, processing, model refinement and validation statistics are summarized 
in Table 4.1.  
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Data collection NanB-Neu5Ac2en  
Unit Cell           a, b, c(Å) 76.6/82.7/117.4 
                          α, β, γ (°) α= β= γ =90° 
Space group P212121 
Resolution (Å) 30-2.40 (2.49-2.40) 
X-ray source In-house 1.542 Å 
No. of observations 105254 
No. of unique reflections 29767 
Completeness  100 (99.6) 
I/σI 6.3 (2.8) 
Redundancy 5.1 (4.8) 
Rmerge  0.138 (0.353) 
Vm (Å3Da-1) 1 molecule/a.u. 2.51 
Solvent (%) 51.1 
Refinement  
No of used reflections 28251 
Percentage observed (%) 99.1 
No. of atoms  
                    Protein 5189 
                    Ligands 20 
                    Water 463 
Mean B-factor (Å2)  
                    Protein 22.1 
                    Ligands 20.1 
                    Water 21.8 
R factor 0.196 
R free 0.278 
r.m.s.d (bond Å /Angle°) 0.012/1.50 
Validation  
Clash score 14.95 
Rotamer outliers (%) 2.26 
Cβ deviations >0.25 Å 2 
Residues with bad 
bonds/angles (%) 0/0.15 
MolProbity Score 2.16 
Ramachandran 
favoured/outliers (%) 96.7/0.3 
 
Table 4.1 Data collection, processing, structure refinement and validation statistics of NanB-
Neu5Ac2en complex. Numbers in parentheses refer to the highest-resolution shell. 
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Figure 4.1 Stereo image of unbiased Fo-Fc electron-density map contoured at 3 σ with the final 
refined Neu5Ac2en superimposed. Data collected to 2.4 Å with a NanB crystal soaked with 10 mM 
Neu5Ac2en for about 15 min. 
 
 
In the complex structure of NanB and Neu5Ac2en, the ligand is well ordered in the 
catalytic cleft with a B-factor of 20 Å2. Superimposition of NanB-Neu5Ac2en complex 
and native NanB structures shows an r.m.s.d. of 0.54 Å over 657 Cα atoms. In fact, 
NanB shows a very rigid active site with no significant conformational change upon 
the ligand binding, except a slight rotation of the sidechains of Asn352 and Asn353. 
All the conserved catalytic residues are directly involved in the hydrogen bonds 
formation with the ligands. In addition, the glycerol group of Neu5Ac2en also interacts 
with Asp270, Asn352 and Arg557. Moreover, there are two water molecules (W1 and 
W2) appearing in the active site of NanB near the ligand, both of which help promote 
interactions between the ligand-stabilizing residues (Figure 4.2). List of the details of 
potential interactions between NanB, Neu5Ac2en and the two molecules are 
summarized in Table 4.2. 
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Figure 4.2 Stereo view of the complex structure of NanB and Neu5Ac2en. The structures of native 
NanB and NanB-Neu5Ac2en are shown in gray and blue respectively. The sidechains of Asn352 and 
Asn353 rotated in the complex. All potential hydrogen bonds are indicated with dashed lines. 
 
 
 
Neu5Ac2en 
atoms 
Protein/  
water atoms 
Distance 
(Å) Protein atoms 
Protein/  
water atoms 
Distance 
(Å) 
O-1 A Arg245-N-η1 2.73 Asp270-O-δ1 H2O (W1) 2.33 
 Arg245-N-η2 2.87 Asp327-O-δ2 H2O (W2) 3.03 
 Arg619-N-η1 2.71 Asn352-O-δ1 H2O (W1) 3.02 
O-1 B Arg619-N-η1 3.34 Tyr509-O H2O (W2) 2.52 
 Arg619-N-η2 2.73 Glu541-O-ε1 H2O (W2) 2.54 
 Arg557-N-η1 3.49  Tyr509-O 2.57 
O-4 Arg264-N-η2 2.86 Glu541-O-ε1 Tyr509-O 2.86 
 Asp327-O-δ1 2.75  Arg557-N-η1 2.68 
O-7 Asp270-O-δ1 2.77    
 H2O (W1) 2.96    
O-8 Asn352-N-δ2 2.74    
O-9 Arg557-N-η2 2.91    
O-10 H2O (W1) 2.50    
N-5 Asp327-O-δ2 3.12    
 
Table 4.2 List of potential interactions of the NanB-Neu5Ac2en complex.?
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Superimposition of the complex structures of CNanA-Neu5Ac2en and NanB-
Neu5Ac2en revealed an r.m.s.d of 1.82 Å over 470 Cα atoms in the catalytic domains. 
Neu5Ac2en sits in a relatively similar position in the active sites of both sialidases. 
However, when focusing on the protein-ligand interactions, it is clear that there are 
some difference in the hydrogen-bonding patterns between CNanA and NanB with 
Neu5Ac2en (Figure 4.3). For example, the glycerol group of Neu5Ac2en in CNanA 
complex rotates slightly along the C-7 to C-8 bond when compared to the NanB-
Neu5Ac2en complex, resulting in the C-8 and C-9 hydroxyls sitting in different 
locations from that in NanB. Due to this a subtle rotation, residues Tyr590, Gln602 and 
Tyr695 in CNanA get close enough to form several hydrogen bonds with the C-8 and 
C-9 hydroxyl group. As aforementioned in Chapter 2, the Gln602 side chain has a 
close contact with Tyr695 via a water molecule W2. These may further stabilize this 
specific hydrogen bond pattern of CNanA with Neu5Ac2en. The glutamine residue 
Gln602 in the NanA active site was not commonly seen in other sialidases, which was 
only previously found in C. perfringens sialidase NanI (Newstead et al., 2008). 
Moreover, as previously discussed in Chapter 2, the sliding Phe443 upon Neu5Ac2en 
binding in NanA further tightens the hydrophobic interactions between protein and 
ligand.  
Therefore, CNanA has more intensive interactions with Neu5Ac2en than NanB. 
Moreover, in the NanC model structure, no hydrogen bond can be formed in this 
region with the glycerol group of Neu5Ac2en due to the presence of two aromatic 
Trp581 and Phe396, which may even push the glycerol group Neu5Ac2en away from 
binding in tightly (previously shown in Figure 3.5). These diverse structural features 
could significantly affect the binding affinity of Neu5Ac2en to NanA, NanB and 
NanC.  
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Figure 4.3 Stereo view of the superimposed complex structures of Neu5Ac2en with CNanA and 
NanB. The CNanA-Neu5Ac2en complex is shown in green and NanB-Neu5Ac2en complex is shown in 
blue. The conserved catalytic residues appear in identical positions and are not labelled. In CNanA and 
NanB active sites, the glycerol group of the bound ligand Neu5Ac2en adopts different orientation. 
Residues that could interact with the ligand are highlighted, which include Tyr590, Gn602 and Tyr695 
of CNanA, and Asn352 and Thr539 of NanB. In NanA, a unique Phe443 would slide to make the 
catalytic cavity half-closed upon Neu5Ac2en binding, which further tightens the ligand binding.  
  102 
4.2.2 Kinetic characterization of Neu5Ac2en inhibitions 
 
Kinetic studies were employed to study the inhibition of Neu5Ac2en towards the three 
S. pneumoniae sialidases. Estimation of the initial reaction rate was done with 
appropriately diluted proteins with the fluorogenic sialidase substrate MUAN at 37 °C 
in a TD-70 fluorometer. The initial rates were well defined as linear phase within 6 
min in 10 mM phosphate pH 6.5, 150 mM NaCl. The binding constant Km towards 
NanA, NanB and NanC are found to be 40 µM, 20 µM and 15 µM respectively. Based 
on the Michaelis-Menten equation, MUAN substrate concentrations were varied from 
below to above Km. The inhibitor concentrations were varied based on fluorometer 
readings to ensure the fluorescence in a measureable range. A Dixon plot was used to 
characterize the inhibitions and Neu5Ac2en appears to be a competitive inhibitor of all 
three S. pneumoniae sialidases (Figure 4.4). Neu5Ac2en inhibits NanA with a Ki of 
about 2.5 µM. However, this ligand only inhibits NanB and NanC with a Ki of 0.3 mM 
and 1.3 mM respectively. This is in accord with the structural differences among the 
three sialidases.  
Therefore, Neu5Ac2en suppresses NanA activity with reasonable binding affinity, but 
exist as a very poor inhibitor to both NanB and NanC. Furthermore, Neu5Ac2en 
cannot be used as drug against pneumococci, because NanC could easily relieve the 
inhibition of Neu5Ac2en towards all the S. pneumoniae sialidases by hydrating 
Neu5Ac2en to Neu5Ac, as is shown in previous chapter (Chapter 3, Section 3.4.3).          
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Figure 4.4 Dixon plot of the inhibitions of Neu5Ac2en to NanA, NanB and NanC (a, b and c). 
Neu5Ac2en appeared to be a competitive inhibitor to the three sialidases. The calculated Ki values of 
Neu5Ac2en to NanA, NanB and NanC were 2.5 µM, 0.3 mM and 1.3 mM respectively. 
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4.3 CHES forms complex structures with CNanA and NanB 
 
CHES molecules were serendipitously found bound to NanB derived from crystals 
grown in crystallization buffer containing 0.1 M CHES (10% PEG 8K, 0.1 M CHES 
and 0.25 M NaCl). In the high-resolution structure to 1.7 Å, two CHES molecules are 
clearly seen in the final structures, one is bound in the active site, and the other bound 
to the opposite side (Figure 4.5 & Figure 4.6). Furthermore, soaking CNanA crystals 
with 100 mM CHES also get this molecule bound in the active sites of both CNanA 
monomers (Figure 4.7). 
Data collection and processing statistics are summarized in Table 4.3; model 
refinement and validation statistics are in Table 4.4.  
 
 
Data collection NanB-CHES CNanA-CHES 
a, b, c(Å) 76.6/82.7/116.7 47.0/96.5/218.6 
Unit Cell   
α, β, γ (°) α= β= γ =90° α= β= γ =90° 
Space group  P212121 P212121 
Resolution (Å) 30-1.70 (1.76-1.70) 20-1.99 (2.02-1.99) 
X-ray source In-house 1.542 Å In-house 1.542 Å 
No. of observations 234069 279225 
No. of unique reflections 75667 63158 
Completeness  92.1 (62.7) 91.0 (53.8) 
I/σI 16.0 (2.4) 16.8 (4.4) 
Redundancy 3.1 (1.6) 4.4 (2.4) 
Rmerge  0.083 (0.363) 0.090 (0.264) 
Vm (Å3Da-1) 2.50 2.27 
Solvent (%) 50.8 45.9 
 
Table 4.3 Data collection and processing statistics of two datasets. Numbers in parentheses refer to 
the highest-resolution shell. 
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Refinement NanB-CHES CNanA-CHES 
Resolution (Å) 30-1.70 (1.76-1.70) 20-1.99 (2.02-1.99) 
No of used reflections 71846 63112 
Percentage observed (%) 92.0 91.1 
No. of atoms   
                    Protein 5189 7442 
                    Ligands 26 40 
                    Water 797 715 
Mean B-factor (Å2)   
                    Protein 17.1 19.1/22.5 (A/B) 
                    Ligands 20.9 17.5/21.0 (A/B) 
                    Water 28.1 25.8 
R factor 0.194 0.179 
R free 0.229 0.231 
r.m.s.d (bond Å /Angle°) 0.008/1.10 0.005/1.09 
Validation   
Clash score 4.16 12.63 
Rotamer outliers (%) 0.69 1.99 
Cβ deviations >0.25 Å 0 6 
Residues with bad 
bonds/angles (%) 0/0 0.11/0.43 
MolProbity Score 1.34 2.24 
Ramachandran 
favoured/outliers (%) 97.3/0 94.0/0.64 
 
Table 4.4 Data collection and model refinement statistics of the CHES complexes 
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Figure 4.5 Stereo image of unbiased Fo-Fc electron-density map contoured at 3 σ with the final 
refined CHES superimposed. CHES formula: C8H17NO3S; MW: 207.29 g/mol. (a) The CHES 
molecule bound to the active site; (b) the other one bound non-specifically into the cavity opposite to the 
active site. Data collected to 1.7 Å with a NanB grewin 100 mM CHES.  
 
                           
Figure 4.6 The structure of NanB in complex with two CHES molecules. Two CHES molecules are 
found bound to NanB, one at the active site (the top one with some residues highlighted), and the other 
at the opposite cavity of the catalytic centre (the bottom one).   
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Superimposition of NanB-CHES complex and native NanB structures shows an 
r.m.s.d. of 0.47 Å over 657 Cα atoms. Binding of CHES into NanB does not induce 
any conformational change in the active site. The CHES molecule interacts with all the 
catalytic residues directly or via some water molecules. In particular, two of the three 
oxygen atoms from the sulfonic acid group are hydrogen-bonded with the arginine 
triad. And the amino group of CHES interacts with Asp270; this amino group also 
interacts with Arg264 or Asp327 via the water molecule W3. The cyclohexyl ring of 
CHES sits in the hydrophobic pocket (Figure 4.7a). This ring seems to be flexible upon 
binding to the protein, as the one in the active site adopts a boat configuration, while 
the other one of non-specific binding is in a chair conformation. 
Superposition of the NanB-Neu5Ac2en and NanB-CHES complex structures shows 
that both compounds are bound in the same position without inducing any significant 
conformational changes of NanB (Figure 4.7b). Moreover, in both of the complex 
structures, a conserved water molecule (labelled as W2 in Figure 4.7b) networks 
Asp327, Tyr509 and Glu541. The only difference between the complex structures is 
that the Asn352 sidechain flips over to cater for the glycerol moiety of Neu5Ac2en, 
which does not happen upon CHES binding. W3 appeared at an interesting position in 
the CHES complex structure. This water molecule sits in a similar position to the C-4 
hydroxyl group (O-4 atom) of Neu5Ac2en and potentially networks the amino group 
of CHES with three other residues (Arg264, Asp270 and Asp327). The intensive 
interactions between CHES and NanB, as well as the high similarity of the CHES 
binding pattern to Neu5Ac2en to NanB, indicate that CHES might have some 
inhibitory effects over NanB.  
Details of potential ligand-protein interactions are summarized in Table 4.5. 
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a 
 
 
b 
 
Figure 4.7 CHES forms complex with NanB. (a) The 1.7 Å complex structure of NanB with CHES, 
the Fo-Fc map was shown in cyan at the contour level of 3σ; (b) superimposition of the complex 
structures of NanB with Neu5Ac2en and CHES (blue). 
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The CHES molecules also form complex with CNanA following a highly similar 
binding pattern to NanB-CHES complex as described above. The sulfonic group forms 
hydrogen bonds with the three-arginine cluster in CNanA active site, where the amino 
group interacts with Asp372 directly and with Asp417 via the water molecule W1’. In 
the hydrophobic pocket, the cyclohexyl ring is accommodated in with a boat 
configuration (Figure 4.9). In contrast to the CNanA-Neu5Ac2en complex, no 
conformational change was induced upon CHES binding. The r.m.s.d. of apo-form 
CNanA structure and CNanA-CHES complex is only 0.17 over 470 Cα atoms. Details 
of potential hydrogen bonding interactions between CHES and CNanA are listed in 
Table 4.5.  
The complex structures of CHES with both NanB and CNanA strongly indicate this 
molecule could show some inhibitory effects to sialidases. To test if this is true, 
enzymatic kinetics using CHES were performed. It is found that CHES acts as an 
competitive inhibitor toward all three sialidases from S. pneumoniae. It inhibits NanA, 
NanB and NanC with similar Ki values, which are 0.65 mM, 0.50 mM and 0.7 mM 
respectively (Dixon plot not shown). Therefore, CHES might be used a new 
framework of sialidase inhibitor development in the future.  
 
 
 
 
 
Figure 4.8 Stereo image of unbiased Fo-Fc electron-density map contoured at 3 σ with the final 
refined CHES superimposed. Data collected to 1.99 Å with a CNanA crystal soaked with 100 mM  
CHES for 10 min. 
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NanB-CHES complex CNanA-CHES complex 
CHES/water 
atoms 
NanB/  
water atoms 
Distance 
(Å) 
CHES/water 
atoms 
CNanA/  
water atoms 
Distance 
(Å) 
O-1 Arg245-N-η1 3.04 O-1 Arg347-N-η1 2.44 
  Arg245-N-η2 3.04   Arg347-N-η1 3.42 
  Arg619-N-η1 2.77   Arg721-N-η1 2.70 
 O-2 Arg619-N-η2 2.93  O-2 Arg721-N-η2 2.86 
 Arg557-N-η1 2.97  Arg663-N-η1 2.78 
 Arg557-N-η2 3.06  Arg663-N-η2 2.80 
N Asp270-O-δ1 3.00 N Asp372-O-δ2 2.82 
 H2O (W2) 2.72  H2O (Wa) 3.12 
H2O (W2) Arg264-N-η2 3.50 H2O (W1’) Asp417-O-δ1 2.67 
 Asp327-O-δ1 2.68  Asp417-O-δ2 3.31 
H2O (W3) Asp327-O-δ2 2.69 H2O (W2’) Asp417-O-δ2 2.64 
 Tyr590-O 2.52  Glu541-O-ε2 2.72 
 Glu541-O-ε1 2.82  Tyr590-O 2.59 
 
Table 4.5 List of potential interactions of CHES with CNanA and NanB.?
?
?
?
?
 
 
Figure 4.9 CHES forms complex with CNanA. The 1.99 Å CNanA-CHES complex structure is shown 
in green, with the native structure of CNanA superimposed (shown in grey).?
  111 
4.4 Starting SBDD work towards S. pneumoniae sialidases inhibition 
 
Neu5Ac2en is shown to be a poor inhibitor for the S. pneumoniae sialidases. 
Moreover, NanC can easily hydrate this compound to Neu5Ac. Designing of new drug 
candidates based on the current CNanA and NanB structures is necessary and currently 
feasible with high-quality crystals. Therefore, preliminary work of SBDD towards 
pneumococcal sialidase inhibition is under way. The first route we selected is using 
CHES molecule as the template to design new compounds with higher binding affinity. 
A second strategy selected is the FBDD approaches, which include using the 
fluorescence-based thermal shift assays as the high-throughput technique to screen 
again a large library of commercially available compounds. Computational docking 
and X-ray crystallographic studies are also included in the approaches. 
 
 
4.4.1 CHES molecule as a new template of novel drug design   
 
The 200 Da small molecule CHES is only a poor sialidase inhibitor with weak binding 
affinity to NanA, NanB and NanC (Ki of about 0.6 mM), however, this molecule 
provides a novel framework for developing specific inhibitors of S. pneumoniae 
sialidases. In the active sites of NanA or NanB, CHES forms hydrogen bonds with 
some of the catalytic residues, and the cyclohexyl ring sits well in the hydrophobic 
pocket. However, besides the sulfonic group, amide group and cyclohexyl moieties of 
CHES, no direct interactions are established between the enzyme and atoms on other 
parts of the CHES backbone. This makes abundant free space in the CHES skeleton for 
further modifications.??
Moreover, the water molecules around the active site of CNanA or NanB also provide 
some hints of the CHES skeleton modifications, especially the one behind the amide 
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group that networks the Arg366/264, Asp372/270 and Asp417/372 (NanA/NanB) as is 
presented in the previous section. In fact, there are still many other water molecules 
bound and being stabilized in the active sites of NanA and NanB, which indicate some 
good positions of extending the current CHES template (Figure 4.10). Due to the fact 
that NanA and NanB exhibit significantly different topology around the catalytic 
cavity, the water molecules also provide the trace of designing NanA-specific or 
NanB-specific inhibitor in the future. 
 
a 
 
 
 
 
 
 
 
b 
 
 
 
 
 
 
Figure 4.10 The surface of CNanA and NanB with CHES and water molecules shown. (a) The 
CNanA-CHES complex structure; (b) the NanB-CHES complex structure.  
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Based on current findings, it is quite possible to increase the interactions of CHES 
derivatives with the sialidase functional residues by imposing additional sidechains to 
the CHES backbone or the ring moiety. Till now, some CHES-similar molecules were 
designed with PRODRG server (Schuttelkopf and van Aalten, 2004). These include the 
addition of a hydroxyl or methyl group to CHES backbone between the sulfonic and 
amide group, or modification of the cyclohexane group to get more electrostatic 
interactions in the binding pocket.  
These compounds were subsequently investigated by computational docking method 
such as the GOLD (Genetic Optimisation for Ligand Docking) program. GOLD uses a 
genetic algorithm (GA) for ligand docking and contains a scoring function that is used 
to evaluate the results (Jones et al., 1997). The protocol of GOLD docking is detailed 
in Appendix Section I-12. Docking of CHES molecule was used as a control, which 
was docked in a very similar position as seen in the experimental complex with a Gold 
evaluation score of 66 in both CNanA and NanB. The result of CHES docking to 
CNanA is shown in Figure 4.11. Since CHES is only a weak-binding molecule to S. 
pneumoniae sialidases, any docking with the GOLD score higher than 66 would be 
considered as a hit with significance.  
After several rounds of intial designing and docking, the top hits with energetically 
favourable contacts with the functional residues are highlighted for synthesis (Table 
4.6) by our collaborators in St Andrews (NJW group or SJC group).  
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Figure 4.11 Comparison of the docked CHES with the CNanA-CHES complex. The docked CHES 
(carbon atoms coloured in pink) appears at a similar position as that observed in the complex structure. 
 
 
Gold Score 
Structure Formula Label 
CNanA NanB 
Synthesis 
 C8H17NO3S CHES 66 66 Sigma 
 
C9H19NO3S CHES_1 68 73 NJW group 
 
C10H21NO4S CHES_2 70 70 NJW group 
 
C10H21NO4S CHES_3 82 71 NJW group 
 
C8H10N2O5S CHES_4 -- -- SJC group 
 
Table 4.6 Some compounds designed based on the CHES skeleton. Gold docking method was 
selected to get an initial hint of whether the designed compounds are worthy of synthesizing in the lab.  
N
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Among the several hits shown above, CHES_3 molecule shows the highest GOLD 
docking score when it was docked to the active site of CNanA. In addition to 
interactions between the enzyme and the sulfonic group, the amino group and the 
cyclohexyl ring, CHES_3 is proposed to form hydrogen bonds with Arg366 and 
Asp372, due to the presence of a 2-hydroxyl ethyl group at the C-1 position of the 
CHES template (Figure 4.12). Docking results of other compound are not shown here. 
Further kinetic and crystallographic studies will be performed once all the compounds 
are obtained. Moreover, if experimental data could also confirm the current virtual 
docking results, more intensive modifications would be carried out afterwards. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 The virtual docking of designed compounds to CNanA with GOLD. Highlight of 
docked compound CHES_3 (shown in gray carbons). CNanA-CHES complex structure is superimposed 
to show the observed position of CHES. CHES_3 sits in the identical position as CHES molecule and 
presents a very high Gold score of 82. The 2-hydroxyl ethyl group is supposed to form additional 
interactions with Asp372 and Arg366.  
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4.4.2 The fragments screening approaches 
 
The fluorescent-based thermal shift assay is employed for the first-line screening 
method for proteins of pharmacological interest. In this assay, the changes of protein 
thermodynamic stability upon ligand binding are assessed by a thermal unfolding 
curve and the midpoint temperature (Tm) of the protein unfolding transition is 
considered as the key parameter. In practice, a final concentration of 1-5 mM 
fragments is set for the screening, where the protein concentration is fixed at 1 µM per 
reaction. Those fragments that can induce a shift of Tm over 1 °C could be considered 
as positive hits. The first library of 100 small compounds from Structural Genomics of 
Pathogenic Protozoa (SGPP) Consortium (Seattle, Washington, USA) was purchased 
for the initial screening against NanA, NanB and NanC. Eight hits were obtained from 
one hundred fragments by thermal shift assay (Table 4.7).  
 
 
 
Figure 4.13 The fluorescence-based thermal shift assay. The thermal unfolding curve of the protein 
NanB is shown in blue, whereas the curves of protein with added compounds are shown in green (4-
(hydroxymethyl) imidazole hydrochloride) and orange (arecaidine hydrochloride) respectively. 
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ΔTm (°C) 
Fragments Structure Formula 
NanA NanB 
4-(hydroxymethyl) 
imidazole 
hydrochloride  
C4H6N2O.HCl 4 4 
(s)-(+)-
hexahyromandelic 
acid  
C6H11CH(OH)CO2H 4 4 
2-(2,5-dimethyl-1,3-
thiazol-4-yl) acetic 
acid  
C7H9NOS 3 4 
3-aminopyrrolidine 
 
C4H10N2.2HCl 3 3 
shikimic acid 
 
C7H10O5 3 3 
3,5-
pyridinedicarboxylic 
acid  
C7H5NO4 2.5 2 
5-fluoroondole-2-
carboxylic acid  
C9H6FNO2 2 2 
arecaidine 
hydrochloride 
 
C7H11NO2.HCl 2 1.5 
cyclopentylacetic 
acid  
C5H9CH2CO2H 1 1.5 
 
Table 4.7 The hits of the thermal shift assay screening against the Seattle library. The hits for both 
NanA and NanB are similar. 
N
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The top hits for both NanA and NanB are identical and most of the compounds shown 
in Table 4.7 have a carboxyl group linked to other hydrophobic moieties. It is widely 
recognized that the carboxyl group of the sialidase substrate sialic acid plays a key role 
in protein-ligand interactions. Therefore, the carboxyl group in the current fragment 
hits might also interact with the conserved arginine triad in the sialidase active site, 
resulting a shift of values in the thermal shift assays.  
However, the thermal shift assay is highly sensitive to any factor that would affect the 
protein thermostability, such as the change in pH, or the ionic strength of the buffer. 
Therefore, it is still difficult to tell if the listed hits really stabilize the sialidases by 
binding to their active sites. To distinguish those false positive hits from the real ones, 
every two hits from Table 4.7 were mixed with the cryo solution of CNanA or NanB at 
the final concentration of 10 mM. Crystals of CNanA or NanB were soaked in the 
prepared fragments-containing cryo-protectant for 15 min before mounting for X-ray 
diffraction. Unfortunately, none of these fragments were seen bound to CNanA or 
NanB in crystals till now. One possibility is that the soaking concentration is not 
sufficient to form complex structure. The next step could be growing more crystals for 
soaking experiments with higher concentrations of the fragments, as only weak 
binding affinity is expected even from a real hit.  
In addition, some new libraries of fragments are under construction in the lab. Testing 
of the new compounds with the thermal shift assay, STD NMR and cocktail soaking 
techniques in the near future is on schedule. Although no essential progress has been 
achieved so far, the starting work of our SBDD approaches is still meaningful in some 
sense.  
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4.5 Discussion 
Neu5Ac2en inhibits many sialidases with micromolar to millimolar binding affinity. 
However, it still failed to suppress the activity of some enzymes in the sialidase 
superfamily, for example, the leech sialidase NanL (Chou et al., 1994). Nonetheless, 
Neu5Ac2en is still one of the most important core templates for sialidase inhibitor 
design, based on which, Zanamivir and Oseltamivir were successfully developed for 
treating the influenza viruses (Kim et al., 1997; von Itzstein et al., 1993).  
Our results in the present study show that Neu5Ac2en can only inhibit S. pneumoniae 
NanA with a Ki at micromolar level (2.5 µM), but it is unable to suppress NanB and 
NanC with high binding affinity, the Ki values of Neu5Ac2en towards NanB and NanC 
are 0.3 mM and 1.3 mM respectively. The complex structures of CNanA-Neu5Ac2en 
and NanB-Neu5Ac2en revealed that this compound is not able to form as many 
interactions with NanB and NanC as is seen in NanA, due to the major differences in 
the active sites of the pneumococcal sialidases. In addition, as is shown in previous 
chapter, the major problem of Neu5Ac2en in S. pneumoniae sialidases inhibition 
would be NanC, which can easily hydrate this molecule to Neu5Ac and thus demolish 
the inhibitory effects. Neu5Ac2en, therefore, may not be an ideal scaffold for SBDD 
approaches towards S. pneumoniae sialidases in the current case.  
Very surprisingly, the 200 Da CHES molecule was found to form stable complex 
structures with both NanA and NanB at identical positions where Neu5Ac2en binds. 
The complex structures clearly show that the sulfonic group of CHES interacts with 
the arginine triad; its amino group forms hydrogens bonds with Asp270 and Asp327 
via a water molecule, and the cyclohexyl ring sits in the hydrophobic pocket. In the 
kinetic studies, CHES exhibits some inhibitory effects on the three sialidases with a 
similar Ki value of about 0.65 mM. Moreover, the simplicity of this small molecule 
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backbone provides abundant chances for further modifications. CHES skeleton 
therefore could be a good framework to start with. The computational docking of 
several virtual CHES derivatives provides some good reference values to the selection 
of compounds for laboratory synthesis (Table 4.6). 
On the other hand, the fragment-based screening approaches against the first small 
molecules library of 100 fragments could possibly yield other solutions, although no 
substantial breakthrough has been achieved to date. In this route, the fluorescence-
based thermal shift assay was used as the first-line high-throughput screening 
technique. This assay is measuring the fluorescent signal changes of the protein 
unfolding process during a thermal denaturation treatment. Further evaluation of the 
shift of the Tm could provide accurate analysis of thermal stability or ligand-binding 
affinity (Lo et al., 2004). Unfortunately, none of the current findings in the first 100 
compounds library has been confirmed by the STD-NMR or crystallographic studies 
so far. Further screening against other library will be done soon. 
Experimental data of the current work appears very promising, especially as two of the 
CHES-type compounds, show potential for developing drug leads.              
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Chapter 5 
 
Structure and mechanism of the sialidase-like enzyme PA2794 from 
P. aeruginosa 
 
5.1 Summary 
P. aeruginosa encodes a protein (PA2794) with the predicted sequence showing some 
features of a sialidase. This protein, designated as PaNA, was expressed solubly in E. 
coli. Very surprisingly, PaNA failed to show sialidase activity in the assay with 
MUAN. This chapter describes the structural and kinetic studies on PaNA. 
PaNA was crystallized at 20 % PEG 6K, 0.1 M bicine, pH 5.0. The crystal has a cubic 
unit cell (a=b=c= 125.1 Å, α=β=γ= 90°) with space group P213. PaNA shares limited 
sequence identity with other sialidases, and MR attempts were unsuccessful. Phase 
determination was eventually achieved by single-isomorphous replacement combined 
with anomalous scattering (SIRAS) using a mercury derivative. In the final structure, 
PaNA forms a trimer around a three-fold crystallographic axis. The catalytic domain of 
PaNA displays a classical sialidase fold; and an immunoglobulin (Ig)-like domain 
trimerizes the monomers. In silico docking showed that sialic acid could not form a 
complex with PaNA due to the bulky Phe129 blocking the binding of sialic acid. A 
Phe129Ala mutation makes PaNA a poor sialidase that could be used for mechanistic 
studies. PaNA is missing an aspartic acid that normally acts as an acid/base in 
sialidases, however, this role is proposed to be taken by a charge relay of His45-Tyr21-
Glu315, as confirmed by the NMR studies. The computational docking also indicates 
that PaNA could actually be a pseudaminidase specifically recognizing pseudaminic 
acid, instead of sialic acid. 
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5.2 Expression, purification and crystallization of PaNA  
The PaNA gene was cloned from the P. aeruginosa genomic DNA. Recombinant 
PaNA in a pEHISTEV vector was expressed well in E coli BL21 (DE3) cells with 1 
mM IPTG induction overnight at 16 °C. The over-expressed protein was assessed with 
SDS-PAGE and protein identification was confirmed by MALTI-TOF MS. This 47 
kDa protein was found prone to precipitate from solution, therefore 10 % glycerol was 
added to all buffers used in the purification approaches for stabilizing the protein. 
HisTrap, anion exchange and gel filtration columns were included in the three-step 
purification strategy of PaNA. Protein yielded from all purification steps does not 
show any sialidase activity. Therefore, MALDI-TOF was used to confirm protein 
identity. A top band of about 130 kDa persistent all along with PaNA was also 
confirmed by MALDI-TOF to be the same protein, which might be the aggregated or 
polymeric form of PaNA (Figure 5.1). 
Purified PaNA was concentrated to 3.5 mg/ml in 50 mM Tris-Cl, pH 7.5, 150 mM 
NaCl, 10 % glycerol based on the PCT results. After screening against several 
commercial crystallization kits, PaNA was found to be crystallizable at either (1) 10 % 
PEG 6K, 0.1 M bicine, pH 9.0 or (2) 10 % PEG 8K and 0.1 M imidazole pH 8.0. The 
final optimized PaNA crystallization condition was 20 % PEG 6K, 0.1 M bicine, pH 
5.0. Cubic shaped crystals appeared in two days and reached the maximum size of 
about 0.15×0.15×0.15mm in about two weeks (Figure 5.2). All PaNA mutants were 
expressed and purified following the same procedure described above. F129A & 
E315Q was also crystallized in (1) 5 % PEG 6K, 0.1 M bicine, pH 9.0 or (2) 7 % PEG 
8K and 0.1 M imidazole pH 8.0. 
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Figure 5.1 The three-step purification of PaNA. PaNA is about 48kDa in SDS-PAGE gel. Nickel 
affinity (HisTrap), anion exchange (Anion) and size exclusion (Gel filtration) chromatography were 
used for PaNA purification. No sialidase activity could be detected with PaNA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Crystal of PaNA grown in 20 % PEG 6K, 0.1 M bicine, pH 5.0. The crystal appeared in 
two days and reached its maximum size of about 0.15 × 0.15 × 0.15mm in about two weeks.   
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5.3 Data collection and experimental phasing 
Native datasets were collected to 2.5 Å. The PaNA crystal belongs to the cubic unit 
cell (a=b=c= 125.1 Å, α=β=γ =90°) with P213 space group (Data collection statistics 
are summarized in Table 5.1). However, all attempts to solve the PaNA structure with 
molecular replacement failed, which may be due to the fact that this protein shares 
very limited sequence identities with any other sialidase (up to 17%).  
Experimental phasing with heavy atoms was therefore selected for the phase 
determination (Taylor, 2003). A variety of heavy metal derivatives including 
K2Hg(NO3)4, Sm(NO3)3 and pCMBS were tried with PaNA crystal soaking 
experiments. Prior to data collection, each crystal was transferred to heavy atom 
containing cryo-protectant of 20% glycerol, 15 % PEG 6K, 0.1 M bicine pH 5.0 and 5-
10 mM heavy metal derivatives for 30 min or overnight. In the first stage, 13 datasets 
were collected with the 1.542 Å in-house X-ray generator (see Appendix I Section I-9). 
The heavy-atom datasets were scaled together with the native PaNA dataset using 
SCALEIT program in the CCP4 suite. For the initial MIR (multiple isomorphous 
replacement) efforts, the heavy atom sites localization and phase calculations were all 
performed with the SOLVE program (Terwilliger, 2003) using two heavy-atom 
datasets combinations each time. However, all the electron density maps (EDMs) 
generated from above heavy atom combinations are very ambiguous and hard to 
interpret, which maybe due to non-isomorphism between datasets.  
A mercury dataset (the twelfth heavy atom dataset collected, labeled as Mercury H12) 
was subsequently collected to 2.09 Å (Data collection statistics are summarized in 
Table 5.1). SOLVE localized a single mercury site (x= 0.022, y= 0.717, z= 0.014, 
occupancy= 0.382), with a figure of merit of 0.42 and Z-score of 7.5 to 3.5 Å 
resolution. All MIR efforts with any other datasets could only localize the single heavy 
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atom site in the Mercury H12. Therefore, the Mercury H12 dataset was used for 
SIRAS phasing (Giacovazzo et al., 2002) along with the native dataset in SOLVE. As 
is seen in the EDM generated from SIRAS at 3.5 Å, the margin between the protein 
and solvent became visible, although it was not good enough for interpretation (Figure 
5.3). The RESOLVE program significantly improved the initial phases and a 
RESOLVE model was built out (Terwilliger, 2004). This model was incomplete and 
still far from a final structure determination, however, it seems to present a sialidase 
six-blade propeller fold with an associated domain that are roughly similar to the final 
structure (Figure 5.4).  
Moreover, a sphere mask of 50 Å was calculated using DM program with solvent 
flattening and histogram matching options selected (Cowtan and Zhang, 1999). This 
was used for RESOLVE map improvement in the CCP4 suite (CCP4). The final 
calculated maps from FFT task showed very clear protein-solvent boundary around a 
three-fold crystallographic symmetric axis (Figure 5.5), which was adequate for the 
following model building.                 
 
 
  126 
Data collection Native PaNA Mercury H12 
a, b, c(Å) 125.1/125.1/125.1 125.3/125.3/125.3 Unit Cell   
α, β, γ (°) α= β= γ =90° α= β= γ =90° 
Space group  P213 P213 
Resolution (Å) 30-2.50 (2.64-2.50) 30-2.09 (2.21-2.09) 
No. of observations 129075 146358 
No. of unique reflections 22343 35442 
Completeness  97.9 (91.8) 92.1 (65.5) 
I/σI  20.1 (2.5) 21.6 (2.9) 
Redundancy 5.8 (3.0) 4.1 (1.9) 
Rmerge  0.079 (0.420) 0.042 (0.246) 
Vm(Å3Da-1) 3.47 3.49 
Solvent (%) 64.6 64.8 
 
Table 5.1 Data collection and processing statistics of the native PaNA and a mercury datasets. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 The EDM from SOLVE at 3.5 Å. The edge between the protein solvent is visible, but this 
map is still not interpretable.  
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Figure 5.4 The model built by RESOLVE. (a) Residues built in the chains are all alanines; (b) cartoon 
representation of the RESOLVE model, which roughly shows a six-bladed propeller fold.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 The map and mask calculated in DM. Clear protein-solvent boundary was displayed, view 
from the three-fold symmetric axis. This map is used for the following model building. 
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5.4 Model building, refinement and validation 
 
The ARP/wARP program was used to build the PaNA model with the MTZ file 
generated from DM and the PaNA sequence file of 438 residues. After 50 building 
cycles, 18 chains of 351 residues in total were built in the model with an R factor of 
20.6 and a connectivity score of 0.89.  
Although there were still more than 130 residues missing in the ARP-wARP model, 
the majority of 351 placed residues match the maps very well, except residues 118-
148, 225-240, 267-293 and some single residues missing sporadically (Figure 5.6a). 
With this model from ARP-wARP, the PaNA structure was subsequently rebuilt in 
Coot manually. In the final PaNA model, almost all the residues (residues 2-438) in the 
predicted sequence are visible. The restrained refinement of the PaNA structure against 
the 2.09 Å Mercury H12 dataset using Phenix Refine yields an R factor and Rfree of 
0.176 and 0.208 respectively (Figure 5.6b).  
Refinement statistics are summarized in Table 5.3 below. Moreover, the density for the 
mercury atom interacting with Cys265 can be clearly seen (Figure 5.7).       
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Figure 5.6 Comparison of the initial PaNA model and the final refined PaNA monomer. (a) The 
first model built by ARP-wARP; (b) the final model.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 The EDM around Cys265. The 2Fo-Fc map and Fo-Fc map are at 1 and 20σ respectively. 
A grey cross was put in the centre of the difference map density locating the position of the mercury 
atom. 
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The crystal soaking and co-crystallization experiments of PaNA with Neu5Ac2en, 
Neu5Ac and CHES all failed to show anything bound to the protein. Therefore, no 
complex structure of PaNA has been obtained to date. The best native PaNA dataset 
was collected to 1.9 Å in-house with a crystal soaked with 0.1 M CHES pH 9.0 and the 
refined apo form PaNA structure contains residues 7-438 with the R/Rfree of 
0.175/0.198. The first 6 residues are not visible in this structure, which might be due to 
the pH change in crystal soaking. Another dataset collected to satisfactory resolution, 
2.64 Å, is from a Phe129Ala/Glu315Gln mutant crystal (Discussed below). Crystals 
from other mutants are still under optimization. The refined structure further confirmed 
the site mutation and no obvious conformational change happened after these 
mutations. The r.m.s.d between the native and Phe129Ala/Glu315Gln mutant 
structures is 0.19 Å over 430 Cα atoms. Data collection, processing, model refinement 
and validation statistics are summarized in Table 5.2 and Table 5.3.  
Data collection Best apo form  F129A/E315Q 
a, b, c(Å) 126.2/126.2/126.2 125.1/125.1/125.1 Unit Cell   
α, β, γ (°) α= β= γ =90° α= β= γ =90° 
Space group  P213 P213 
Resolution (Å) 30-1.90 (2.00-1.90) 30-2.64 (2.74-2.64) 
No. of observations 142004 71316 
No. of unique reflections 50018 18478 
Completeness  94.6 (69.9) 95.3 (79.7) 
I/σI 17.9/2.1 7.0 (2.1) 
Redundancy 2.8 (1.2) 3.9 (3.0) 
Rmerge  0.042 (0.314) 0.10 (0.373) 
Vm (Å3Da-1) one molecule/a.u. 3.57 3.46 
Solvent (%) 65.5 64.5 
 
Table 5.2. Data collection and processing statistics of the best PaNA and the Phe129Ala 
/Glu315Gln datasets. Single letter code is used in the table for concision. 
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Refinement PaNA (apo best) Mercury H12 F129A&E315Q 
Resolution (Å) 30-1.90  30-2.09 30-2.64 
Residues visible 7-438 2-438 2-438 
No of used reflections 49985 35371 17503 
Percentage observed (%)? 94.4 92.0 95.4 
No. of atoms    
                    Protein 3285 3331 3285 
                    Ligands 0 1 (Hg) 0 
                    Water 417  341 180 
Mean B-factor (Å2)    
                    Protein 21.8 27.0 45.8 
                    Ligands 0 43.3 0 
                    Water 29.7 33.2 42.0 
R factor 0.175 0.176 0.265 
R free 0.198 0.208 0.323 
r.m.s.d (bond distance Å 
/Angle°) 0.013/1.47 0.010/1.15 0.006/0.927 
Validation    
Clash score 9.27 13.24 7.39 
Rotamer outliers (%) 2.36 2.03 1.46 
Cβ deviations >0.25 Å 2 0 1 
Residues with bad 
bonds/angles (%) 1.62/1.85 0/0.23 0/0 
MolProbity Score 2.00 2.15 1.85 
Ramachandran 
favoured/outliers (%) 96.5/0 95.9/0 95.4/0.23 
 
Table 5.3 Structure refinement and validation statistics of PaNA structures.          
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5.5 Overall structure of PaNA 
437 residues of PaNA excluding the first methionine are visible in the final model and 
many conformational details of this P. aeruginosa virulent enzyme are revealed with 
this structure. Three PaNA monomers form a trimer around a crystallographic 3-fold 
axis (Figure 5.8). This trefoil-like trimeric structure is unique in the sialidase super 
family. To date, PaNA is the second polymeric bacterial sialidase that has been 
reported, the first one is the dimeric structure of S. pneumoniae NanA (PDB code 
2VVZ) previously described in Chapter 2.  
The PaNA monomer contains two distinct domains, a conserved catalytic domain and 
an extra domain linked by a 7-residue coil (residues 328-334). The core catalytic 
domain spans from residue 13 to 327 and exhibits a classic six-bladed β-propeller fold, 
which is most similar in structure to the catalytic domain of M. viridifaciens sialidase 
MvNA (PDB code 1EUS). The two proteins superimpose with an r.m.s.d of 2.3 Å for 
277 Cα atoms although they just share 17% sequence identity. This sialidase fold is 
well conserved among all sialidases. In addition, there are three Asp boxes present in 
this domain of PaNA, which is also a hallmark for non-viral sialidases and may 
contribute to maintaining the β-propeller fold of bacterial sialidases. Moreover, the 
opposite side of the proposed active site in each monomer stacked together around the 
symmetric axis with a buried interface between the monomers of about 600 Å2. The N-
terminal of PaNA with residues 2-12 is composed of many hydrophobic side chains 
including Tyr4, Phe5, Ile7, Pro8, Leu11 and Val12 form a coil. The presence of this 
coil facilitates interactions between the sialidase domains and further stabilizes the 
PaNA trimeric conformation. The three putative catalytic sites in this PaNA trimer 
radiate to three different directions of 120° apart from each other around the symmetric 
axis, which may enable the enzyme to achieve maximal efficiency of substrate 
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recognition and binding in vivo. As is shown in Figure 5.9, the surface charge potential 
of PaNA could be favorable for sialic acid-like substrates attachment and recognition. 
The PaNA trimer also has an asymmetric electrostatic distribution as seen in other 
sialidases. This surface charge pattern helps to orientate the PaNA active site 
specifically towards negatively charged sialyl substrates.  
 
   
  
Figure 5.8 The overall structure of PaNA. (a, b) Orthogonal views of the PaNA trimer; (c, d) 
orthogonal views of the PaNA monomer.  
90° 
90° 
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Figure 5.9 The solvent accessible surface of PaNA coloured according to electrostatic potential.  
 
90° 
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The extra domain contains residues 335-438, which fold into 11 β strands. The strands 
form two anti-parallel β sheets packing against each other (Figure 5.10). Such a 
topology stands for an Ig-like β-sandwich fold (Clarke et al., 1999). Moreover, this 
domain is the essential part that trimerizes PaNA monomers to the trefoil architecture 
(Figure 5.11). The three identical units pack against each other tightly and the 
calculated buried interface between monomers is about 500 Å2. This type of trimeric 
association between the Ig-like folds is similar to some tumor necrosis factor (TNF)-
like cytokine trimers, such as the mouse TNF (PDB code 2TNF) (Baeyens et al., 
1999). The r.m.s.d of the two Ig-like trimersiation domain structures superimposition is 
4.6 Å among 214 Cα atoms. The extra domain of PaNA was designated as 
trimersiation domain (TD) in this context. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Stereo view of the Ig-like trimersiation domain of PaNA. The TD domain (residue 335-
438) is linked to the C-terminal of the catalytic domain via a 7-residue loop. In this domain, two anti-
parallel β sheets packed against each other, which stands for an Ig-like β-sandwich fold.  
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Figure 5.11 The TD domain of PaNA. The three identical TD domains from three monomers of PaNA 
were shown in different colours. (a) Views from the side of the PaNA; (b) views from the three-fold 
symmetric axis.  
90° 
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5.6 The proposed active site of PaNA 
Unlike all other sialidases, the catalytic cavity of P. aeruginosa PaNA is very broad 
and shallow. At the widest space, the PaNA active site is about 14 Å ×18 Å and no 
well-marked enclosure of a good hydrophobic pocket is actually formed (Figure 5.12). 
This conformation might not be advantageous for a highly specific binding of sialic 
acid. Compared to the MvNA-Neu5Ac2en complex structure (PDB code: 1EUS), it is 
easy to find out that the nucleophile tyrosine Tyr297 and the associated residue Glu182 
are still present in PaNA structure. However, PaNA lacks some conserved key residues 
of sialidases around the active site (Figure 5.13). For example, all sialidases studied to 
date have a three-arginine cluster that interacts with the carboxylate group of sialic 
acid and the first arginine residue is normally conserved in the RIP motif (Taylor, 
1996). In contrast, this carboxylate-interacting arginine is missing from PaNA active 
site, although the second and third arginine residues, Arg198 and Arg260, are still 
there in the similar positions to those of MvNA. Moreover, the conserved acid/base 
functional aspartic acid residue in sialidases is also missing from PaNA. Instead, PaNA 
has a histidine His45 located in the loop above the active site where the aspartic acid 
normally sits and may take its role. This loop could be flexible upon ligand binding 
due to a sequence with less side chains restraints (His45-Val46-Gly47-Gly48). 
Furthermore, the Phe129 of PaNA is even positioned in a way that would clash with 
the acetamido group of Neu5Ac and derivatives. These structural features strongly 
suggest that PaNA is not a normal sialidase that specifically recognizes and binds sialic 
acid and sialilated substrates, in line with our kinetic findings that PaNA does not 
display reasonable sialidase activity as expected.  
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Figure 5.12 The topology around the proposed active site of PaNA. Residues around the proposed 
catalytic cavity are labelled.   
   
Figure 5.13 Superimposition of the structurs of PaNA and MvNA-Neu5Ac2en complex. PaNA is 
cloured in green, while MvNA is shown in pale brown. The residues at similar positions are labelled in 
the order of PaNA/MvNA. Single letter code is used for concision. ?
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5.7 In silico docking of Pse5Ac7Ac and Neu5Ac 
In P. aeruginosa, pseudaminic acid (Pse5Ac7Ac, 2 in Figure 5.14) is found in LPS and 
pili (Comer et al., 2002; Rocchetta et al., 1999) and this chemical has been suggested 
to be the real substrate of PaNA in vivo (Soong et al., 2006). In fact, the flagella of 
Campylobacter coli (C. coli) and Campylobacter jejuni (C. jejuni) are also decorated 
with Pse5Ac7Ac, or a dihydroxyproprionyl form Pse5Pr7Pr (5) that are all O-linked, 
via O-2, to certain flagellin serine and threonine residues (Logan et al., 2002; McNally 
et al., 2006; Thibault et al., 2001). Compared to sialic acid, the pseudaminic acid and 
related compounds have a different stereochemistry at C-5, where the acetamido group 
is at the axial orientation (Figure 5.14). However, no Pse5Ac7Ac compound is 
commercially available and all attempts to obtain a complex structure of PaNA with 
the sialic acid derivatives are unsuccessful. 
 
 
Figure 5.14 Chemical structures of sialic acid and pseudaminic acid compounds.  
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In order to investigate the potential binding of sialic acid and pseudaminic acid to 
PaNA, some ligands, Neu5Ac and Pse5Ac7Ac in boat conformation and Neu5Ac2en 
in a half-chair configuration, were tried with two different docking packages, GOLD 
and AutoDock (Goodsell et al., 1996). The MvNA structure was used as a positive 
control, and both programs docked Neu5Ac2en into the active site precisely (Data not 
shown).  
In the case of PaNA, both programs also yield very similar docking results. 
Pse5Ac7Ac can be docked into the PaNA active site at an energy-favourable position 
showing all possible interactions with the conserved residues. The estimated Ki of 
Pse5Ac7Ac by AuotoDock is about 15 µM. As is shown in Figure 5.15, the docked 
Pse5Ac7Ac is superimposed well on Neu5Ac2en at the observed position in the 
MvNA crystal structure. However, Neu5Ac or Neu5Ac2en does not show reasonable 
energy favourable contacts with PaNA in the docking experiments. The estimated Ki 
values are all over 80 µM, much higher than that of Pse5Ac7Ac.  
Phe129 appears to be the key residue for pseudaminic acid substrate selection in 
PaNA. The bulky sidechain of Phe129 may block sialic acid substrates by invoking 
clashes with the acetamido group of Neu5Ac at C-5. However, this clash can be 
tolerated by the altered orientation of the C-5 acetamido group of Pse5Ac7Ac (Figure 
5.15). These docking results indicate that Phe129 may be responsible for PaNA 
substrate specificity towards pseudaminic acid. It is therefore possible that a single 
residue mutation of Phe129 to alanine might free a lot of space for accommodating the 
acetamido group of sialic acid. Docking of Neu5Ac2en to the Phe129Ala structure 
further supports this postulation (Figure 5.16). In addition, the axial orientation of the 
Pse5Ac7Ac acetamido group would also preclude an aspartic acid being present at the 
same position as Asp92 in MvNA to act as the acid/base.  
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Figure 5.15 Stereo views of the docked Pse5Ac7Ac to the proposed active site of PaNA. The carbon 
atoms of Pse5Ac7Ac are shown in gray. The Neu5Ac2en (carbon shown in yellow) from MvNA-
Neu5Ac2en complex is superimposed to indicate the relative position.     
  
Figure 5.16 Stereo views of docked Neu5Ac2en molecule to the Phe129Ala/Glu315Gln mutant 
structure. The surface and carbon atoms of Phe129A/Glu315Gln crystal structure is shown in gray and 
the wild type PaNA structure is shown in green.  
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5.8 The Phe129Ala mutation of PaNA 
The in silico docking studies suggest that Phe129 is key in the pseudaminic acid 
substrate selection of PaNA, and moreover, the site mutation of phenylalanine to a 
small side chain residue is likely to free some space for accommodating the acetamido 
group of sialic acid. A Phe129Ala mutant of PaNA was therefore obtained. The kinetic 
studies show that wild type PaNA does not cleave the substrate at all, while Phe129Ala 
mutant released significant amount of the fluorescent agent 4-MU from the sialidase 
substrate MUAN in 120 hr (Figure 5.17). These results indicate that the mutation of 
Phe129 turns this enzyme into a sialidase with very weak enzymatic activity, which is 
sufficient to have a means of investigating the roles of other amino acid residues in 
PaNA active site.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 The sialidase activity assays of wild type and Phe129Ala mutant of PaNA. In 1 ml 
reaction, 35 µg/ml protein was incubated with 100 µM MUAN at 37 °C in 0.1 M Tris, 150mM NaCl pH 
7.5 for 0 hr to 120 hr before measuring the fluorescence at 360/465 nm. 
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5.9 A proposed charge relay of PaNA 
PaNA does not have the aspartic acid residue that normally acts as an acid/base 
catalyst in all other sialidases. His45, in a similar position to the aspartic acid in other 
sialidases, might compensate for this defect in PaNA. A rotation of His45 around its 
Cα-Cβ bond to another preferred rotamer position makes it closer to the possible 
substrate sitting position. Moreover, if this proposal is right, His45 could make a 
hydrogen bond interaction with the ring hydroxyl of Tyr21 that was already in 
hydrogen bond contact with Glu315 (Figure 5.18). This suggested that the charge of 
His45 might be modulated through a charge relay system involving Glu315, Tyr21 and 
His45. To test this hypothesis we made the three dual mutants: Phe129Ala with 
His45Gly, Phe129Ala with Tyr21Phe and Phe129Ala with Glu315Gln. 
   
  
Figure 5.18 Stereo view of the proposed charge relay of His45-Tyr21-Glu315. After a rotamer 
rotation of the sidechain of His45, the distance between His45 and the O2 of the docked Pse5Ac7Ac is 
about 3.5 Å. This move of His45sidechain would not affect the charge relay of His45-Tyr21-Glu315. 
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5.10 NMR studies of the catalysis of PaNA and its mutants  
1H-NMR spectroscopy further confirmed that PaNA is not able to cleave the sialidase 
substrate MUAN. As is shown in Figure 5.19, almost all MUAN remained intact over 
the 100 hr reaction time. There are indeed very tiny peaks of 4-MU and Neu5Ac 
present in the spectrum; however, these peaks might be due to the self-degradation of 
MUAN seen previously.  
In contrast, Phe129Ala mutant was found capable of cleaving most MUAN in 100 hr 
reactions to release the fluorescent agent 4-MU (Hb/Hc δ= 7.52 ppm, Hd δ= 6.70 ppm 
and C-a δ=6.0 ppm) and the sialic acid Neu5Ac (H3eq δ= 2.08 ppm, H3ax δ= 1.68 
ppm and NHCOCH3 δ= 1.90 ppm), which is in line with previous kinetic results 
shown in Section 5.9 of the current chapter. Very surprisingly, there is also very 
significant amount of Neu5Ac2en detected in the reactions (H3 at δ= 5.52 ppm and 
NHCOCH3 at δ= 1.92 ppm). The ratio of Neu5Ac2en: Neu5Ac was changing with the 
reaction time, it decreased from 1: 3 (24 hr) to 1: 2.87 (48 hr), and finally down to 1: 
2.5 at 100 hr (Integrated data not shown). However, the ratio of released Neu5Ac2en: 
4-MU is about 1: 4, which remains constant throughout the reactions from 12 hr to 100 
hr (Appendix II-6). These results suggest that the production of Neu5Ac was not from 
Neu5Ac2en hydration, but from the hydrolysis of MUAN directly. 
In separate experiments, Phe129Ala is shown to be unable to convert Neu5Ac to 
Neu5Ac2en, or vice versa, Neu5Ac2en cannot be hydrated to Neu5Ac by this enzyme 
(Data not shown). Therefore, both Neu5Ac and Neu5Ac2en are direct products 
released by Phe129Ala from MUAN in this experiment.   
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Figure 5.19 1H NMR spectra of the 100 hr reactions of MUAN with PaNA wild type and F129A.  
Wild type PaNA does not cleave MUAN, while Phe129Ala processed most MUAN to release both 
Neu5Ac and Neu5Ac2en in the reactions.  
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To investigate the roles of the proposed charge relay formed by His45-Tyr21-Glu315, 
NMR studies toward the corresponding PaNA mutants (Phe129Ala, 
Phe129Ala/His45Gly, Phe129Ala/Tyr21Phe or Phe129Ala/Glu315Gln mutants) were 
performed. NMR spectra were taken after certain time intervals after α2,3-sialyllactose 
was incubated with one of the mutants. As expected, PaNA mutants only show very 
poor sialidase activity in cleaving α2,3-sialyllactose, with only about 30% of the 
substrate was processed in 48 hr (Figure 5.20).  
As with the previous reactions with MUAN, the Phe129Ala mutant also produces both 
Neu5Ac and Neu5Ac2en in a similar ratio (about 2.8: 1) from α2,3-sialyllactose in the 
48 hr reaction time. Phe129Ala is the only mutant of PaNA that releases both Neu5Ac 
and Neu5Ac2en at the same time from sialilated substrates. 
The Phe129Ala/Glu315Gln double mutant of PaNA solely release Neu5Ac from α2,3-
sialyllactose, while Phe129Ala/His45Gly mutant just produces Neu5Ac2en. These 
mutations showed opposite effects towards the Phe129Ala catalysis, which might 
suggest the acidic or basic properties of the charge relay might orientate a substitution 
reaction (produces Neu5Ac) or an elimination reaction (produces Neu5Ac2en). An 
alternative explanation could be that this mutation affects the efficacy of activating a 
water molecule for a nucleophilic attack. Different from all above reactions, the 
mutation of the central residue Tyr21 in the charge relay completely kills the enzyme’s 
ability to process α2,3-sialyllactose.  
Therefore, these NMR results of the PaNA mutants strongly suggest the participation 
of His45-Tyr21-Glu315 charge relay in PaNA catalysis.  
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Figure 5.20 NMR spectra of the reactions of PaNA mutants with 3SL. Phe129Ala mutant produces 
both Neu5Ac and Neu5Ac2en from 3SL. Phe129Ala/Glu315Gln produces Neu5Ac and 
Phe129Ala/His45Gly releases Neu5Ac2en. Phe129Ala/Tyr21Phe does not cleave 3SL at all.  
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5.11 Discussion  
The P. aeruginosa enzyme PA2794 has been previously found to be essential in the 
pathogenesis of P. aeruginosa by facilitating the biofilm formation and bacterial 
colonization (Soong et al., 2006). This 438-residue protein was annotated as a putative 
sialidase due to the presence of three Asp-box motifs in the sequence analysis. But in 
fact, it only shares up to 17% sequence identity to other sialidases. Moreover, different 
from the previous reports with partially purified enzyme (Cacalano et al., 1992; Leprat 
and Michel-Briand, 1980), the PaNA we obtained in the current study does not show 
any notable sialidase activity compared to other sialidases such as NanA, NanB or 
NanC from S. pneumoniae. Using MUAN as the probe, the manifest sialidase activity 
of PaNA is at least 10,000 fold lower than that of NanA (Data not shown). 
Nonetheless, this protein could still be classified into the sialidase superfamily as an 
atypical enzyme, since it contains a core catalytic domain exhibiting the sialidase six-
bladed β-propeller fold, as is predicted by the fold recognition server (Figure 1.9 b) 
and observed in PaNA crystal structure (Figure 5.8).  
PaNA exists as an unusual trimer, which is associated by the extra Ig-like trimersation 
domain. Previously in Chapter 1 and Chapter 2, the viral sialidase tetramers (Crennell 
et al., 2000; Varghese et al., 1983), the bacteriophage endosialidase trimer 
(Stummeyer et al., 2005) and S. pneumoniae NanA dimer (Chapter 2) have been 
presented and discussed. However, such a unique trimeric assembly of PaNA has 
never been seen. In PaNA trimer, the three catalytic domains form a regular triangle 
viewing from the top, with the active sites pointing away from the 3-fold symmetric 
axis (Figure 5.8). The solvent-accessible surface of PaNA presents an asymmetric 
electrostatic distribution similar to other sialidases, the active site side is mainly 
positively charged and the other sides are significantly negatively charged, which 
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could facilitate PaNA targeting the negatively charged substrates and avoid some non-
specific bindings (Figure 5.9).     
The catalytic cleft of PaNA also shows a different conformation from other sialidases. 
In PaNA, the active site is very shallow and open, with no clear hydrophobic pocket 
there for accommodating the C-5 acetamido group of sialic acid. Virtual docking 
studies indicate the incapability of PaNA in cleaving sialosides might be attributed to 
the presence of Phe129, of which the bulky sidechain may generate a significant steric 
hindrance for Neu5Ac2en around the C-5 acetamido group (Figure 5.15 and Figure 
5.16). Mutation of Phe129 to alanine by site directed mutagenesis (SDM) significantly 
increases the sialioside processing capacity of this enzyme (Figure 5.17 and Figure 
5.19). Therefore, Phe129 is possibly responsible for a substrate selection of PaNA 
towards specific kinds of carbohydrates rather than the Neu5Ac analogues. This is in 
line with the previous findings that P. aeruginosa does not use sialic acids in vivo 
(Wozniak et al., 2003). Instead, a specific 9-carbon sugar pseudaminic acid was 
proposed to be a possible substrate for PaNA (Soong et al., 2006). Moreover, the 
flagella of certain Pseudomonas, Campylobacter and Helicobacter species are found 
decorated with pseudaminic acid, and such decorations are essential for the proper 
assembly of flagella components (Szymanski and Wren, 2005). The virtual docking of 
Pse5Ac7Ac to PaNA yielded an energy favorable protein-ligand interaction pattern, 
with no clash between the C-5 group and the sidechain of Phe129 (Figure 5.15). 
Therefore, PaNA could be a pseudaminidase (named after the substrate pseudaminic 
acid) that recognizes and processes pseudaminic acid linked glycans, rather than a 
normal sialidase expressed for sialic acid removal. Unfortunately, no suitable 
pseudaminic acid or any suitable derivatives are currently available for a further 
verification.  
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Since the mutation of Phe129 to alanine could turn PaNA into a poor sialidase, it is 
therefore possible to study the mechanism of PaNA with the mutated enzyme and 
common sialilated substrates, such as MUAN and α2,3-sialyllactose. Due to the fact 
that PaNA does not possess the acid/base aspartic acid residue, a proposed charge relay 
of three residues His45-Tyr21-Glu315 might be able to take its role. As is shown 
above in Figure 5.20, the mutation of His45 to glycine makes this enzyme only 
produce Neu5Ac2en from 3SL, which indicates that no effective hydration of the 
catalytic intermediate oxocarbonium could occur in the absence of His45. Tyr21 is in 
the middle part of the charge relay and mutation of this residue to phenylalanine 
completely disabled this enzyme, which suggests that the electron flow in the charge 
relay has to be transferred via the hydroxyl group of Tyr21, or no water molecules can 
be activated without the reactive tyrosine. In addition, the Glu315Gln mutant only 
makes Neu5Ac from 3SL. In this case, glutamine cannot undergo a formal 
deprotonation like the glutamate, but it may be enough of an interaction to "activate" 
the whole charge relay system to fulfill the acid/base role as aspartic acid catalyst does 
in other hydrolytic sialidases. Based on these finding, a proposed mechanism of PaNA 
catalysis is shown in Figure 5.21 below.  
In this newly proposed mechanism, the potential electron flow of the novel His45-
Tyr21-Glu315 charge relay is indicated with red arrows, which would compensate the 
role of an acid/base aspartic acid seen in all other sialidases. In general, the roles of all 
other residues are supposed to be similar to other sialidases. For instance, the arginines 
would stabilize the caboxylate group of the substrates and further help distort the 
bound ligand to a boat conformation; the nucleophile tyrosine and its associated 
glutamate residue would handle the nucleophilic attack.  
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Figure 5.21 The proposed catalytic mechanism of PaNA sialidase/pseudaminidase.  
 
 
In summary, PaNA, the enzyme PA2794 from P. aeruginosa, has been misunderstood 
for a long time as a classic sialidase ever since it was characterized (Cacalano et al., 
1992; Leprat and Michel-Briand, 1980; Soong et al., 2006). The present crystal 
structure, as well as detailed docking and NMR kinetic studies revealed that PaNA is 
not a classic hydrolytic sialidase. This enzyme is probably a pseudaminidase that 
specifically recognizes and processes pseudaminic acids for some virulent roles in P. 
aeruginosa pathogenesis. The proposed mechanism is also superficially similar to that 
of normal sialidases, except for the newly identified His45-Tyr21-Glu315 charge relay 
system for compensation of the missing acid/base aspartic acid. Therefore, based on 
the current findings, this enzyme could be classified into a novel subtype in the 
sialidase superfamily. All in all, further investigations using the real substrates, 
pseudaminic acid linked glyconjugates, still need to be performed. 
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Summary and future work 
In the current study, the crystal structures of NanA catalytic domain (including two 
complex structures with Neu5Ac2en and CHES), full-length NanB (including two 
complex structures with Neu5Ac2en and CHES) from S. pneumoniae and PaNA from 
P. aeruginosa were presented. Kinetic and NMR studies of these enzymes were also 
performed, which yielded some novel findings about their diverse catalytic properties. 
These results, in some sense, add further evidences of sialidase as virulence factors in 
some infectious diseases. Moreover, some sialidases like NanC do not simply cleave 
terminal sialic acids from cell surface glycans, but also handle diverse roles in vivo.  
In S. pneumoniae, both NanA and NanB have been previously reported to be essential 
in pneumococcal virulence, and NanB could compensate, in part, the loss of NanA in 
nanA gene knock-out strains (Burnaugh et al., 2008; Manco et al., 2006). However, no 
further understanding of the underlying molecular mechanism has been achieved. Here 
in the present study, NanA is found to be a classic hydrolytic sialidase for major 
virulence and NanB acts as an IT trans-sialidase that is possibly for nutritional roles. 
NanC, in contrast, presents dual functions of both synthesizing and hydrating 
Neu5Ac2en to regulate the actions of NanA and NanB. The present results, for the first 
time, unveiled the long-standing mystery of why this bacterium expresses three 
sialidases at the molecular biology level. Furthermore, the crystal structures of CNanA 
and NanB provide precise conformational information about these sialidases. The 
different topology around CNanA and NanB active sites confers different substrate 
specificity. Moreover, the kinetics studies and complex structures revealed why 
Neu5Ac2en merely shows poor inhibition towards pneumococcal sialidases. Based on 
the current findings, NanA, NanB and NanC can now be postulated to handle disparate 
and cooperative functions, presumably key in different stages of pneumococcal 
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colonization and infection. To date, the crystallographic study of NanC is still ongoing, 
and therefore solving the crystal structure of NanC will be one of the main focuses in 
the near future.  
The crystal structures of CNanA and NanB also make the structured-based drug 
discovery possible. In addition, the serendipitous discovery of CHES molecule as a 
novel pneumococcal sialidase inhibitor, albeit a poor one, provides a new template for 
SBDD. Some preliminary work shows promising aspects with both CHES-skeleton 
inhibitor design and fragment-based screening approaches. Chemical synthesis of 
some designed CHES similar molecules is on schedule. Once the new compounds are 
obtained, kinetic and crystallographic studies will be carried out for evaluation and 
more intensive modification. Moreover, new libraries of about 1000 fragments are 
under construction. Further screening of NanA, NanB and NanC against these with the 
thermal shift assay to identify more hits has been planned.  
In fact, it is still distant from the fulfilment of the research towards pneumococcal 
sialidases. Recently, sialic acid is suggested to be a signalling molecule in S. 
pneumoniae biofilm formation, as well as the regulation of NanA and NanB 
expression. Moreover, the free sialic acid also promotes the pneumococcal 
translocation from the nasopharyngeal colonization to the lung infections (Trappetti et 
al., 2009). Such regulation by sialic acid may be based on an operon system postulated 
in Appendix II-7. However, no further evidence has yet been obtained to support this 
idea. Therefore, some structural studies towards elements in the proposed operon that 
might be regulated by sialic acid would be of great interest. 
In the case of P. aeruginosa, the putative sialidase was found directly involved in the 
biofilm formation of this pathogenic bacterium (Soong et al., 2006). Moreover, this 
enzyme is one of the conserved P. aeruginosa virulence factors identified to date 
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(Lanotte et al., 2004). Different from previous report by Soong et al. (2006), PaNA 
does not show any sialidase activity in the current study, although this protein presents 
some structural features in common with other sialidases, for instance, the three Asp 
boxes in the sequence and the six-bladed β-propeller fold of the core catalytic domain. 
The virtual docking results suggested that this enzyme could be a pseudaminidase that 
specifically recognizes pseudaminic acid, instead of sialic acid. Phe129 is the key 
residue that confers such substrate selectivity. Therefore, the present results resolved 
the misunderstanding of PaNA as a classic sialidase, but further study is necessary to 
precisely define PaNA as a pseudaminidase, a novel subtype in the sialidase 
superfamily. Thus, obtaining pseudaminic acid to gather some direct evidences is quite 
essential. Currently, our collaborators in Griffith University, Australia are working on 
the synthesis of pseudaminic acid. In addition, the identification of a novel charge 
relay of His45-Tyr21-Glu315 taking the acid/base catalyst role in PaNA is also 
interesting. Further work towards characterization of this charge relay remains to be 
carried out. Furthermore, SBDD towards PaNA inhibition based on the current crystal 
structure is also on the schedule.  
Meanwhile, our recent bioinformatics data mining identified several hypothetical 
proteins in the pseudaminic acid producing Helicobacter pylori (H. pylori) strains, 
which show promise of being annotated as pseudaminidase, although no RIP motif or 
Asp box is found in the sequence (Data not shown). If these proteins were proved to be 
pseudaminidase, more weight would be added to the novel sialidase subtype. 
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Appendix I 
 
Material and Methods 
 
I-1. Plasmid construction and site-directed mutagenesis 
The nanA, nanB and nanC genes from S. pneumoniae (nanA gene in a pQE30 vector, 
nanB in a pGEM T-easy vector and nanC in a pET21b vector) were kindly provided by 
Professor P. J. Andrew (Leicester, UK) and Professor M. R. Oggioni (Siena, Italy) 
respectively.  
The PaNA gene (PA2794) was directly cloned from the genomic DNA of P. 
aeruginosa PAO1-LAC strain purchased from the American Type Culture Collection 
(ATCC catalogue No. 47085D).  
All these genes were then sub-cloned into the commonly used expression vectors in the 
lab, such as pET23b (Novagen) and pEHISTEV (Liu and Naismith, 2009). The routine 
gene cloning procedures are described as below. Target genes were firstly amplified by 
the polymerase chain reactions (PCR) using the primer pairs shown in Table I-1. The 
PCR products were analyzed with 0.8% agarose gel electrophoresis with 0.5 µg/ml 
ethidum bromide (EB). The DNA bands of expected sizes were excised from gels and 
purified with the QIAquick PCR purification Kit (Qiagen). The purified DNA 
segments and selected vectors were then digested with appropriate restriction enzymes 
combinations (Restriction enzymes were all purchased from Promega). Cohesive end 
ligation of the digested vector and DNA insert was performed at room temperature for 
overnight in the presence of T4 DNA ligase (Promega). Transformation of E. coli 
DH5α competent cells (Invitrogen) with the ligated DNA was achieved via the heat 
shock method: the cells/DNA mixture (cell/DNA ratio: 20 µl/1 µl) was firstly kept on 
an ice for 30 min, and then subjected to heat shock at 42 °C for 45 sec followed by an 
  156 
ice bath for 2 min. The cells were subsequently shaken at 37 °C for 1 hr in 200 µl pre-
warmed Luria Bertani medium before plating out. Colonies grown on the LB plates 
were randomly picked out for inoculation in 10 ml LB medium with 100 µg/ml 
ampicillin (for pET23b constructs selection) or 50 µg/ml kanamycin (for pEHISTEV 
constructs selection) at 37 °C overnight. Plasmid DNA was extracted from harvested 
cells by using Promega Mini-Prep Kit (Promega). Plasmids containing the positive 
constructs were identified with specific restriction enzyme digestions and confirmed 
by DNA sequencing by University of Dundee. 
 
Templates Primer sequences 
(Restriction enzyme sites shown in bold) 
Vector Expressed 
protein 
Protein 
Labels 
1. GTGATTATAGCTAGCATGAATAAAAGAGGTC nanA-
pQE30 2. CGATTGGAGGTCTCGAGTTTTGTTAAATC 
pEHISTEV Full-length 
NanA 
NanA 
3. CCGAAGGAGTGAACCATGGATACTTATTTTG nanB-
pGEM 4. GATTTCTAGTCAGAATTCAGCTAAATCCATGC 
pET23b Full-length 
NanB 
NanB 
5. GGTCCCATGGTCTTAGAAAAAAATAATGTTACT nanC-
pET21b 6. GGGGCCTCGAGTTAATTCTTTTTCAGATCTTCA 
pEHISTEV NanC  
(aa86-740) 
NanC 
7. ACCTCCATGGAAGGAGCGGCTTTAACAGAGA nanA-
pQE30  8. GGGCCTCGAGTTAGACCAATACTTCTGAGTCG 
pEHISTEV NanA  
(aa319-822) 
CNanA 
9. CCTGCTAGCATGGAAGGAGCGGCTTTAACAGAG nanA-
pQE30  10.CGACCTCGAGATCCTTGCTCAAAAAGTCCCAAT 
pET23b NanA  
(aa319-791) 
CNanA2 
11. CCGAAGGAGTGAACCATGGATACTTATTTTG ATCC-
47085 12. GATTTCTAGTCAGAATTCAGCTAAATCCATGC 
pEHISTEV PaNA PaNA 
 
Table I-1 The list of primers for gene cloning in the current projects. Restriction enzymes used 
inlcude NcoI (GCTAGC), XhoI (CTCGAG), EcoRI (GAATTC), NheI (GCATGC). 
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The site mutations of PaNA gene were performed with the site-directed mutagenesis 
kit from Strategene. The Phe129Ala mutant and three corresponding double mutants 
Phe129Ala/Tyr21Phe, Phe129Ala/His45Gly and Phe129Ala/Glu315Gln were 
obtained. According to the standard protocol, 16-cycle PCR reactions were carried out 
with primers listed in Table I-2. The original PaNA gene was used as the template for 
Phe129Ala mutation; while for all the double mutants the Phe129Ala-pEHISTEV 
plasmid was used as the template DNA. The PCR products were treated with DpnI 
enzyme (1 µl per reaction) at 37 °C for 1 hr to get rid of the original DNA templates. 
Transformation of E. coli DH5α competent cells with the digested PCR products and 
small-scale inoculation of colonies were done following the same procedure described 
above. Extracted plasmids from harvested cells were sequenced to confirm the 
mutation sites. 
 
Mutations Primer sequences  Protein labels 
1. GGTGGGGCGGATTATAATGCTGCTCATGGAAAAAGTTTTC F129A 
 2. GAAAACTTTTTCCATGAGCAGCATTATAATCCGCCCCACC 
F129A 
3. GGCTCTGTATGAATCATATTTCGATCATTTTGGCC F129A/Y21F 
4. GGCCAAAATGATCGAAATATGATTCATACAGAGCC 
F129A/ Y21F 
5. GCGGGCAACAGAGGGTGTAGGTGGTAGTG F129A/H45G  
6. CACTACCACCTACACCCTCTGTTGCCCGC 
F129A /H45G 
7. GGGTAATCTATTCAGGCAGACGTCTTCTACGACG F129A/E315Q 
8. CGTCGTAGAAGACGTCTGCCTGAATAGATTACCC 
F129A/ E315Q 
 
Table I-2 Primers used in site-mutagenesis of PaNA genes. Single letter code for the amino acid 
residues are used for explicit presentations. Nucleotide code for aimed site mutations are shown in bold 
italic font.  
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II-2. Protein over-expression in the E. coli systems 
All the recombinant plasmids were subsequently introduced into E. coli BL21 (DE3) 
expression strain (Novagen). To find out the optimal conditions for protein production, 
some small-scale expression trials were conducted. For each of the protein expression 
trials, one single colony was picked out and put into 10 ml LB medium with 50 µg/ml 
ampicillin or kanamycin. The culture was then shaken at 37 °C time until the optical 
density at 600 nm (OD600) of the cultures reached 0.6. To initiate the protein 
expression, IPTG was added to the culture medium to a final concentration of 1 mM. 
To compare the effects of temperature on the expression yield and protein solubility, 
these cells continued to be cultured at 37 °C, 200 r.p.m. for 3 h or overnight at different 
temperatures such as 25 °C. 20 °C or 16 °C. The cells were harvested with centrifuge 
at 4 °C, 3000 r.p.m. for 15 min and the proteins were extracted from cell pellets using 
the BugBuster protein extraction reagent (Novagen). The crude extracts were then 
centrifuged at 4 °C, 13000 r.p.m. for 5 min to separate the soluble proteins from the 
cell debris. The samples were resolved by SDS-PAGE, and protein bands of expected 
sizes were excised for the MALDI-TOF MS analysis.  
For large-scale protein over-expression, 40 ml overnight culture from a single colony 
was inoculated in 4 L LB medium with shaking at 37 °C. When OD600 of the culture 
was around 0.6, 1 mM IPTG was added to induce the protein expression. In the cases 
of NanA, CNanA and CNanA2 expressions, the cells were shaken at 200 r.p.m for 3 hr 
at 37 °C; while for NanB and NanC, the cultures were shaken overnight at 25 °C; and 
for PaNA and its mutants, the best expression condition was 16 °C induction for 
overnight. The cells were all harvested with centrifuge at 4 °C, 8000 r.p.m. for 25 min 
and pellets were kept at -20 °C.  
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I-3. Protein purification 
The harvested cell pellets were re-suspended in Buffer A (20 mM phosphate, pH 7.4) 
and fragmentized with 5×30 s sonication on ice. Protease inhibitor cocktail tablets (1 
tablet per 25 ml extract, Roche Diagnostics) and DNase I (Sigma, the final 
concentration is 20 µg/ml) were added to the crude cell extracts immediately after the 
sonication treatments. The cell lysates were then centrifuged at 4 °C, 25000 r.p.m. for 
25 mins to remove the cell debris. The supernatants were collected and filtered with 
the 0.2 µm syringe-driven filter before the following protein purification steps.  
The purification protocol of full-length NanA was modified according to previously 
published protocol (Lock et al., 1988). Soluble protein extract was loaded to a 5 ml 
HisTrap HP column (GE Healthcare) on a BioCad 700E perfusion chromatography 
system (GMI Inc. USA). The bound proteins were eluted with 300 mM imidazole in 
Buffer A. Protein purity was monitored by SDS-PAGE and MALDI-TOF MS analysis. 
Grinded ammonium sulphate solid powder was then gradually added to the collected 
fractions with stirring until the salt saturation reached 45% (w/v). The precipitated 
proteins were collected by centrifugation at 4 °C, 25000 r.p.m for 20 min, then re-
dissolved in 40 ml Buffer A. After dialysing overnight at 4 °C in Buffer A, the protein 
was applied to a Red-A dye-ligand chromatography gel (Sigma). Fractions with 
relatively sialidase activities were pooled and dialysed against 10 mM Tris-Cl pH 8.0 
(Buffer B) overnight at 4 °C. Anion exchange Q FF column (GE Healthcare) and 120 
ml Sephacryl-200 gel filtration column (Sigma) were used coherently and those 
fractions with significant sialidase activity were kept and analyzed with SDS-PAGE. 
The purified protein NanA was concentrated and stored at -80 °C for future use. 
The purification strategies for all other proteins (NanB, NanC, CNanA, CNanA2, 
PaNA and mutants) were similar, except that all the protein purification buffers used 
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for NanC, PaNA and the mutants contained 10% glycerol (v/v). In general, soluble cell 
extract was firstly run through a 5 ml HisTrap column and a gradient of imidazole 
ranging from 30 mM to 750mM in phosphate buffered saline (PBS) buffer (20 mM 
phosphate, 150 mM sodium chloride, pH 7.4) was applied to elute the bound proteins. 
Those fractions with relatively high purity protein of expected molecular sizes shown 
in SDS-PAGE gels were kept. After overnight dialysis in Buffer B, the proteins were 
subsequently loaded to a 5 ml anion exchange column and eluted with gradient salt 
ranging from 0 to 500 mM in Buffer B. Eluted proteins was collected and stored at 4 
°C for further purification. NanB and NanC need to be dialyzed again in Buffer B and 
run through a Red-A dye-ligand chromatography gel before concentrated for size 
exclusion chromatography. All the other proteins were concentrated for gel filtration 
directly after the anion exchange step. The Sephacryl-200 column pre-equilibrated in 
50 mM Tris-Cl, 150 mM NaCl, pH 8.0 was used for the last gel filtration step. High-
purity proteins were pooled and concentrated, which were all stored at -80 °C for 
future use. 
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I-4. The sialidase activity assays and kinetic studies 
The sialidase activity was measured with the fluorogenic substrate 2′-(4-
methylumbelliferyl)-α-d-N-acetylneuraminic acid (MUAN) (Sigma), which was made 
as 10 mM stocks with distilled, deionised water and kept at -20 °C. In this assay, the 
appropriately diluted protein samples were put into a 1 ml reaction volume containing 
0.1 mM MUAN in a buffer system composed of 0.1 M sodium acetate pH 5.6 (buffer 
can be changed for different research purposes). Reactions were incubated at 37 °C for 
5 min and then stopped by adding 2 ml 0.25 M glycine buffer, pH 10.5. The relative 
fluorescence of released 4-methylumbelliferone (4-MU) was determined in a 3 ml 
optical cuvette by TD-700 fluoremeter (Turner Designs, USA) at the wavelengths of 
365 nm for excitation and 450 nm for emission. For the activity assays for PaNA and 
mutant, the incubation time was extended to 100 hr due to the lower reaction speed. 
Modified MUAN sialidase activity assay protocol was also used for the kinetic 
characterization of the sialidases NanA, NanB and NanC with different inhibitors, such 
as Neu5Ac2en and CHES. Briefly, all the reactions were fixed with 50 ng purified 
NanA, 200ng NanB or 300 ng NanC respectively in individual assay, but varying the 
MUAN concentrations from 10µM to 100µM in the presence or absence of different 
concentrations of CHES (Sigma) or Neu5Ac2en (Sigma). The reaction velocity was 
presented as ΔFluorescence/min, which was recorded by amount of MU released in 
5min. At least three replicates of each reaction were performed. The double reciprocal 
plot was made with MacExcel (Microsoft Office 2004, USA).  
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I-5. The thiobarbituric acid (TBA) assays 
To characterize the substrate specificity of NanA, NanB and NanC, the quantification 
of Neu5Ac released from specific substrates, such as α2,3, α2,6 or α2,8 linked 
sialyllactoses (Dextra Laboratories, Reading, UK), was performed with the TBA assay 
(Aminoff, 1961; Warren, 1959). 
In detail, after incubating the enzymes with 30 µg substrates in 100 µl 0.1 M sodium 
acetate, pH 5.5 at 37°C for 1hr in 10 ml test tubes, the reactions were treated with 0.25 
ml 25 mM H5IO6, 0.125 M H2SO4, pH 1.2 in a 37°C water bath for 30 min. Yellow 
colour of the liberated iodine would appear during the water bath. 0.2 ml 2% NaAsO2, 
0.5 M HCl was then added to the reactions to remove the excess periodate. The tubes 
with the reaction solutions were subsequently shaken for 1-2 min until the reactions 
turned colourless. Afterwards, 2 ml 0.1 M 2-thiobarbituric acid, pH 9 was added to 
each test tubes. The reactions were then boiled for 7.5 min to 15 min until some pink 
colour appeared in solutions. Afterwards, the cooled reaction was shaken with 3ml n-
butanol: 12 M HCl (v/v, 19:1) and centrifuged to separate the phases. The upper 
butanol pink layer was recovered for absorbance measurement at 549 nm (OD549) in a 
spectrometer.  
The amount of released Neu5Ac was calculated according to the equation: 
The amount of Neu5Ac released in nmol = V × OD549/(ε × l) 
V is the final volume of the reaction in ml; ε is the molar extinction coefficient 
(57,000) and l is the length of light path in cm (Warren, 1959).  
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I-6. The limited proteolysis of full-length NanA 
Limited proteolysis with trypsin enzyme was used to identify the sequence coverage of 
the stable catalytic domain of NanA. The lyophilized sequencing grade modified 
trypsin and the trysin resuspension buffer V542A were purchased from Promega. Each 
aliquot of 20 µg trypsin was re-suspended in 100 µl V542A buffer supplied with the 
enzyme. To achieve the maximum enzyme activity, the trypsin solution was heated at 
30 °C for 15 min before use.  
For NanA proteolysis, the optimal ratio of trypsin to NanA in the reactions was found 
to be 1 : 100 (w/w). Therefore, for each reaction, 2 µg trypsin was mixed up with 200 
µg pure full-length NanA in a 1.5 ml ependorf (EP) tube. The reaction mixture was 
then then incubated at 37 °C without shaking. After different reaction time, i.e. 0.5 hr, 
1 hr, 2 hr and 4 hr, 20 µl of the reaction solution were transferred to new 0.5 ml tube 
and stored at -20 °C. 
The reaction products at different reaction time were later analyzed by SDS-PAGE. 
The NanA fragments of interests with MWs over 30 kDa were excised from the gels 
and submitted for the MALDI-TOF MS analysis to identify the exact sequence 
coverage.  
Two versions of truncated NanA were designed based on this assay and bioinformatics 
studies, which were designated as CNanA (residues 319-822) and CNanA2 (residues 
319-792) respectively. The cloning, expression and purification procedures of both 
proteins were described in above sections. 
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I-7. Protein crystallization screening and optimization 
Purified full-length NanA, NanB, NanC and PaNA/mutants were concentrated to 5.3 
mg/ml, 5.7 mg/ml, 8.5 mg/ml and 3.5 mg/ml respectively according to the results of 
pre-crystallization tests (PCT, Hampton Research). Both CNanA and CNanA2 were 
concentrated to 10.9 mg/ml for crystallization trails.  
All the following crystallization experiments were carried out at 20 °C by using the 
sitting-drop vapour-diffusion method. Initially, the commercialized kits such as 
Premier (Wilmad LabGlass), Classics (Jena Bioscience), Index (Hampton Research) 
and Wizzard  (Emerald BioSystems) conditions were selected for protein 
crystallization screening by the high-throughput Rhombix Screen robot system 
(Rhombix). Those wells with crystalline materials growing were marked for further 
examination. To distinguish the protein crystals from salt crystals, 0.1 µl Izit dye was 
mixed with the drops with tiny crystals for 30 min before being observed in a light 
microscope. Those could be stained into a dark blue colour were protein crystals and 
the corresponding crystallization conditions were selected as the optimization starting 
points. In each optimization round, the salt or precipitant concentrations were varied 
around the initial conditions identified. In some exceptional cases, the pH values of the 
crystallization buffers were also manually screened for an optimal condition. 
For a manual protein crystallization, each reservoir well of the 96-well protein 
crystallization tray (Douglas Instruments) was filled with 100 µl reservoir solution. 
The crystallization drops were made up of equal amount of protein solution and 
reservoir solution (1-2 µl each). The tray were sealed with sealing tape and kept at 20 
°C for the crystal to form and grow. Once the crystals reached their maximum sizes in 
about two weeks, they were subjected to X-ray diffraction (Detailed in Section 6).  
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The initial crystallization conditions of NanB were found to be (1) 10% PEG 8K, 0.1 
M NaCl, 0.1 M CHES pH 9.5 and (2) 10% PEG 8K and 0.1 M imidazole pH 8.0. After 
rounds of optimization, the best conditions for NanB crystallization are (1) 10% PEG 
8K, 0.15 M NaCl, 0.1 M CHES pH 9.5 and (2) 7% PEG 8K and 0.1 M imidazole pH 
8.0. NanB crystals appeared in about three days and reached their maximum sizes 
around 2 weeks. Most crystals were about 0.5 × 0.1 × 0.05 mm (Pictures were 
previously shown in my previously submitted MRes Thesis). The NanB-Neu5Ac2en 
complex was obtained by soaking the crystals in the presence of 10 mM Neu5Ac2en 
for 15 min. 
The full-length NanA and NanC failed to crystallize. However, both versions of the 
catalytic domain of NanA (CNanA and CNanA2) were crystallized at 20% PEG 4K, 
0.1 M MES pH 6.0. The optimized condition was 30% PEG 4K, 0.1 M MES pH 6.0. 
The crystals of CNanA also grew in the presence of 10 mM Neu5Ac2en. The largest 
crystals were about 0.7 × 0.1 × 0.1 mm in size (Figure 2.6 in Chapter 2). The CNanA-
CHES complex was obtained by soaking the crystals with 100 mM CHES in the 
crystallization buffer. 
In addition, both PaNA and Phe129Ala/Glu315Gln were crystallized at either (1) 10 % 
PEG 6K, 0.1 M bicine, pH 9.0 or (2) 10 % PEG 8K and 0.1 M imidazole pH 8.0. And 
the final optimized condition was 20 % PEG 6K, 0.1 M bicine, pH 5.0. The crystals of 
PaNA reached its maximum size of about 0.15 × 0.15 × 0.15mm in about two weeks 
(Figure 5.2 in Chapter 5). Crystals of other PaNA mutants were very small and did not 
diffract X-rays well.  
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I-8. X-ray diffraction data collection and processing 
Prior to mounting crystals, the cryo-protectant solutions were made by mixing up the 
appropriate crystallization buffers with 20-25% (v/v; final concentration) glycerol. To 
make sure no ice could form in the cryo solutions at -176 °C, these buffers were 
checked with an empty loop in the liquid nitrogen flow.  
The protein crystals were picked out from the crystallization trays with a crystal 
mounting loop of suitable size and then transferred into a 10µl cryo-protectant drop 
standing for a few minutes at room temperature. A single cryo-protected crystal was 
picked up from the cryo-drop and mounted onto the in-house X-ray machine (Rigaku-
MSC Micromax-007 HF X-ray generator, fixed wavelength of 1.514Å) at -176 °C. 
After the crystal was tuned onto the focus of X-ray beam line, some preliminary data 
were collected with the Rigaku R-AXIS or Saturn 944+ CCD detectors at suitable 
crystal-to-detector distance.  
The Rigaku system data processing software was used to assess the crystal diffraction 
quality and obtain the initial parameters of the crystal form, such as the specific unit 
cell and space group. Afterwards, the strategies for further comprehensive data 
collection could be proposed by the Rigaku program package. Alternatively, the 
preliminary data analysis and strategy design could also be done with the Mosflm 
programs (Powell, 1999) or HKL2000 packages (Otwinowski and Minor, 1997) as 
aforementioned in previous chapters.  
The data collection statistics of different crystals were detailed in different chapters, 
which will not be repeated here. The Mosflm programs or HKL2000 packages were 
used for formal data assessments and data processing.  
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I-9. Structure determination, model building, refinement and validation 
The initial phases of both CnanA and NanB structures were determined by MR. The 
structures of C. perfringens NanI (PDB code: 2BF6) and the leech NanL (PDB code: 
1SLI) were selected for CNanA and NanB MR as the search models respectively. The 
ARP-wARP or Phenix programs in were selected to build the structures for both 
proteins. NanB was successful with ARP-wARP and more than 98% residues were 
built in. The automated model-building wizard of the Phenix package built 85% of the 
residues in CNanA model using the first 2.5 Å resolution dataset collected. Protein 
models were rebuilt with O or Coot. After each rounds of refinements with REFMAC5, 
the structures were inspected and rebuild again using O or Coot. The final structures 
were validated with MolProbity before deposited into PDB. 
For the PaNA structure determination, experimental phasing with heavy atoms was 
used. K2Hg(NO3)4, Sm(NO3)3, pCMBS and some other derivatives were selected in the 
PaNA crystal soaking trials. Prior to data collection, each crystal was transferred to 
heavy atom containing cryo-protectant of 20% glycerol, 15 % PEG 6K, 0.1 M bicine 
pH 5.0 and 5-10 mM heavy metal derivatives for 30 min or overnight. A number of 
datasets were collected with the 1.542 Å in-house X-ray generator (Table I-3). The 
SOLVE/RESOLVE program package was used to localize the heavy metal sites. All 
MIR efforts with any other datasets could only localize the single heavy atom site in 
the Mercury H12 dataset. Therefore, the Mercury H12 dataset was used for SIRAS 
phasing along with the native dataset in SOLVE/RESOLVE program. Moreover, the 
DM program was used to improve the phase. Automated model building using ARP-
wARP successfully built most of the residues in. Model rebuilding, refinement and 
validation processes were similar to the CNanA and NanB structures described above. 
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Table I-3 Heavy atoms that used for PaNA phasing. * RF_I represents the R-factor of intensity 
between each of the heavy-atom dataset and the native dataset, which was calculated from SCALEIT 
program of CCP4 suite. 
 
 
No. 
Heavy  
atom 
Soaking 
time 
Resolu-
tion (Å) 
a=b=c 
(Å) 
Rmerge 
(%) 
I/SigI Labels RF_I * 
1 None  2.5 125.1 7.9/42.0 20.1/2.5 Native -- 
2 K2Pt[CN]4 5 min 2.6 124.9 4.9/20.5 22.5/6.1 H1 0.234 
3 pCMBS 30 min 2.6 125.1 5.0/23.7 17.0/4.0 H2 0.141 
4 pCMBS 12 h 2.6 125.3 4.8/13.3 18.4/8.4 H3 0.294 
5 Hg(NO3)2 30 min 2.8 124.3 9.8/25.1 11.4/2.3 H4 0.445 
6 Hg(NO3)2 12 h 3.2 124.8 9.8/39.5 11.7/3.6 H5 0.342 
7 Hg(NO3)2 24 h 2.6 125.3 6.8/18.4 13.5/5.5 H6 0.532 
8 Au[CN]2 1 h 2.6 125.6 5.3/23.4 17.8/4.6 H7 0.499 
9 Sm(NO3)3 15 min 2.8 125.3 14/28.8 6.7/2.2 H8 0.296 
10 K2Pt[CN]4 10 min 2.8 124.7 8.5/32.6 9.9/2.0 H9 0.127 
11 K2Pt[CN]4 20 min 2.6 124.9 7.8/23.7 10.4/3.3 H10 0.203 
12 Hg(NO3)2 1 h 2.4 125.5 4.7/15.0 15.4/5.6 H11 0.434 
13 Hg(NO3)2 20 min 2.1 125.3 4.2/24.6 21.6/2.9 H12 0.273 
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I-10. 1H NMR experiments 
1H NMR spectroscopy was employed to monitor the reactions of S. pneumoniae 
sialidases, PaNA and its mutants with MUAN, α-2,3-sialyllactose or α-2,6-
sialyllactose. Deuterated water (D2O, 99.9%, Sigma) was used in all chemicals and 
buffer preparations.  
In each reaction, 13.5 µl of 70µM NanA, NanB and NanC or 30 µl 50 µM PaNA and 
its mutants with 13.5 µl of MUAN, 3SL or 6SL (30 mM in D2O) and 563 µl PBS in 
D2O pH 7 were mixed. The reactions were then transferred into a 5 mm NMR tube 
(Aldrich). After the reactions were incubated at room temperature for a certain time 
period, 1D 1H NMR spectra were measured on a 500MHz Bruker spectrometer at 20 
°C with 256 scans and a relaxation delay of 2 s. Residual water signal was suppressed 
by continuous low power irradiation of the water signal during the relaxation delay. 
With the same NMR parameters setting, all the experiments stated above were also 
repeated in 50 mM sodium acetate in D2O at pH 5. No obvious difference was seen in 
the reactions performed at different pH values. The spectra of the reactions at pH 5 
have strong acetate peaks interfering with the products released and therefore not 
shown in the main text (Appendix II-2 and II-3).  
In other NMR experiments, to test if the sialidases could hydrate Neu5Ac2en, 20 µl 
200mM Neu5Ac2en was used in each reactions with same amounts of enzymes stated 
above (Figure 3.12). Moreover, to test if NanB could act as a trans-sialidase, a mixture 
of 25 µl N-acetyllactosamine (Galβ1-4GlcNAc, 52mM in D2O) and 14 µl of 3SL in 49 
µl PBS D2O were incubated with NanB for 48 hr. Spectra were shown in Appendix II-
4.  
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I-11. The fluorescence-based thermal shift assay 
The fluoresence-based thermal shift assay was performed as described previously (Lo 
et al., 2004). Each well of the 96-well iCycler iQ PCR plate (Bio-Rad, Hercules, CA) 
was filled with 50 µl reaction solutions consisting of 1 µl 50 µM protein, 0.25 µl of 
500 × Sypro orange protein dye (the original stock was supplied at 5000 × in DMSO), 
5 µl of compounds at different concentrations and 43.75 µl Buffer B. After sealing the 
plate with optical film on top, the reactions were put into the iCycler iQ5 Real-Time 
PCR Detection System (Bio-Rad, Hercules, CA). The plate was then heated from 25 
°C to 89 °C at the rate of increasing 0.5 °C per min. The fluorescence intensity of each 
well was measured at the excitation/emission wavelength of 490/530 nm. The real-
time fluorescent signals were automatically recorded by the CCD camera and 
simultaneously quantified by the iCycler iQ Optical System Program Version 3.1 (Bio-
Rad, Hercules, CA).  
The melting curves were also generated by the program and could be further sorted out 
using the same program. Data could also be processed with Excel and Word 
(Microsoft Office 2004, USA). To determine the Tm of each melting curve, the baseline 
was first subtracted from the top of thermal ramp; then the midpoint coordinate of the 
subtracted thermal ramp could be decided by calculation, where the x value of the 
coordinate represents the Tm temperature. 
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I-12. Computational docking of small molecules 
The coordinate files of the ligands were generated, aided by the PRODRG server 
(Schuttelkopf and van Aalten, 2004). Initially, the genetic algorithm (GA) docking 
program GOLD v4.01 (Jones et al., 1997) was used for docking the compounds to the 
proposed catalytic cavity of the protein structures. Briefly, a 10 Å radius sphere around 
the conserved nucleophilic tyrosine residues was defined as the ligand binding pocket. 
For each compound, the hydrogen atoms were added with Pymol program before the 
individual docking runs. Ten independent runs were carried out and ten GOLD 
docking solutions were yielded, which were ranked by the GOLD energy score. To 
minimize the artificial effects, the top solutions were always selected for the following 
analysis.  
A second docking program used was AutoDock (Goodsell et al., 1996). This program 
was used to dock boat conformations of Neu5Ac and Pse5Ac7Ac to PaNA and 
Neu5Ac to MvNA as a positive control. Grid maps were calculated for a 30Å box 
centreed on the hydroxyl oxygen of the putative nucleophile Tyr297, and a Lamarkian 
genetic algorithm was used to perform 100 docking experiments. Step sizes used were 
0.2 Å for ligand translations and 5º for ligand orientations and torsion angles. 
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Appendix II  
 
Supplementary results 
 
II-1. The model structure of NanC catalytic domain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-1 The model structure of NanC catalytic domain & inserted domain made with SWISS-
MODEL. The model structure was refined with Refmac5 and validated with MolProbity. 
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II-2. NMR spectra of NanA with 3SL at pH 5.0 and pH 7.0 
 
Figure II-2 The NMR spectra of NanA with 3SL at pH 5.0 and pH 7.0. The reaction products were 
identical. Acetate has very strong peak interfering with Neu5Ac, thereby was not used in the main body 
of the thesis. 
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II-3. NMR spectra of NanB with 3SL at pH 5.0 and pH 7.0 
 
Figure II-3 The NMR spectra of NanB with 3SL at pH 5.0 and pH 7.0. 
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II-4. NMR spectra of NanB with 3SL and N-Acetyllactosamine 
 
Figure II-4 The NMR spectra of NanB with 3SL and N-Acetyllactosamine. NanB does not show 
trans-sialidase catalytic roles, since no Neu5Ac residue was seen transfer to the acceptor N-
Acetyllactosamine. 
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II-5. NMR spectra of NanC with 6SL 
 
Figure II-5 The NMR spectra of NanC with 6SL. NanC was shown incapable of cleacving α2,6-
siallyllactose. 
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II-6. NMR spectra of Phe129Ala mutant of PaNA with MUAN 
 
 
 
 
Figure II-6 The time-course NMR spectra of Phe129Ala mutant of PaNA with MUAN. 
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II-7. The proposed sialic acid-regulated operon system in S. pneumoniae 
 
 
 
 
 
 SPR1518  SPR1520 SPR1527 SPR1528  SPR1531   SPR1536    SPR1538                     SPR1622 
 
 
 
 
 
 
 
 
 
Figure II-7 The proposed sialic acid-regulated operon system in S. pneumoniae. The operon is 
proposed based on the R6 strain gene annotation (Hoskins et al., 2001). Similar locus is seen in the other 
strains, such as previously mentioned TIGR4. The gene encoding the third sialidase NanC is found in a 
distant locus. 
 
ORFs Annotations of encoded proteins  
SPR1518 Phosphosugar-binding transcriptional regulator 
SPR1520 N-acetylneuraminate lyase (NAlyase) 
SPR1527 ATP-binding cassette (ABC) transporter, sugar binding protein (SBP) 
SPR1528 Phosphoenolpyruvate-dependent sugar phosphotransferase system (PTS) 
SPR1531 Sialidase NanB 
SPR1536 Sialidase NanA 
SPR1538 Acetyl xylan esterase (Axe) 1 
SPR1622 M regulator protein trans-acting positive regulator (MgrA) 
NAlyase ABC-SBP  PTs-EII       NanB        NanA        Axe1                           MgrA 
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